\r\n\t(1) Sustainable Waste Management; \r\n\t(2) Micro(nano)plastics in the Environments; \r\n\t(3) Electronic Waste and Circular Economy; \r\n\t(4) Reducing, Recycling and Recovery of Agricultural and Food Waste; \r\n\t(5) Biomass Valorization: Waste to Resources; \r\n\t(6) Governmental Policy on Waste Management and Valorization.
\r\n
\r\n\tThis book will offer a timely opportunity for knowledge exchange of sustainable management agenda for biological waste and remediation of soil, water and air in the local context, which satisfies the environmental compatibility, financial feasibility and social needs. It will deliberate on state-of-the-art treatment technologies, advanced management strategies, and political issues pertaining to recycling and recovery of organic waste.
",isbn:"978-1-80355-913-1",printIsbn:"978-1-80355-912-4",pdfIsbn:"978-1-80355-914-8",doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!1,isSalesforceBook:!1,hash:"4ef7ac85e87a3131afb9b858b79aa870",bookSignature:"Associate Prof. Tao Zhang",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/11256.jpg",keywords:"Waste Management, Microplastics, Nanoplastics, Electronic Waste, Agricultural Waste, Food Waste, Recycling, Recovery, Biomass, Resources, Governmental Policy, Environmental Protection",numberOfDownloads:15,numberOfWosCitations:0,numberOfCrossrefCitations:0,numberOfDimensionsCitations:0,numberOfTotalCitations:0,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"November 10th 2021",dateEndSecondStepPublish:"December 8th 2021",dateEndThirdStepPublish:"February 6th 2022",dateEndFourthStepPublish:"April 27th 2022",dateEndFifthStepPublish:"June 26th 2022",remainingDaysToSecondStep:"5 months",secondStepPassed:!0,currentStepOfPublishingProcess:5,editedByType:null,kuFlag:!1,biosketch:'Dr. Zhang was a visiting scholar at Arizona State University in 2014 and at the University of Hohenheim in 2017. He is the director of the Circular Economy Committee of the Chinese Society for Environmental Sciences and Water Treatment and Recycling Committee of the Chinese Society for Environmental Sciences. He has been authorized 17 invention patents in China and has won the Chinese prize for the "Outstanding Young Scientist” in 2019.',coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"185487",title:"Associate Prof.",name:"Tao",middleName:null,surname:"Zhang",slug:"tao-zhang",fullName:"Tao Zhang",profilePictureURL:"https://mts.intechopen.com/storage/users/185487/images/system/185487.jpg",biography:"Dr. Tao Zhang is an Associate Professor and Ph.D. Supervisor at the College of Resources and Environmental Sciences, China Agricultural University, China. His academic background covers waste management, wastewater treatment, utilization of agricultural waste. He is awarded the Scientific Chinese - Outstanding Young Scientist Award, the Innovation Award for Industry-University-Research Cooperation of China, the Character Award - Invention and Entrepreneurship Award of China Association of Inventions. His H-index is 23 (Scopus) and he has published more than 50 papers in Chemical Engineering Journal, Water Research, Journal of Hazardous Materials, Green Chemistry, Renewable and Sustainable Energy Reviews, and so on. Amongst, 11 ESI Highly Cited Paper and 4 ESI Hot Paper. He has authorized more than 20 Chinese invention patents.",institutionString:"China Agricultural University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"3",institution:{name:"China Agricultural University",institutionURL:null,country:{name:"China"}}}],coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"7",title:"Business, Management and Economics",slug:"business-management-and-economics"}],chapters:[{id:"81303",title:"The Role of Biochar Systems in the Circular Economy: Biomass Waste Valorization and Soil Remediation",slug:"the-role-of-biochar-systems-in-the-circular-economy-biomass-waste-valorization-and-soil-remediation",totalDownloads:15,totalCrossrefCites:0,authors:[null]}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"429339",firstName:"Jelena",lastName:"Vrdoljak",middleName:null,title:"Ms.",imageUrl:"https://mts.intechopen.com/storage/users/429339/images/20012_n.jpg",email:"jelena.v@intechopen.com",biography:"As an Author Service Manager, my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"7326",title:"Phosphorus",subtitle:"Recovery and Recycling",isOpenForSubmission:!1,hash:"463481a56cd0f4b649285f54a9e5008c",slug:"phosphorus-recovery-and-recycling",bookSignature:"Tao Zhang",coverURL:"https://cdn.intechopen.com/books/images_new/7326.jpg",editedByType:"Edited by",editors:[{id:"185487",title:"Associate Prof.",name:"Tao",surname:"Zhang",slug:"tao-zhang",fullName:"Tao Zhang"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10975",title:"Sewage",subtitle:"Recent Advances, New Perspectives and Applications",isOpenForSubmission:!1,hash:"0933f9b6aa7b8c65e710e951e674997d",slug:"sewage-recent-advances-new-perspectives-and-applications",bookSignature:"Tao Zhang",coverURL:"https://cdn.intechopen.com/books/images_new/10975.jpg",editedByType:"Edited by",editors:[{id:"185487",title:"Associate Prof.",name:"Tao",surname:"Zhang",slug:"tao-zhang",fullName:"Tao Zhang"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10215",title:"Circular Economy",subtitle:"Recent Advances, New Perspectives and Applications",isOpenForSubmission:!1,hash:"161dc2ffcd5ef7e5f8144938ed7fe477",slug:"circular-economy-recent-advances-new-perspectives-and-applications",bookSignature:"Tao Zhang",coverURL:"https://cdn.intechopen.com/books/images_new/10215.jpg",editedByType:"Edited by",editors:[{id:"185487",title:"Associate Prof.",name:"Tao",surname:"Zhang",slug:"tao-zhang",fullName:"Tao Zhang"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophile",surname:"Theophanides",slug:"theophile-theophanides",fullName:"Theophile Theophanides"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"314",title:"Regenerative Medicine and Tissue Engineering",subtitle:"Cells and Biomaterials",isOpenForSubmission:!1,hash:"bb67e80e480c86bb8315458012d65686",slug:"regenerative-medicine-and-tissue-engineering-cells-and-biomaterials",bookSignature:"Daniel Eberli",coverURL:"https://cdn.intechopen.com/books/images_new/314.jpg",editedByType:"Edited by",editors:[{id:"6495",title:"Dr.",name:"Daniel",surname:"Eberli",slug:"daniel-eberli",fullName:"Daniel Eberli"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"57",title:"Physics and Applications of Graphene",subtitle:"Experiments",isOpenForSubmission:!1,hash:"0e6622a71cf4f02f45bfdd5691e1189a",slug:"physics-and-applications-of-graphene-experiments",bookSignature:"Sergey Mikhailov",coverURL:"https://cdn.intechopen.com/books/images_new/57.jpg",editedByType:"Edited by",editors:[{id:"16042",title:"Dr.",name:"Sergey",surname:"Mikhailov",slug:"sergey-mikhailov",fullName:"Sergey Mikhailov"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"21337",title:"Diagnosis and Treatment Options for Brain Metastasis of Melanoma",doi:"10.5772/20382",slug:"diagnosis-and-treatment-options-for-brain-metastasis-of-melanoma",body:'\n\t\t
\n\t\t\t
1. Introduction
\n\t\t\t
Metastasis to the brain is a devastating and common consequence for patients with malignant melanoma. A significant number of patients with melanoma eventually develop brain metastasis at the time of death. Patients are often symptomatic from their lesions and a large percentage of those with neurological deficits eventually die from the brain metastasis. Diagnosis does not typically occur until late in the disease course, which can preclude many treatment options. Additionally, rapid progression of the disease state and worsening health status magnifies the difficulties of treatment. Currently, contrast-enhanced computer tomography (CT) and magnetic resonance imaging (MRI) remain the main diagnostic modalities. Confirmation is usually achieved with surgical biopsy or resection. After diagnosis, treatment options are somewhat limited - surgical management, radiation therapy, and chemotherapy are most commonly used either alone or in combination.
\n\t\t\t
This chapter provides a description of the common presenting symptoms, diagnostic modalities, and treatment options for patients with metastatic melanoma to the brain. This chapter will also discuss emerging technologies which may have notable impacts on the future of disease management. Ultimately, prompt diagnosis and treatment for patients with brain metastases may have important implications for the duration and quality of life of these patients.
\n\t\t
\n\t\t
\n\t\t\t
2. Epidemiology and demographics
\n\t\t\t
In general, patients with intracranial metastases significantly outnumber those with primary brain tumors. However, there are a small number of population-based epidemiological studies that address the true incidence of intracranial metastases, and studies devoted primarily to intracranial melanoma metastases are even less common [1]. Along with the limitations inherent to most surveys, such as sampling size and variability, there are several other limiting factors. This includes inadequate reporting, difficulty attaining ante-mortem diagnosis, and greater emphasis cancer databases place on the incidence of primary tumors rather than metastasis [2]. As a result, it is quite likely that current population-based epidemiological studies underestimate the true incidence of cancer metastasizing to the brain [2]. A significant amount of the reported data now originates from clinical, neurosurgical, and autopsy series which are subject to their own limitations as well. However, as methods of diagnosis and treatment continue to improve, a more accurate picture can be portrayed.
\n\t\t\t
Malignant melanoma is one of the most common systemic cancers to metastasize to the central nervous system (CNS). Following lung and breast carcinoma, melanoma historically has the third highest incidence of metastasis to the brain [3]. One recent study has indicated it may now surpass that of breast carcinoma, most likely a result of increasing rates over time [1]. Of cases with metastasis to the brain, melanoma is the primary tumor for about 5 to 21 percent of these patients [4]. CNS involvement or deficits are the first manifestation of melanoma in 9 to 12 percent of patients [5]. For those that carry a diagnosis of melanoma, between 12 to 60 percent can expect to develop metastases to the brain [6, 7]. However, because it only accounts for 5% of metastatic cancers [8], the total number of cases or individuals is often erroneous [1]. Although melanoma is a less common cancer, it has the highest propensity for metastasis to the brain [1, 9]. An estimated 49 to 73 percent of patients who die from melanoma will have developed brain metastases by the time of death and are found on autopsy [10, 11]. It is responsible for the deaths in an estimated 20 to 55 percent of affected patients, and contributes to death in up to 95 percent of all cases [11-13]. Thus, the impact and consequences of metastatic melanoma are quite detrimental in medicine.
\n\t\t\t
Anyone with a diagnosis of melanoma is at risk for developing CNS metastases. Previous studies have tried to elucidate these factors that increase the risk of CNS metastases. Among the demographic aspects intrinsic to patient demographics, only male gender was found to show greater predominance in patients with brain metastases [14]. Of the characteristics of the primary lesion, melanomas appearing wide, thick, or ulcerated or with acral lentiginous or nodular histological findings were more frequently found in patients who developed brain metastases[14]. Also, primary lesions arising from the mucosal surfaces, skin of the head and neck, or skin of the trunk were more frequently found in this group [14, 15]. Patients with involvement of the lymph nodes or visceral organs, especially the lungs or multiple visceral organs, showed an increased likelihood of metastasizing to the brain [14, 16]. These factors are also associated with shortened overall survival time survival times [14, 16]. Interestingly, with the exception of primary lesions of the head and neck region, these factors did not affect survival after a diagnosis of a brain metastasis [14]. Other factors that were evaluated, such as the patient’s race, pigmentation of the primary tumor, and pregnancy at the time of melanoma diagnosis, were not significantly correlated with the development of brain metastases[14]. The average age of presentation of patients with brain metastases is 48 to 53 years old, which is similar to that of patients with extracranial metastases[14, 17].
\n\t\t
\n\t\t
\n\t\t\t
3. Pathophysiology
\n\t\t\t
Metastases to the brain requires a complex series of steps, each mediated by a combination of intricate molecular mechanisms that are not completely understood. Each of these steps typically involves overcoming various physiological barriers including the blood-brain barrier [2]. Similar to other systemic cancers, as the primary melanoma matures, the process of angiogenesis increases the vascular supply to sustain the metabolic needs of the cancer cells and allows the tumor to grow. It progressively invades the surrounding host tissue and eventually spread hematogenously by invading local venules or lymph channels, which drain into the venous circulation [2]. Because venous circulation returns to the right side of the heart, the first capillary beds the circulating tumor cells encounter are typically found in the lungs. These tumor cells are generally larger than the capillary vessels and may arrest in these pulmonary capillary beds. As a result, patients typically have lung metastases earlier in the time course of melanoma. They may often be identified at the time intracranial metastases are diagnosed. Between about 27 to 68 percent of affected patients may have concurrent lung metastases, which further shortens the survival time [14, 18, 19]. In order to reach arterial circulation and thus the cerebral vasculature, these melanoma cells must reach the left side of the heart either by: (1) metastasizing to the lung and invading the pulmonary venous circulation, (2) traversing the lung capillary bed to the pulmonary venous circulation, or (3) crossing through a patent foramen ovale thus bypassing the pulmonary circulation [2].
\n\t\t\t
When tumor cells reach the left side of the heart and systemic circulation, the most important factors involved in promoting intracranial metastasis are the blood supply and greater preference for brain tissue [2]. The cerebral vasculature receives approximately 15 to 20 percent of the cardiac output in the resting state, which increases the likelihood that circulating tumor cells will reach the brai n[2]. It would be expected to receive a proportional amount as well, however the distribution of metastases based on blood flow, or the mechanical hypothesis, does not account for the high propensity of melanoma to metastasize to the brain compared to other cancers [20]. Instead, the seed and soil hypothesis likely contributes to the metastasis and plays an important role in explaining this phenomenon. This hypothesis postulates that certain genetic alterations in the tumor cells (the seed) influences them to show preference for the brain and find its microenvironment a more favorable place (the soil) to support their growth [20]. These alterations may include increased expression of adhesion molecules that show preferential adhesion to brain endothelial cells [21, 22] and increased production of degradative enzymes enabling tumor cells to penetrate the endothelium and the basement membrane [23]. Locally produced growth factors in the brain may also stimulate growth of the metastatic cells [24].
\n\t\t\t
When tumor cells reach the cerebral vasculature, they may arrest in the capillary beds due to their greater size. In order to form metastases, they must extravasate across the microvasculature of the blood-brain barrier into the brain parenchyma [2]. The blood-brain barrier is a continuous, non-fenestrated endothelium composed of tight junctions and protects against the invasion of microorganisms and also the interaction of most drugs, including chemotherapeutic drugs [25]. However, it provides little protection against the invasion of metastatic cells into the brain parenchyma and may even be altered to a leakier barrier in primary tumors and metastases [26]. The cells adhere to and penetrate the basement membrane and astrocytic foot processes, eventually reaching the parenchyma.
\n\t\t\t
In the end, only about 0.1 percent of the initial circulating tumor cells survive the protective mechanisms of the body to form distant metastases [7]. Additionally, metastasis typically occurs relatively late in the disease course for most patients with malignant melanoma. This may be explained by CNS involvement occurring as a result of a late metastatic event from another distant metastatic site, such as the lungs [7]. It may also be possible that metastasis is actually an early event in the disease course, but relatively slow metastatic growth results in delayed neurological effects and delayed detection [7].
\n\t\t
\n\t\t
\n\t\t\t
4. Pathology
\n\t\t\t
The histopathology of intracranial metastases mimics that of the primary melanoma. Melanoma can metastasize to virtually any portion of the intracranial cavity. The most common site is the parenchyma, but involvement of any anatomic structure in the CNS can occur, including the dura, leptomeninges, choroid plexus, pituitary, and pineal glands. As with other systemic cancers that metastasize to the brain, the distribution reflects the size and volume of the region and its vasculature. Thus, a significant majority are supratentorial, the most common location being the cerebral hemispheres along the vascular distribution of the border zones (water-shed areas) between the anterior and middle cerebral arteries as well as the middle and posterior cerebral arteries [6, 14]. In total, the parietal lobe is involved in about 26 to 45%, frontal love in 21 to 36%, temporal lobe in 19%, occipital lobe in 11%, cerebellum in 7%, and cerebellum in <1%. The spinal cord is rarely involved [6, 14]. About 75 percent of metastases are found in the gray-white junction, where supplying cerebral vessels are slightly constricted, resulting in reduction of blood flow and thus increased risk of tumor cells arrest [6]. Melanoma is also known to have an increased likelihood of developing multiple metastases. Approximately 16 to 61% of patients will have more than one intracranial lesion at the time of diagnosis [14, 17, 18]. Individual lesions are usually relatively small with the largest typically measuring between 1 to 4 cm in diameter, while few are rarely greater than 4 cm. Larger intracranial lesions are noticeably less common and will most often be solitary [6, 14, 18]. Similar to other systemic cancers, the metastases from melanoma tend to expand as roughly spherical masses and establish well-defined interfaces with the surrounding brain parenchyma. Thus, expansion pushes the normal surrounding tissue aside rather than invading it. This contrasts from most primary brain tumors which often show diffusely infiltrated margins [27].
\n\t\t\t
Metastases from melanoma have the highest risk of hemorrhage as compared to other systemic metastases to the brain. Hemorrhage is found on neuroimaging in 27 to 40% of patients with intracranial lesions, while histopathological evaluation has indicated that 62 to 71% of patients have evidence of a prior hemorrhage [6, 18]. The bleeding may be confined to the intracranial lesion itself, extend into the area surrounding it, or expand into an intracerebral hematoma. When multiple metastases are present, simultaneous hemorrhage usually occurs rather than isolated hemorrhage of individual lesions [28]. This most often results in subacute progression which is characteristic of non-hemorrhagic brain metastases. Occasionally, it can cause significant complications such as hematomas and hydrocephalus from obstruction of cerebrospinal fluid flow [18]. Vasogenic edema surrounding brain metastases is also common and can cause similar effects as hemorrhage.
\n\t\t
\n\t\t
\n\t\t\t
5. Clinical findings
\n\t\t\t
The clinical presentation of melanoma metastases to the brain does not significantly differ from that of other intracranial metastases or primary brain tumors. The presenting signs and symptoms are dependent on the number and location of the lesions as well as the rate of growth. Regardless of etiology, most CNS lesions produce clinical effects either through compression of surrounding neurological tissue or destruction of neurons. For intracranial metastases, the primary mechanism of action is compression from the local mass effect of tumor expansion or secondary effects from raised intracranial pressure or impediment of cerebrospinal fluid circulation. Most patients present with nonfocal complaints secondary to increased intracranial pressure[19]. Common symptoms of increased intracranial pressure include headaches, mental change, somnolence, and nausea and vomiting. Focal or generalized seizures resulting from irritation of neurons are also common in patients with brain metastases[6]. Patients with a single metastasis often present with additional focal signs and symptoms. This can include such neurological deficits as cranial nerve palsies, visual deficits, hemiparesis, and hemisensory loss[6]. Generally, these nonfocal or focal complaints can present in up 75 percent of patients with brain metastases, whereas the incidence of seizures in patients may be as high 50 percent [6, 14, 29]. Although patients with metastases of melanoma to the brain can present with a range of signs and symptoms, there are still a number of patients who may have few or no obvious indications of an underlying pathology[14, 29]. This may be due insufficient mass effect, however their growth rate compared to primary brain tumors is notably faster. Clinical effects may then be subacute in onset, presenting over weeks rather than months. An acute onset may also occur in such instances as hemorrhagic transformation, dubbed a “tumor TIA”. Thus, it is important for physicians to have a high index of suspicion when dealing with patients at risk of developing brain metastases. It is a strong possibility and should be high on the list of differential diagnosis in any patient with a history of melanoma that presents with new neurological signs or symptoms [6].
\n\t\t
\n\t\t
\n\t\t\t
6. Diagnosis
\n\t\t\t
When there is a high clinical suspicion for metastatic melanoma to the brain based on the history and neurological exam of a patient, neuroimaging is the most important diagnostic modality. Currently, computed tomography (CT) and magnetic resonance imaging (MRI) provide the most beneficial imaging of the CNS. Between these two modalities, MRI with and without gadolinium contrast enhancement is the preferred choice for all systemic metastases. MRI is known to increase the conspicuity of lesions and have increased sensitivity in detecting the presence of additional and smaller metastases to the brain [30, 31]. However, because CT is more readily available in emergent situations, it is often used to image large lesions, hemorrhage, and significant edema, but will be insufficient to definitively rule out intracranial disease [6]. If a single metastasis is found on CT or the scan appears within normal limits, MRI with administration of contrast is warranted because of its improved abilities for detection of lesions [30, 31]. Other radiographic imaging modalities, such as positron emission tomography (PET) with 18F-fluorodeoxyglucose, generally are not useful in the diagnosis or imaging metastatic melanoma of the brain[32].
\n\t\t\t
In the majority of patients, MRI is often the only necessary diagnostic test. However, neuroimaging cannot unequivocally differentiate metastases from other intracranial pathologies. The presence of a lesion on a CT or MRI scan in patient with melanoma or other progressive systemic cancer is not always diagnostic for metastatic spread. The differential diagnosis often includes primary intracranial tumors, cerebral abscess, demyelinating disease, and cerebral infarction or hemorrhage. Each of these etiologies will likely need to be carefully ruled out, however certain characteristics provide for strong evidence of metastases. Brain metastases from melanoma frequently appear bright on T1-weighted images and dark on T2-weighted images. This appearance may be attributed to the production of melanin in the tumor [33, 34]. If hemorrhage occurs, the presence of blood breakdown products can alter the T1-weighted or T2 weighted signal[34, 35]. On CT, brain metastases from melanoma are typically slightly hyperdense compared to the surrounding nervous tissue and exhibit moderate contrast enhancement [6]. Increasing the volume of contrast material injected as well as delaying imaging after the injection of intravenous contrast material may improve detection and conspicuity of lesions on CT examination [36]. When the metastases are small, uniform contrast enhancement is typical, but when larger, peripheral ring enhancement may occur. This ring is usually thicker in comparison to an abscess and more regular than a primary tumor. As noted previously, metastases are usually found at the gray-white junction in the watershed areas of the brain and are typically spherical in shape with more regular margins and a substantial amount of vasogenic edema surrounding a small tumor nidus [6, 14, 27].
\n\t\t\t
After neuroimaging, confirmatory diagnosis can be accomplished through surgical biopsy or, preferably, excision of the entire mass. This allows for definitive differentiation of metastases originating from melanoma versus metastases from possible systemic cancers and other suspected etiologies. If more than one lesion exists, the largest or most symptomatic one should be addressed first for biopsy or resection. Once a brain metastasis has been discovered either through imaging or biopsy, screening for the primary systemic cancer is necessary if one has not already been diagnosed. In contrast, for those patients who have been diagnosed with malignant melanoma but their neurological exam is within normal limits, routine screening of the CNS with neuroimaging rarely identifies metastases and is thus generally not recommended [37].
\n\t\t
\n\t\t
\n\t\t\t
7. Survival
\n\t\t\t
The prognosis of patients with disseminated melanoma is particularly poor if the CNS is involved. Currently, no reliably curative treatments are available for patients and most therapeutic trials for melanoma exclude patients with brain metastases [38]. For those with documented brain metastases, the overall median survival time is between 3.8 and 5.2 months, a notably shorter survival time in comparison to patients with other sites of distant metastases. The survival percentages are inversely proportional to the length of time after diagnosis [39-43]. Additionally, the median time between the diagnosis of primary melanoma and the diagnosis of metastatic melanoma to brain is about 3.1 to 3.7 years [13, 14, 41]. Among a number of clinical and pathologic factors that have been analyzed, the disease free-interval (DFI) is one of a few that independently predicts survival after diagnosis of AJCC stage IV melanoma. Significant survival benefit occurs when the DFI is greater than 12 months. The anatomical site of the primary melanoma has also been shown to have predictive value. There is an almost fourfold difference between sites associated with highest survival and lowest survival rate. Melanomas with primary metastasis from the skin and lymph nodes have a median survival of about 15 months, whereas those from the brain and liver have a median survival of about 4 months. The third factor that independently predicts survival is the preceding stage of disease before the patient is diagnosed with stage IV melanoma. Patients experience significant survival benefit if they develop stage IV melanoma without progressing through stage III and have a DFI greater than or equal to 72 months, or if they progress through stage III to stage IV and have a DFI greater than or equal to 18 months. Other factors such as gender, age, Breslow depth, Clark level, year of diagnosis, and number of metastatic sites have not shown predictive value[39].
\n\t\t
\n\t\t
\n\t\t\t
8. Supportive therapy
\n\t\t\t
Several approaches can be taken to provide patients with supportive measures until more definitive treatment can be considered and administered. This primarily involves the medical management of cerebral edema and the resulting increased intracranial pressure, the control of seizures, and the prevention of other associated complications and conditions. These are generally the most common medical problems in patients with metastasis of melanoma to the brain as well as most other brain tumor. The overall survival in patients with brain metastases treated with only supportive care is approximately 1 to 2 months[14].
\n\t\t\t
\n\t\t\t\t
8.1. Steroids
\n\t\t\t\t
The vasogenic edema that is characteristic of metastases is a significant factor in the morbidity of patients. It occurs as a result of BBB break down, allowing sodium and water to leak into and accumulate in the extracellular space of the brain parenchyma[44, 45]. Corticosteroids have been shown to adequately manage this vasogenic edema and can dramatically improve a patient’s condition[46, 47]. The beneficial effects are often noticeable within 6 to 24 hours after the first dose and reach maximum effect within 3 to 7 days[48]. Its mechanism of action is quite complex and not completely understood. The antiedema effect may be contributed to stabilization and reduction of the permeability of tumor capillaries through endothelial cell interactions[44, 45]. Corticosteroids are usually indicated in any patient who is symptomatic from the metastatic edema and during the course of definitive treatment with radiation or surgery, but it is typically not necessary in asymptomatic patients with small metastases unless treatment with radiation or surgery is expected[49, 50]. Dexamethasone is administered most commonly because it has minimal mineralocorticoid activity and may have a lower risk of complications compared to other corticosteroids[47]. Long-term use of corticosteroids can result in such significant adverse effects as myopathy, osteoporosis and avascular bone necrosis, diabetes mellitus, cognitive dysfunction, gastrointestinal (GI) hemorrhage, bowel perforation, and opportunistic infections, such as Pneumocystis jirovecci pneumonitis and oropharyngeal candidiasis[51].
\n\t\t\t\t
In instances of significant mass effect or acute decompensation of brain metastases, the onset of effects of corticosteroids is not quick enough and thus the approach to medical management changes[45]. Acute decompensation can be due to a number of causes such as intratumoral hemorrhage, obstructive hydrocephalus, seizures, or hyponatremia. The resulting acutely increased intracranial pressure should be addressed immediately in order to minimize the risk of herniation or worse[47]. This involves stabilization of the BBB, minimization of the vasogenic edema, and emergent intervention with surgical debulking or irradiation. Elevation of the head of the bed, hyperventilation, mannitol, diuretics and are all rapid onset measures that can provide support until steroids take effect and should precede any neuroimaging[49, 52].
\n\t\t\t
\n\t\t\t
\n\t\t\t\t
8.2. Antiepileptics
\n\t\t\t\t
Seizures are a common occurrence in patients with brain metastases. The likelihood of seizures is highest in patients with melanoma compared to other cancers including lung and breast carcinoma[51]. Those who present with seizures should generally be treated with antiepileptic drugs (AED)[49]. The use of prophylaxis is often based on individual preference of the treating physician rather than supporting clinical evidence[45]. No significant benefit has been shown with anticonvulsant prophylaxis using phenobarbital, phenytoin, or valproic acid in patients who had no history of seizures[45]. In addition to the lack of efficacy, the risk of potential side effects has been shown to be increased in patients with brain tumors[53]. Overall, almost 25 percent of patients diagnosed with either a primary or metastatic brain tumor and are taking AEDs experience side effects severe enough to warrant a change in or discontinuation of therapy [53]. Thus, it is recommended that prophylactic anticonvulsants should not be routinely used in patients with newly diagnosed brain tumors[53]. However, because there is a high risk of recurrence, long-term treatment with AEDs is indicated after a patient with melanoma metastases to the brain has suffered their first seizure[51]. Phenytoin has historically been the mainstay of anticonvulsant therapy because it is generally effective and well tolerated. Selection of the particular AEDs to administer requires careful consideration of the treatment the patient is receiving. This is because important interactions can occur with other drugs commonly used in treatment for brain metastases, such as antineoplastic agents and dexamethasone, often from activation of hepatic metabolism through the cytochrome P450 enzyme system[49]. Newer AEDs, including levetiracetam and topiramate, typically do not affect cytochrome P450 and have shown greater reduced seizure frequency and fewer side effects[54].
\n\t\t\t\t
Anticonvulsant prophylaxis after supratentorial surgery is generally recommended for patients, including those undergoing resection of brain metastases. AEDs have been shown to be beneficial in preventing early seizures postoperatively[45]. However, there is not strong evidence to support the use of long-term treatment to reduce the incidence of late seizures after supratentorial surgery. Thus, in those patients with brain metastases from melanoma who have not had a seizure, the recommended plan for antiepileptic therapy is to gradually taper and discontinue AEDs after the first postoperative week. This is especially appropriate for patients who are medically stable and are experiencing notable side effects from their anticonvulsant medication[53].
\n\t\t\t
\n\t\t\t
\n\t\t\t\t
8.3. Anticoagulants
\n\t\t\t\t
Patients with any systemic cancer are known to be in a hypercoagulable state, increasing their risk for deep venous thrombosis (DVTs) and venous thromboembolisms (VTEs). This is especially true for brain metastases for which thromboembolic disease contributes significantly to morbidity and mortality[55]. The risk is often greatest in hemiplegic patients and in the postoperative period since patients are often immobile. In order to prevent DVTs and VTEs from occurring after craniotomy, adequate prophylaxis is often necessary. However, this can be difficult due to the possibility of intratumoral hemorrhage and intracranial bleeding with anticoagulation therapy. Current methods of prophylaxis include mechanical and/or pharmacological interventions, however no optimal one has been identified and current recommendations remain controversial[56]. Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are the main pharmacological anticoagulants which inhibit formation of thrombi. Mechanical methods attempt to minimize venous stasis and enhance fibrinolysis. This includes early ambulation, compression stocking, intermittent external pneumatic compression devices, and electrical calf muscle stimulation. In general, both approaches are effective in preventing DVTs and VTEs[57], but heparin may be more effective although at a greater risk of intracranial hemorrhage[45]. Mechanical prophylaxis with concomitant anticoagulation therapy during the postoperative period is not only safe but also protects patients more so than either approach does alone[57].
\n\t\t\t\t
In patients that have developed a DVT, treatment is necessary to prevent a pulmonary embolism (PE), restore lower limb circulation, and resolve other associated problems. Pharmacological treatment with UFH and LMWH are the mainstays of therapy, with LMWH showing better outcomes including fewer bleeding complications. Patients who have strict contraindications against anticoagulation can be treated with placement of an inferior vena cava (IVC) filter[49]. However, these should generally not be the first line of treatment because it has a higher complication rate and are less effective in prevent PE in comparison to anticoagulation. One retrospective study of IVC filter complications occurring in patients with brain tumors and DVT found that there was a complication rate of 62 percent and PE still occurred in 12 percent of cases despite proper placement of the IVC filter[58]. Thus, IVC filters should be reserved for patients that have had recent craniotomy, are at increased risk for intracranial hemorrhage, are poorly compliant with medications, or will have prolonged thrombocytopenia from chemotherapy.
\n\t\t\t
\n\t\t
\n\t\t
\n\t\t\t
9. Definitive treatment
\n\t\t\t
After receiving supportive measures, patients diagnosed with melanoma that has metastasized to the central nervous system must be evaluated for the possibility and type of definitive treatment. Current options available to physicians include whole brain radiation therapy (WBRT), stereotactic surgery, conventional surgical resection, or chemotherapy. These can frequently be used alone or in combination with one other. However, for the majority of patients, these are largely palliative measures. Determining the optimal modality is dependent on a number of factors including the size, number, location, and sensitivity of the lesion, the overall status of the malignant melanoma, the neurological status as measured by the Karnofsky Performance Scale (KPS), general condition of the patient, and the preferences of the patient and his or her family. It can thus be difficult to decide on a course of treatment given the number of issues that need to be considered.
\n\t\t\t
\n\t\t\t\t
9.1. Whole brain radiation therapy
\n\t\t\t\t
The first use of external beam WBRT for treatment of brain metastases was reported in 1954 by Chao et al[59] and again later in 1961 by Chu et al[60]. It has since become an important treatment modality for brain metastases. One of the fundamental benefits of WBRT is that it is a noninvasive means in which to treat the entire brain and provide palliation of symptoms. Thus, it allows for relatively simple targeting of any and all lesions in the brain with radiation including microscopic ones, micrometastases, which are not detected on neuroimaging. This has been demonstrated in studies which showed that prophylactic and postoperative irradiation of the brain decreases subsequent development of intracranial metastases. This effect is most likely due to elimination of micrometastases that were present at the time[61, 62]. External WBRT is thus advantageous and typically considered the mainstay of treatment for most patients with multiple metastatic deposits from melanoma in the brain[38, 63, 64]. More localized treatment modalities would be less beneficial in such situations because it would require targeting of each lesion individually. However, solitary metastases that are too large for either surgical resection or stereotactic surgery or those that impinge on sensitive areas of the brain are often treated with WBRT[63, 65].
\n\t\t\t\t
The broad application of radiation to the brain can also be an important disadvantage. This is because it not only affects the malignant tissue, but the normal tissue is also exposed to the harmful effects of ionizing radiation. Side effects are typically dependent on the total dosage, dosing interval, and fraction size. Acute side effects of external WBRT include memory loss, fatigue, headaches, temporary hair loss, scalp rash or desquamation, hyperpigmentation, otitis media, and cerebral edema[63, 66]. Somnolence syndrome is a set of symptoms, often seen in children, involving lethargy, anorexia, and irritability that present 1 to 4 months after treatment. There are generally no focal neurological deficits with this syndrome[66-68]. If the patient survives long-term, late side effects may occur which include cerebral edema, atrophy, focal radiation necrosis, white matter demyelination, leukoencephalopathy, endocrinopathy, and progressive cognitive dysfunction[69-71]. A recent randomized controlled trial found that patients suffered significantly greater decline in learning and memory functions after receiving WBRT compared to patients only receiving stereotactic radiosurgery[72]. These consequences should be considered if the patient has the potential to survive for a prolonged amount of time following radiation treatment. Another issue that is important when considering external WBRT for treatment of metastatic melanoma to the brain is the significant resistance melanoma has to this mode of radiation therapy. Of all the primary tumor types, malignant melanoma is considered to be one of the most radioresistant to WBRT[73]. Larger fractions may be necessary in order to achieve desired effect, increasing the likelihood for negative side effects[74]. However, because there are few other effective modalities for treatment of multiple metastases in the brain, it is still commonly used in these patients.
\n\t\t\t\t
The Radiation Therapy Oncology Group (RTOG) conducted several extensive phase III randomized trials to evaluate the efficacy of various treatment schedules. The results of which indicated that 30 Gy administered in 10 fractions of 3 Gy over a period of 2 weeks results in palliative results and survival time equivalent to more protracted and higher-dose schedules[75, 76]. This has since become the most commonly used external WBRT schedule in the United States for brain metastases in general. Although this is often inadequate for long-term tumor control except in the most radiosensitive histologies, it allows for minimization of toxicity and negative side effects of irradiation. The median survival after administration of WBRT to patients with brain metastases is typically improved to about 3 to 6 months but is dependent on the number of lesions, the radiosensitivity of the metastases, and the status of the underlying cancer. Despite its known general resistance to radiation therapy, studies have shown local tumor response of melanoma metastases to the brain after administration of WBRT[77, 78]. Many fractionation schemes have been devised with larger doses per fraction in an attempt to enhance this tumor response. However, a review of several retrospective series has revealed that no scheme is better than the current standard of 30 Gy in 10 fractions[38]. Improved clinical outcomes may occur after WBRT, showing mildly increased median survival times to about 2.0 to 6.1 months[79-82]. When patients are stratified according to the RTOG recursive partitioning analysis (RPA), the effect of WBRT can be better extrapolated. The RPA separates patients into three prognostic groups according to their KPS, extracranial disease, and patient age. Those in RPA class 1 frequently have the best prognosis due to younger age (<65 years) and higher KPS scores (>70) whereas RPA class 3 often have the worst prognosis due to lower KPS scores (<70). The survival times after WBRT expectedly correlate with RPA class. Those with brain metastases originating from melanoma had median survival times of about 7.1 to 10.5 for patients in class 1, 4.2 to 5.9 for patients in class 2, and 1.8 to 2.3 for patients in class 3[82, 83].
\n\t\t\t\t
Despite only having minimal effects on the survival time, using external WBRT and supportive management in patients with metastatic melanoma of the brain has demonstrated palliation of symptoms[79]. Symptomatic improvement is an important effect that can enhance the quality of life given the bleak prognosis despite all treatment modalities. Patients often have improvement of headaches, weakness, and mental status. There are some who question its ability to reverse neurological symptoms and suggest omitting WRBT melanoma metastases are fewer than four[72]. However, WBRT still currently remains the mainstay of treatment for patients with multiple brain metastases but is not typically first-line in solitary metastases [65]. It is a viable adjuvant therapy in addition to serving as an option for primary therapy. In cases of single brain metastases, surgical resection or stereotactic radiosurgery are usually the preferable option for primary therapy unless both are contraindicated. Patients that additionally have advanced systemic disease or conditions that preclude surgery or radiosurgery in addition to a solitary lesion would likely be better suited for WBRT.
\n\t\t\t
\n\t\t\t
\n\t\t\t\t
9.2. Surgical resection
\n\t\t\t\t
Surgical resection was first reported for use in the treatment of brain metastases in 1926 by Grant[84]. As noted earlier, metastatic brain tumors characteristically form well-circumscribed and rounded masses at the junction of the gray and white matter. This renders them highly amenable to surgical resection. Additionally, with modern neurosurgical techniques and the available new technologies such as functional mapping, intraoperative ultrasonography, and computer assisted stereotaxy, surgical resection can be accomplished with increased precision and control. It has become a mainstay of treatment despite the development of newer methods including WBRT or stereotactic radiosurgery. This is because it offers several advantages over both. Surgery (Figure 1) provides immediate palliative action and relief of symptoms with removal of the lesion, which decreases the intracranial pressure, alleviates compression and mass effect on the surrounding parenchyma, prevents or stops hemorrhage and edema into the intracranial space, and restores CSF flow if obstruction has occurred. No other treatment modality can provide this immediate effect which is critical in emergent situations such as impending herniation or posterior fossa tumors. Removal of the tumor with surgical resection additionally provides diagnostic advantages. It is the only modality that allows for physical extraction of the mass in order to determine a histological and pathological diagnosis. This is important in patients in which the etiology of the lesion is uncertain or the primary cancer has not been identified. Studies have demonstrated that up to approximately 11 percent of suspected cranial metastases are actually found to be nonmetastatic lesions, such as cerebral abscesses or primary tumors, on pathological evaluation[85]. Surgical resection also avoids some of the prominent drawbacks of WBRT, most notably the resistance of melanoma metastases to radiation therapy and the negative effects of diffuse radiation on normal neurological tissue. Instead, it circumvents the use of radiation and surgically localizes the area of the metastases, minimizing damage to the rest of the unaffected brain parenchyma and avoiding the acute and long-term side effects depicted in WBRT. Surgical resection is thus most advantageous for solitary or a limited number of metastases to brain where diffuse involvement does not occur. However, there is still significant morbidity and mortality associated with surgical resection given its invasive nature. These risks continue to gradually improve with the advancement of available procedures and tools, as was seen with the utilization of CT and MRI neuroimaging. Several recent studies have shown the risk of mortality to be between 0 to 14.2 percent during the postoperative period [14, 18, 86, 87] which is compared to earlier reports of mortality in up to 22 percent of patients[87].
\n\t\t\t\t
Given the limited survival time of patients harboring metastatic melanoma of the brain, postoperative neurological deficits and prolonged recovery times are best avoided if possible. Patient selection is important in minimizing poor outcomes and maximizing the response to treatment. In general, surgical resection is most appropriate for patients with a
\n\t\t\t\t
Figure 1.
Representative patient with intracranial metastatic melanoma who underwent surgical resection. A, pre-operative contrast-enhanced axial and B, coronal T1 magnetic resonance image (MRI) demonstrating left frontal metastasis with intratumoral hemorrhage. C, post-operative contrast-enhanced axial and D, coronal T1 MRI demonstrating gross total resection of the metastasis.
\n\t\t\t\t
single brain metastasis, limited systemic disease, and favorable KPS score (>70). Metastases greater than 3 cm in diameter should be preferentially treated with surgery because large tumors typically have minimal response to the other modalities[88]. Selection of patients with multiple metastases to the brain remains somewhat controversial. Several retrospective studies have examined the efficacy of surgical resection alone in the treatment of brain metastases from melanoma. It is clear that surgical resection of a single melanoma metastases greater extends the survival time in comparison WBRT alone or supportive therapy alone. In these studies, the median survival time after surgery varies between 5 and 22 months with the more recent ones showing a median survival time between 8 and 16 months[87-89]. In contrast to solitary metastasis, the role of surgical intervention in cases of multiple brain metastases remains controversial due to lack of randomized control trials[63]. Previously, this was typically a contraindication, but one retrospective study challenged this notion. Bindel et al[90] compared patients with single and multiple brain metastases that were treated with surgical resection. Patients that underwent partial resection of multiple metastases, complete resection of multiple metastases, and resection of a single metastasis all had similar rates of surgical morbidity and mortality of approximately 8 to 9 percent and 0 to 4 percent, respectively. However, those patients that underwent only a partial resection demonstrated a median survival time of about 6 months, whereas those that were treated with complete resection were found to have a longer median survival time of about 14 months. This provided evidence that total surgical resection of multiple metastases was comparable to resection of a solitary metastasis in efficacy. Several ensuing studies showed similar support for the use of surgical resection in the presence of multiple metastases[91, 92]. Thus, surgical resection of multiple metastases can be supported, although the general recommendation limits the number to less than 3 lesions in patients that have limited or controlled systemic disease.
\n\t\t\t\t
A regimen that has been frequently discussed in the treatment of brain metastases is the combination of surgery plus external WBRT. Several studies have been conducted to compare the value of surgical resection followed by WBRT to that of either modality alone. Patchell et al[85] and Vecht et al[93] both demonstrated that those patients who were treated with the combination regimen had longer median survival times that those patients who received only WBRT. In contrast, Mintz et al[94] found that there was no survival advantage or improved quality of life with the administration of WBRT after surgery. This finding may be due to the overall lower patient performance status and greater prevalence of patients with more severe extracranial disease in their study. Patchell et al[85] actually demonstrated that patients with active systemic disease had a poorer prognosis when treated with surgical resection and WBRT. Studies comparing surgery alone with the adjunctive WBRT have also shown mixed results. Dosoretz et al[95] found that WBRT at a total dose of 30 Gy showed no survival advantages after surgical resection of a solitary metastasis. DeAngelis et al[70] and Hagen et al[96] also reported no effect on survival time, but noted WBRT postoperatively may reduce the risk of recurrence and thus recommend its use in patients after surgical resection for a single metastasis. Patchell et al has also further investigated the advantages of this combination regimen. In this prospective trial, patients were randomized to treatment with external WBRT or observation after surgery for a solitary brain metastasis. The results showed that patients who received the WBRT postoperatively had improved tumor control as seen by lower recurrence of metastases anywhere in the brain as well as at the site of resection. As with DeAngelis et al[70] and Hagen et al[96], this trial did not demonstrate prolonged survival time in patients receiving the adjunctive WBRT and did not slow the functional decline of patients, as measured by their KPS scores. Other studies have specifically addressed its use in melanoma metastases and have shown similar nonsignificant affect on prolonging survival times.
\n\t\t\t
\n\t\t\t
\n\t\t\t\t
9.3. Stereotactic radiosurgery
\n\t\t\t\t
Stereotactic surgery (SRS), also known as Gamma Knife, was first introduced in 1951 by Leksell[97]. Since then, it has developed into a sophisticated system that has the ability to accurately target an intracranial lesion and administer focal, collimated beams of ionizing radiation produced from a linear accelerator (linacs) or cobalt-60 sources. The radiation dose is administered in a single fraction via numerous crossfiring of beams of radiation that converge onto the targeted sight. The crossfiring of these beams from numerous directions allows for rapid radiation falloff in the surrounding tissue and thus minimize extraneous exposure. The advantage of SRS lies in its ability to administer localized treatment while sparing the rest of the normal brain parenchyma from the diffuse irradiation that occurs in WBRT. Moreover, the mechanism of action of SRS is thought to be different than WBRT and may instead affect the tumor vasculature, which would increase its effectiveness against the typically radioresistant cancers including malignant melanoma[98]. The advantage of SRS (Figure 2) over surgical resection is attributed to its ability to reach small, deep metastases in the brain without significant disruption to the rest of the brain parenchyma. Thus, it avoids the prolonged recovery time, increased length of hospital stay, and high costs that occur with an invasive surgery and instead only requires the administration of a single-fraction of radiation. Although it generally avoids these immediate side effects of surgical resection, delayed complications from SRS can occur which typically resemble other radiation-induced side effects such as radiation necrosis. This occurs in less than 10 percent of patients and is dependent on the volume treated and dose administered.
\n\t\t\t\t
Figure 2.
Representative patient with intracranial metastatic melanoma who underwent stereotactic radiosurgery. A, pre-radiation contrast-enhanced axial T1 magnetic resonance image (MRI) demonstrating right occipital lobe metastatic melanoma. B, post-radiation contrast-enhanced axial T1 MRI.
\n\t\t\t\t
There are a few disadvantages of SRS in comparison to the other treatment modalities. In comparison to surgery, its minimally invasive approach cannot provide immediate treatment effects which are often important in critical or life-threatening situations such as impending herniation. The inability to remove metastases also prevents a definitive histological diagnosis, and given the chance a suspected cranial metastases may actually be a nonmetastatic lesions, pathological diagnosis can be of great importance[85]. Also, increased risks in treating large metastases have hindered its use for those tumors that are larger than 3 cm in diameter. This is due to the limited conformity that can be achieved for large tumors, resulting in decreased response with increasing tumor size and increased radiation doses to the surrounding brain parenchyma[99]. Mehta et al[100] noted that tumors less than 2 cm3 in volume showed a total response rate of 78 percent whereas as tumors greater than 10 cm3 in volume demonstrated a total response rate less than 50 percent. Thus, SRS is typically recommended for patients with lesions less than 3 cm on neuroimaging, patients with lesions that are surgically inaccessible, patients that are asymptomatic, or patients that cannot tolerate surgery.
\n\t\t\t\t
Multiple studies examining the efficacy of SRS have shown generally positive results. For all types of metastatic histologies, the local control rate after treatment with SRS ranges between 85 and 90 percent at one year[101-103]. For metastatic melanoma to the brain, the local control rate was shown to be approximately 90 to 97 percent[103-105]. Clinically, stabilization or improvement of neurological symptoms after treatment was noted in about 78 to 100 percent of patients[104, 106]. Patients also demonstrated a median survival time comparable to that of surgical resection which was found to be about 5 to 14 months[106-110]. However, as with the other treatment modalities, patient factors and selection affects outcome. Those with minimal extracranial disease typically fared better than their counterparts more extrcranial disease. This is also true for patients with overall better performance status, as measured by the KPS, compared to those with lower performance status. Patients with solitary brain lesions additionally demonstrated longer survival times than those patients with multiple brain lesions. However, an increased number of metastases should not be a reason to withhold SRS treatment[106-110].
\n\t\t\t\t
Combination therapy has been studied and utilized in the treatment of metastatic melanoma to the brain. A landmark RTOG-sponsored study[111] compared the treatment of brain metastases using WBRT alone and SRS plus WBRT. Patients were first stratified according to the number of brain metastases and the extent of their extracranial disease and then randomized to treatment with WBRT only and SRS plus WBRT. There was a significant survival advantage for those harboring a solitary lesion treated with the combination therapy. There was no survival advantage for patients with multiple metastases treated with the combination approach. However, patients treated with WBRT and SRS were more likely to have improved or stable performance status and also decreased need for steroid use after therapy. There was no difference in mental status change and no increase in toxicity with the SRS and WBRT administration. The authors thus concluded that the combination approach of SRS plus WBRT should be the standard treatment for patients with a single unresectable brain metastasis. For patients with two to three bran metastases, despite the survival advantage the combination treatment should be considered because it results in improvement in the overall performance status.
\n\t\t\t\t
To date, there are no prospective, randomized control trials comparing SRS with surgical resection. However, a few retrospective studies have provided insight into a comparison between the two treatment modalities. Auchter et al[112] designed a multi-institutional retrospective analysis comparing the outcome of patients treated with surgery and SRS and found no difference in the overall survival, functional independence, or recurrence rate. O’Neill et al[113] conducted a similar comparison and found no difference in median survival time after treatment with either approach. However, there was a significant difference in local tumor control, with no recurrence occurring after administration of SRS and about 58 percent recurrence after surgical resection. Bindel et al[114] conducted a smaller study in which patients undergoing SRS or surgical resection were matched on the basis of age, sex, primary tumor histology, extent of systemic disease, pretreatment KPS score, time to diagnosis of brain metastases, and number of brain metastases. The results demonstrated an overall survival advantage for surgical resection with a median survival time of 16.4 months compared to 7.5 months in the SRS treated group. Surgical resection also showed superiority to SRS in terms of local recurrence and morbidity. Thus, they favored the use of surgery over SRS for the treatment of solitary brain metastases. Cho et al[115] conducted a more encompassing study analyzing the treatment of solitary brain metastases with WBRT only, surgery plus WBRT, or SRS plus WBRT. The results demonstrated that the actuarial survival time was the same for the combination surgery group and the SRS surgery group, and both had longer survival times than patients receiving WBRT alone. Cho et al thus concluded that SRS is a reasonable and potentially more attractive alternative than surgical resection for single brain metastases. There are still several ongoing trials that include SRS in the treatment plan for brain metastases.
\n\t\t\t
\n\t\t\t
\n\t\t\t\t
9.4. Chemotherapy
\n\t\t\t\t
The use of chemotherapy for the treatment of extracranial melanoma has generally shown a poor response. Thus, it is not surprising that the response of melanoma metastases to the brain is also poor. The effect of cisplatin and etoposide has been shown to have a 0 percent response rate while other common metastatic cancers such as NSCLC and breast carcinoma have shown up to a 39 percent response. A significant obstacle for chemotherapeutic action on intracranial metastases is the BBB which limits the passage of large molecules into the brain parenchyma. Even after penetrating the BBB, some agents are rapidly eliminated and only have a transient effect. Attempts have been made to identify agents that can adequately cross the BBB to have tumorcidal effects. Fotemustine, a nitrosurea with high penetrations, has been shown to have response rates ranging from 12 to 25 percent in phase II European trials but is not available in the United States[116, 117]. Temozolamide, a dacarbazine analogue with high penetration, was approved for use by the FDA for use in primary brain tumors and was found to have a modest response rate of 7 percent for metastatic melanoma[118]. Combination chemotherapy has also been explored for increased effectiveness. A combination regimen of temozolomide and thalidomide, an antiangiogenic agent, has been explored because of its action against the vascularization of the tumor. Although the response was slightly better, this was at the expense of increased toxicity. A combination of chemotherapy and external WBRT is also being actively explored. Mornex et al[119] compared fotemustine alone versus fotemustine and WBRT and found that the response rates and survival times were not significantly different. Similarly, a phase III trial comparing WBRT alone and temozolomide plus WBRT demonstrated improved response rate but no prolonged survival time[120]. In general, current evidence does not support routinely administering chemotherapeutic agents for the treatment of cerebral metastases from melanoma.
\n\t\t\t
\n\t\t\t
\n\t\t\t\t
9.5. Immunotherapy
\n\t\t\t\t
Melanoma is a highly immunogenic tumor and treatment with immunotherapy has been attempted to halt the metastatic process. Predominantly from case studies, the overall response has not been optimal. Traditionally, the diagnosis of brain metastases has been an exclusionary criterion for receiving immunotherapy in patients with melanoma. However, biological response modifiers (BRMs) and cellular immunotherapy have been able to induce infrequent responses from brain metastases. One case report noted the near complete response in a patient with brain metastases after a treatment regimen of interleukin-2 (IL-2), interferon (IFN), and 5-fluorouracil[121]. Anecdotal cases of partial or complete responses have also been reported after ipilimumab therapy for metastatic melanoma to the brain which was treated earlier by surgery or SRS[122]. Another case report identified a patient with brain metastasis refractory to IL-2 and chemotherapy was responsive to lymphodepletion followed by infusion with autologous MART-reactive tumor infiltrating lymphocytes (TILs) and high doses of IL-2[123]. Hong et al[124] investigated the response rate and response duration of melanoma brain metastases to adoptive cell therapy (ACT) with autologous antitumor lymphocytes plus IL-2 following a lymphodepleting preparative regimen. They found that greater than 50 percent of patients had complete or partial response to the treatment regimen with rare occurrence of negative side effects. Majer et al[125] conducted a study of 70 patients with or without brain metastases treated with temozolomide or DTIC plus the BRMs IL-2 and IFN-α 2B. They demonstrated that patients with brain metastases who were treated previously with SRS had a prolonged median survival time of 15.8 months versus 11.1 months in patients without brain involvement. Overall, there have been limited studies and trials into the use of immunotherapy and additional investigation into its efficacy is needed.
\n\t\t\t
\n\t\t
\n\t\t
\n\t\t\t
10. Conclusions
\n\t\t\t
Metastasis to the brain is a devastating and common consequence for patients with malignant melanoma. A significant number of patients with melanoma eventually develop brain metastasis at the time of death. Current treatment options typically include surgery and radiation therapy for brain metastases but the number of options is increasing. Prolonged survival depends on prompt diagnosis and treatment for patients harboring these lesions.
\n\t\t
\n\t\n',keywords:null,chapterPDFUrl:"https://cdn.intechopen.com/pdfs/21337.pdf",chapterXML:"https://mts.intechopen.com/source/xml/21337.xml",downloadPdfUrl:"/chapter/pdf-download/21337",previewPdfUrl:"/chapter/pdf-preview/21337",totalDownloads:11154,totalViews:557,totalCrossrefCites:0,totalDimensionsCites:4,totalAltmetricsMentions:0,impactScore:3,impactScorePercentile:86,impactScoreQuartile:4,hasAltmetrics:0,dateSubmitted:"November 8th 2010",dateReviewed:"April 26th 2011",datePrePublished:null,datePublished:"October 5th 2011",dateFinished:null,readingETA:"0",abstract:null,reviewType:"peer-reviewed",bibtexUrl:"/chapter/bibtex/21337",risUrl:"/chapter/ris/21337",book:{id:"523",slug:"treatment-of-metastatic-melanoma"},signatures:"Khan K. Chaichana and Kaisorn L. Chaichana",authors:[{id:"38678",title:"Prof.",name:"Kaisorn",middleName:null,surname:"Chaichana",fullName:"Kaisorn Chaichana",slug:"kaisorn-chaichana",email:"kchaich1@jhmi.edu",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:null},{id:"135687",title:"Prof.",name:"Khan",middleName:null,surname:"Chaichana",fullName:"Khan Chaichana",slug:"khan-chaichana",email:"khan_chaichana@intechweb.com",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:{name:"Johns Hopkins University School of Medicine",institutionURL:null,country:{name:"United States of America"}}}],sections:[{id:"sec_1",title:"1. Introduction",level:"1"},{id:"sec_2",title:"2. Epidemiology and demographics",level:"1"},{id:"sec_3",title:"3. Pathophysiology",level:"1"},{id:"sec_4",title:"4. Pathology ",level:"1"},{id:"sec_5",title:"5. Clinical findings",level:"1"},{id:"sec_6",title:"6. Diagnosis",level:"1"},{id:"sec_7",title:"7. Survival",level:"1"},{id:"sec_8",title:"8. Supportive therapy",level:"1"},{id:"sec_8_2",title:"8.1. Steroids ",level:"2"},{id:"sec_9_2",title:"8.2. Antiepileptics",level:"2"},{id:"sec_10_2",title:"8.3. Anticoagulants",level:"2"},{id:"sec_12",title:"9. Definitive treatment",level:"1"},{id:"sec_12_2",title:"9.1. Whole brain radiation therapy",level:"2"},{id:"sec_13_2",title:"9.2. Surgical resection",level:"2"},{id:"sec_14_2",title:"9.3. Stereotactic radiosurgery",level:"2"},{id:"sec_15_2",title:"9.4. Chemotherapy",level:"2"},{id:"sec_16_2",title:"9.5. Immunotherapy",level:"2"},{id:"sec_18",title:"10. Conclusions",level:"1"}],chapterReferences:[{id:"B1",body:'\n\t\t\t\t\n\t\t\t\t\tBarnholtz-Sloan, J.S., et al., Incidence Proportions of Brain Metastases in Patients Diagnosed\n\t\t\t\t\t1973t to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol, 2004. 22(14): 2865\n\t\t\t\t\t2872.\n\t\t\t'},{id:"B2",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tGavrilovic\n\t\t\t\t\t\t\tI. T.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPosner\n\t\t\t\t\t\t\tJ. B.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBrain\n\t\t\t\t\t\t\tmetastases.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tepidemiology\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tpathophysiology\n\t\t\t\t\t\t\tJ.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tNeuroonc\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2005 75(1): 5\n\t\t\t\t\t14.\n\t\t\t'},{id:"B3",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tJohnson\n\t\t\t\t\t\t\tJ. D.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tYoung\n\t\t\t\t\t\t\tB.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tDemographics\n\t\t\t\t\t\t\tof.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tbrain\n\t\t\t\t\t\t\tmetastasis.\n\t\t\t\t\t\t\n\t\t\t\t\t Neurosurg Clin N Am, 1996 7(3): 337\n\t\t\t\t\t344.\n\t\t\t'},{id:"B4",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSuki\n\t\t\t\t\t\t\tD.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tThe\n\t\t\t\t\t\t\tepidemiology.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tof\n\t\t\t\t\t\t\tbrain.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmetastasis\n\t\t\t\t\t\t\tin.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tIntracranial\n\t\t\t\t\t\t\tMetastases.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tcurrent\n\t\t\t\t\t\t\tmanagement.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tstrategies\n\t\t\t\t\t\t\tR.\n\t\t\t\t\t\t\n\t\t\t\t\t Sawaya, Editor. 2004 Wiley-Blackwell: Malden, MA. 20\n\t\t\t\t\t34.\n\t\t\t'},{id:"B5",body:'\n\t\t\t\t\n\t\t\t\t\tCoit, D.G., Role of surgery for metastatic malignant melanoma: a review. Semin Surg Oncol, 1993 9(3): 239\n\t\t\t\t\t245.\n\t\t\t'},{id:"B6",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tEwend\n\t\t\t\t\t\t\tM. G.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCarey\n\t\t\t\t\t\t\tL. A.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBrem\n\t\t\t\t\t\t\tH.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tTreatment\n\t\t\t\t\t\t\tof.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmelanoma\n\t\t\t\t\t\t\tmetastases.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tin\n\t\t\t\t\t\t\tthe.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tbrain\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t Semin Surg Oncol, 1996 12(6): 429\n\t\t\t\t\t435.\n\t\t\t'},{id:"B7",body:'\n\t\t\t\t\n\t\t\t\t\tFidler, I.J., et al., The biology of melanoma brain metastasis. Cancer Metastasis Rev, 1999 18(3): 387\n\t\t\t\t\t400.\n\t\t\t'},{id:"B8",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tAhmedin\n\t\t\t\t\t\t\tJ.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCancer\n\t\t\t\t\t\t\tstatistics.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2010 CA Cancer J Clin, 2010. 60(5): 277\n\t\t\t\t\t300.\n\t\t\t'},{id:"B9",body:'\n\t\t\t\t\n\t\t\t\t\tChason, J.L., F.B. Walker, and J.B. Landers, Metastatic carcinoma in the central nervous system and dorsal root ganglia. Cancer, 1963 16(6): 781\n\t\t\t\t\t787.\n\t\t\t'},{id:"B10",body:'\n\t\t\t\t\n\t\t\t\t\tdel la Monte, S., G.W. Moore, and G.M. Hutchins, Patterned distribution of metastses from malignant melanoma in humans. Cancer Res, 1983 43(7): 3427\n\t\t\t\t\t3433.\n\t\t\t'},{id:"B11",body:'\n\t\t\t\t\n\t\t\t\t\tPatel, K.J., et al., Metastatic pattern\n\t\t\t\t\t216 malignant melanome: a study of 216 autopsy cases. Am J Surg, 1978. 135(6): 807\n\t\t\t\t\t810.\n\t\t\t'},{id:"B12",body:'\n\t\t\t\t\n\t\t\t\t\tSkibber, J.M., et al., Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol, 1996 3(2): 118\n\t\t\t\t\t123.\n\t\t\t'},{id:"B13",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBryne\n\t\t\t\t\t\t\tT. N.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCascino\n\t\t\t\t\t\t\tT. L.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPosner\n\t\t\t\t\t\t\tJ. B.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBrain\n\t\t\t\t\t\t\tmetastasis.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tfrom\n\t\t\t\t\t\t\tmelanoma.\n\t\t\t\t\t\t\n\t\t\t\t\t J.B. Posner, Brain metastasis from melanoma. J Neuroonc, 1983 1(4): 313\n\t\t\t\t\t317.\n\t\t\t'},{id:"B14",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSampson\n\t\t\t\t\t\t\tJ. H.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tDemographics\n\t\t\t\t\t\t\tprognosis.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\ttherapy\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t702 702 patients with brain metastases from malignant melanoma. J Neurosurg, 1998. 1998(88): 1\n\t\t\t\t\n\t\t\t'},{id:"B15",body:'\n\t\t\t\t\n\t\t\t\t\tDaryanani, D., et al., Increased incidence of brain metastases in cutaneous head and neck melanoma. Melanoma Res, 2005 15(2): 119\n\t\t\t\t\t124.\n\t\t\t'},{id:"B16",body:'\n\t\t\t\t\n\t\t\t\t\tBallo, M.T., et al., Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys, 2006 64(1): 106\n\t\t\t\t\t113.\n\t\t\t'},{id:"B17",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tStevens\n\t\t\t\t\t\t\tG.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tFirth\n\t\t\t\t\t\t\tI.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCoates\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCerebral\n\t\t\t\t\t\t\tmetastases.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tfrom\n\t\t\t\t\t\t\tmalignant.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmelanoma\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t Radiother Oncol, 1992 23(3): 185\n\t\t\t\t\t191.\n\t\t\t'},{id:"B18",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tWronski\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tArbit\n\t\t\t\t\t\t\tE.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSurgical\n\t\t\t\t\t\t\ttreatment.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tof\n\t\t\t\t\t\t\tbrain.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmetastases\n\t\t\t\t\t\t\tfrom.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmelanoma\n\t\t\t\t\t\t\ta.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tretrospective\n\t\t\t\t\t\t\tstudy.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t91 brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg, 2000. 93(1): 9\n\t\t\t\t\t18.\n\t\t\t'},{id:"B19",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tChoi\n\t\t\t\t\t\t\tK. N.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tWithers\n\t\t\t\t\t\t\tH. R.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tRotman\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tIntracranial\n\t\t\t\t\t\t\tmetastases.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tfrom\n\t\t\t\t\t\t\tmelanoma.\n\t\t\t\t\t\t\n\t\t\t\t\t Cancer, 1985 56(1): 1\n\t\t\t\t\t9.\n\t\t\t'},{id:"B20",body:'\n\t\t\t\t\n\t\t\t\t\tFidler, I.J., The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer, 2003 3(6): 453\n\t\t\t\t\t458.\n\t\t\t'},{id:"B21",body:'\n\t\t\t\t\n\t\t\t\t\tNicolson, G.L., Cancer metastasis: tumor cell and host organ properties important in metastasis to specific secondary sites. Biochem Biophys Acta, 1988 948(2): 175\n\t\t\t\t\t224.\n\t\t\t'},{id:"B22",body:'\n\t\t\t\t\n\t\t\t\t\tNicolson, G.L., Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev, 1988 7(2): 143\n\t\t\t\t\t188.\n\t\t\t'},{id:"B23",body:'\n\t\t\t\t\n\t\t\t\t\tLiotta, L.A., P.S. Steeg, and W.G. Stetler-Stevenson, Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 1991 64(2): 327\n\t\t\t\t\t336.\n\t\t\t'},{id:"B24",body:'\n\t\t\t\t\n\t\t\t\t\tYung, W.K.A., et al., Intracranial metastases, in Cancer in the Nervous System, V.A. Levin, Editor. 2002 Oxford University Press: New York. 321\n\t\t\t\t\t340.\n\t\t\t'},{id:"B25",body:'\n\t\t\t\t\n\t\t\t\t\tShapiro, W.R. and J.R. Shapiro, Principles of brain tumor chemotherapy. Semin Oncol, 1986 13(1): 56\n\t\t\t\t\t69.\n\t\t\t'},{id:"B26",body:'\n\t\t\t\t\n\t\t\t\t\tStewart, P.A., et al., Quantative study of microvessel ultrastructure in human peritumoral brain tissue. Evidence for a blood-brain barrier defect. J Neurosurg, 1987 67(5): 697\n\t\t\t\t\t705.\n\t\t\t'},{id:"B27",body:'\n\t\t\t\t\n\t\t\t\t\tLoeffler, J.S., et al., The treatment of recurrent brain metastases with stereotactic radiosurgery. J Clin Oncol, 1990 8(4): 576\n\t\t\t\t\t582.\n\t\t\t'},{id:"B28",body:'\n\t\t\t\t\n\t\t\t\t\tGraus, F., L.R. Rogers, and J.B. Posner, Cerebrovascular complications in patients with cancer. Medicine, 1985 64(1): 16\n\t\t\t\t\t35.\n\t\t\t'},{id:"B29",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBrega\n\t\t\t\t\t\t\tK.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSurgical\n\t\t\t\t\t\t\ttreatment.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tof\n\t\t\t\t\t\t\tbrain.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmetastases\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t Cancer, 1990 66(10): 2105\n\t\t\t\t\t2110.\n\t\t\t'},{id:"B30",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSchellinger\n\t\t\t\t\t\t\tP. D.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMeinck\n\t\t\t\t\t\t\tH. M.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tThron\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tDiagnostic\n\t\t\t\t\t\t\taccuracy.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tof\n\t\t\t\t\t\t\tM. R. I.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tcompared\n\t\t\t\t\t\t\tto. C. C. T.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tin\n\t\t\t\t\t\t\tpatients.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\twith\n\t\t\t\t\t\t\tbrain.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmetastases\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t J Neuroonc, 1999 44(3): 275\n\t\t\t\t\t281.\n\t\t\t'},{id:"B31",body:'\n\t\t\t\t\n\t\t\t\t\tSze, G., et al., Detection fo brain metastases: comparison of contrast-enhanced MR with unenhanced MR and enhanced CT. AJNR Am J Neuroradiol, 1990 11(4): 785\n\t\t\t\t\t791.\n\t\t\t'},{id:"B32",body:'\n\t\t\t\t\n\t\t\t\t\tTyler, D.S., et al., Positiron emission tomography scanning in malignant melanoma. Cancer, 2000 89(5): 1019\n\t\t\t\t\t1025.\n\t\t\t'},{id:"B33",body:'\n\t\t\t\t\n\t\t\t\t\tDewulf, P., et al., Cerebral metastatic malignant melanoma: CT and MR findings with pathological correlation. J Belge Radiol, 1993 76(5): 318\n\t\t\t\t\t319.\n\t\t\t'},{id:"B34",body:'\n\t\t\t\t\n\t\t\t\t\tIsiklar, I., et al., Intracranial metastatic melanoma: correlation between MR imaging characteristics and melanin content. AJR, 1995 165(6): 1503\n\t\t\t\t\t1512.\n\t\t\t'},{id:"B35",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tWoodruff\n\t\t\t\t\t\t\tW. W.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tIntracerebral\n\t\t\t\t\t\t\tmalignant.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmelanom\n\t\t\t\t\t\t\thigh-field-strength. M. R.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\timaging\n\t\t\t\t\t\t\tRadiology.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t1987 165(1): 209\n\t\t\t\t\t213.\n\t\t\t'},{id:"B36",body:'\n\t\t\t\t\n\t\t\t\t\tDavis, P.C., et al., Diagnosis of cerebral metastases: double-dose delated CT vs contrast-enhanced MR imaging. AJNR Am J Neuroradiol, 1991 12(2): 292\n\t\t\t\t\t300.\n\t\t\t'},{id:"B37",body:'\n\t\t\t\t\n\t\t\t\t\tMiranda, E.P., et al., Routing imaging of asymptomatic melanoma patients with metastasis to sentinael lymph nodes rarely identifies systemic disease. Arch Surg, 2004 139(8): 831\n\t\t\t\t\t837.\n\t\t\t'},{id:"B38",body:'\n\t\t\t\t\n\t\t\t\t\tMcWilliams, R.R., et al., Treatment of brain metastases from melanoma. Mayo Clin Proc, 2003 78(12): 1529\n\t\t\t\t\t1536.\n\t\t\t'},{id:"B39",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBarth\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tWanek\n\t\t\t\t\t\t\tL. A.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMorton\n\t\t\t\t\t\t\tD. L.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPrognostic\n\t\t\t\t\t\t\tfactors.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t1521 1,521 melanoma patients with distant metastases. J Am Coll Surg, 1995. 181(3): 193\n\t\t\t\t\t201.\n\t\t\t'},{id:"B40",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tDavies\n\t\t\t\t\t\t\tM. A.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2010\n\t\t\t\t\tPrognostic factors for survival in melanoma patients with brain metastases. Cancer.\n\t\t\t'},{id:"B41",body:'\n\t\t\t\t\n\t\t\t\t\tFife, K.M., et al., Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol, 2004 22(7): 1293\n\t\t\t\t\t1300.\n\t\t\t'},{id:"B42",body:'\n\t\t\t\t\n\t\t\t\t\tStaudt, M., et al., Determinant of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer, 2010 102(8): 1213\n\t\t\t\t\t1218.\n\t\t\t'},{id:"B43",body:'\n\t\t\t\t\n\t\t\t\t\tRaizer, J.J., et al., Brain and leptomeningeal metastases from cutanous melanoma: survival outcomes based on clinical features. Neuro Oncol, 2008 10(2): 199\n\t\t\t\t\t207.\n\t\t\t'},{id:"B44",body:'\n\t\t\t\t\n\t\t\t\t\tPapadopoulos, M.C., et al., Molecular mechanisms of brain tumor edema. Neuroscience, 2004 129(4): 1011\n\t\t\t\t\t1020.\n\t\t\t'},{id:"B45",body:'\n\t\t\t\t\n\t\t\t\t\tDrappatz, J., et al., Medical management of brain tumor patients. Neurol Clin, 2007 25(4): 1035\n\t\t\t\t\t1071.\n\t\t\t'},{id:"B46",body:'\n\t\t\t\t\n\t\t\t\t\tKaal, E.C. and C.J. Vecht, The management of brain edema in brain tumors. Curr Opin Oncol, 2004 16(6): 593\n\t\t\t\t\t600.\n\t\t\t'},{id:"B47",body:'\n\t\t\t\t\n\t\t\t\t\tRyken, T.C., et al., The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuroonc, 2010 96(1): 103\n\t\t\t\t\t114.\n\t\t\t'},{id:"B48",body:'\n\t\t\t\t\n\t\t\t\t\tGutin, P.H., Corticosteroid therapy in patients with cerebral tumor: benefits, mechanims, problems, practicalities. Semin Oncol, 1975 2(1): 274\n\t\t\t\t\t281.\n\t\t\t'},{id:"B49",body:'\n\t\t\t\t\n\t\t\t\t\tWen, P.Y., et al., Medical management of patients with brain tumors. J Neuroonc, 2006 80(3): 313\n\t\t\t\t\t332.\n\t\t\t'},{id:"B50",body:'\n\t\t\t\t\n\t\t\t\t\tKoehler, P.J., Use of corticosteroids in neuro-oncology. Anticancer Drugs, 1995 6(1): 19\n\t\t\t\t\t33.\n\t\t\t'},{id:"B51",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tKamar\n\t\t\t\t\t\t\tF. G.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPosner\n\t\t\t\t\t\t\tJ. B.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBrain\n\t\t\t\t\t\t\tmetastases.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSemin\n\t\t\t\t\t\t\tNeurol.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2010 30(3): 217\n\t\t\t\t\t235.\n\t\t\t'},{id:"B52",body:'\n\t\t\t\tLayton, A.J. and A. Gabrielli, Elevated intracranial pressure, in Textbook of neurointensive care, A.J. Layton, A. Gabrielli, and W.A. Friedman, Editors. 2004, Saunders: Philadelphia. p. 709-32.'},{id:"B53",body:'\n\t\t\t\t\n\t\t\t\t\tGlantz, M.J., et al., Practice paramenter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neurology, 2000 54(10): 1886\n\t\t\t\t\t1893.\n\t\t\t'},{id:"B54",body:'\n\t\t\t\t\n\t\t\t\t\tMaschio, M., et al., Antiepileptics in brain metastases: safety, efficacy, and impact on life expectancy. J Neuroonc, 2009 98(1): 109\n\t\t\t\t\t116.\n\t\t\t'},{id:"B55",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSchiff\n\t\t\t\t\t\t\tD.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tDeangelis\n\t\t\t\t\t\t\tL. M.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tTherapy\n\t\t\t\t\t\t\tof.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tvenous\n\t\t\t\t\t\t\tthromboembolism.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tin\n\t\t\t\t\t\t\tpatients.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\twith\n\t\t\t\t\t\t\tbrain.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmetastases\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t Cancer, 1994 73(2): 493\n\t\t\t\t\t498.\n\t\t\t'},{id:"B56",body:'\n\t\t\t\t\n\t\t\t\t\tBrowd, S.R., et al., Prophylaxis for deep venous thrombosis in neurosurgery: a review of the literature. Neurosurg Focus, 2004 17(4): E1\n\t\t\t\t\n\t\t\t'},{id:"B57",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tAuguste\n\t\t\t\t\t\t\tK. I.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tQuinones-Hinojosa\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBerger\n\t\t\t\t\t\t\tM. S.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tEfficacy\n\t\t\t\t\t\t\tof.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmechanical\n\t\t\t\t\t\t\tprophylaxis.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tfor\n\t\t\t\t\t\t\tvenous.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tthromboembolism\n\t\t\t\t\t\t\tin.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tpatients\n\t\t\t\t\t\t\twith.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tbrain\n\t\t\t\t\t\t\ttumors.\n\t\t\t\t\t\t\n\t\t\t\t\t Neurosurg Focus, 2004 17(4): E3\n\t\t\t\t\n\t\t\t'},{id:"B58",body:'\n\t\t\t\t\n\t\t\t\t\tLevin, J.M., et al., Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology, 1993 43(6): 1111\n\t\t\t\t\n\t\t\t'},{id:"B59",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tChao\n\t\t\t\t\t\t\tJ. H.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPhillips\n\t\t\t\t\t\t\tR.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tNickson\n\t\t\t\t\t\t\tJ.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tRoentgen-ray\n\t\t\t\t\t\t\ttherapy.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tof\n\t\t\t\t\t\t\tcerebral.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmetastases\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t Cancer, 1954 7(4): 682\n\t\t\t\t\t689.\n\t\t\t'},{id:"B60",body:'\n\t\t\t\t\n\t\t\t\t\tChu, F.C.H. and B.B. Hilaris, Value of radiation therapy in the management of intracranial metastases. Cancer, 1961 14(3): 577081\n\t\t\t\t\n\t\t\t'},{id:"B61",body:'\n\t\t\t\t\n\t\t\t\t\tPatchell, R.A., et al., Postoperative radiotherapy in the treatment of single metastases to the brain. JAMA, 1998 280(17): 1485\n\t\t\t\t\t1489.\n\t\t\t'},{id:"B62",body:'\n\t\t\t\t\n\t\t\t\t\tRaizer, J., Radiosurgery and whole-brain radiation therapy for brain metastases. JAMA, 2006 295(21): 2535\n\t\t\t\t\t2536.\n\t\t\t'},{id:"B63",body:'\n\t\t\t\t\n\t\t\t\t\tPeacock, K.H. and G.J. Lesser,\n\t\t\t\t\tCurrent therapeutic approaches in patients with brain metastases. Curr Treat Options Oncol, 2006 7(6): 479\n\t\t\t\t\t489.\n\t\t\t'},{id:"B64",body:'\n\t\t\t\t\n\t\t\t\t\tFogarty, G., et al., Whole brain radiotherapy after local treatment of brain metastases in melanoma patients- a randomised phase III trial. BMC Cancer, 2011 11(142).\n\t\t\t'},{id:"B65",body:'\n\t\t\t\t\n\t\t\t\t\tKhuntia, D., et al., Whole-brain radiotherapy in the managment of brain metastases. J Clin Oncol, 2006 24(8): 1295\n\t\t\t\t\t1304.\n\t\t\t'},{id:"B66",body:'\n\t\t\t\t\n\t\t\t\t\tButler, J.M., S.R. Rapp, and E.G. Shaw, Managing the cognitive effects of brain tumor radiation therapy. Curr Treat Options Oncol, 2006 7(6): 517\n\t\t\t\t\t523.\n\t\t\t'},{id:"B67",body:'\n\t\t\t\t\n\t\t\t\t\tLittman, P., et al., The somnolence syndrome in leukemic children following reduced daily dose fractions of cranial radiation. Int J Radiat Oncol Biol Phys, 1984 10(10): 1851\n\t\t\t\t\t1853.\n\t\t\t'},{id:"B68",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tFaithfull\n\t\t\t\t\t\t\tS.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBrada\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSomnolence\n\t\t\t\t\t\t\tsyndrome.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tin\n\t\t\t\t\t\t\tadults.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tfollowing\n\t\t\t\t\t\t\tcranial.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tirradiation\n\t\t\t\t\t\t\tfor.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tprimary\n\t\t\t\t\t\t\tbrain.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\ttumors\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t Clin Oncol (R Coll Radiol), 1998 10(4): 250\n\t\t\t\t\t254.\n\t\t\t'},{id:"B69",body:'\n\t\t\t\t\n\t\t\t\t\tDeAngelis, L.M., J.Y. Delattre, and J.B. Posner, Radiation-induced dementia in patients cured of brain metastases. Neurology, 1989 39(6): 789\n\t\t\t\t\t796.\n\t\t\t'},{id:"B70",body:'\n\t\t\t\t\n\t\t\t\t\tDeAngelis, L.M., et al., The role of postoperative radiotherapy after resection of a single brain metastases. Neurosurgery, 1989 24(6): 798\n\t\t\t\t\t805.\n\t\t\t'},{id:"B71",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tLee\n\t\t\t\t\t\t\tY. Y.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tNauert\n\t\t\t\t\t\t\tC.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tGlass\n\t\t\t\t\t\t\tJ. P.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tTreatment-related\n\t\t\t\t\t\t\twhite.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmatter\n\t\t\t\t\t\t\tchanges.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tin\n\t\t\t\t\t\t\tcancer.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tpatients\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t Cancer, 1986 57(8): 1473\n\t\t\t\t\t1482.\n\t\t\t'},{id:"B72",body:'\n\t\t\t\t\n\t\t\t\t\tChang, E.L., et al., Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol, 2009 10(11): 1037\n\t\t\t\t\t1044.\n\t\t\t'},{id:"B73",body:'\n\t\t\t\t\n\t\t\t\t\tBarranco, S.C., M.M. Romsdahl, and R.M. Humphreys, The radiation response of human malignant melanoma cells grown in vitro. Cancer Res, 1971 31(6): 830\n\t\t\t\t\t833.\n\t\t\t'},{id:"B74",body:'\n\t\t\t\t\n\t\t\t\t\tOvergaard, J., The role of radiotherapy in recurrent and metastatic malignant melanoma: a clinical and radiobiological study. Int J Radiat Oncol Biol Phys, 1986 12(6): 867\n\t\t\t\t\t872.\n\t\t\t'},{id:"B75",body:'\n\t\t\t\t\n\t\t\t\t\tBorgelt, B., et al., The palliation of brain metastases: final results of the first two studes by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys, 1981 6(1): 1\n\t\t\t\t\t9.\n\t\t\t'},{id:"B76",body:'\n\t\t\t\t\n\t\t\t\t\tKurtz, J.M., et al., The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys, 1981 7(7): 891\n\t\t\t\t\t895.\n\t\t\t'},{id:"B77",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tRate\n\t\t\t\t\t\t\tW.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSolin\n\t\t\t\t\t\t\tL.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tTurrisi\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPalliative\n\t\t\t\t\t\t\tradiotherapy.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tfor\n\t\t\t\t\t\t\tmetastatic.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmalignant\n\t\t\t\t\t\t\tmelanoma.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tbrain\n\t\t\t\t\t\t\tmetastases.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tbone\n\t\t\t\t\t\t\tmetastases.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tspinal\n\t\t\t\t\t\t\tcord.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tcompression\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t Int J Radiat Oncol Biol Phys, 1988 15(4): 859\n\t\t\t\t\t864.\n\t\t\t'},{id:"B78",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tDoss\n\t\t\t\t\t\t\tL.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMemula\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tThe\n\t\t\t\t\t\t\tradioresponsiveness.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tof\n\t\t\t\t\t\t\tmelanoma.\n\t\t\t\t\t\t\n\t\t\t\t\t Int J Radiat Oncol Biol Phys, 1982 8(7): 1131\n\t\t\t\t\t1134.\n\t\t\t'},{id:"B79",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCarella\n\t\t\t\t\t\t\tR. J.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tValue\n\t\t\t\t\t\t\tof.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tradiation\n\t\t\t\t\t\t\ttherapy.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tin\n\t\t\t\t\t\t\tthe.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmanagement\n\t\t\t\t\t\t\tof.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tpatients\n\t\t\t\t\t\t\twith.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tcerebral\n\t\t\t\t\t\t\tmetastases.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tfrom\n\t\t\t\t\t\t\tmalignant.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmelanoma\n\t\t\t\t\t\t\tRadiation.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tTherapy\n\t\t\t\t\t\t\tOncology.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tGroup\n\t\t\t\t\t\t\tBrain.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMetastases\n\t\t\t\t\t\t\tStudy. I.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tI. I.\n\t\t\t\t\t\t\n\t\t\t\t\t Cancer, 1980 45(4): 679\n\t\t\t\t\t683.\n\t\t\t'},{id:"B80",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tStridslev\n\t\t\t\t\t\t\tI. C.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tHagen\n\t\t\t\t\t\t\tS.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tKlepp\n\t\t\t\t\t\t\tO.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tRadiation\n\t\t\t\t\t\t\ttherapy.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tfor\n\t\t\t\t\t\t\tbrain.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmetastases\n\t\t\t\t\t\t\tfrom.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmalignant\n\t\t\t\t\t\t\tmelanoma.\n\t\t\t\t\t\t\n\t\t\t\t\t Acta Radiol Oncol, 1984 23(4): 231\n\t\t\t\t\t235.\n\t\t\t'},{id:"B81",body:'\n\t\t\t\t\n\t\t\t\t\tEllerhorst, J., et al., Whole brain irradiation for patients with metastatic melanoma: a review\n\t\t\t\t\t87 87 cases. Int J Radiat Oncol Biol Phys, 2001. 49(1): 93\n\t\t\t\t\t97.\n\t\t\t'},{id:"B82",body:'\n\t\t\t\t\n\t\t\t\t\tBuchsbaum, J.C., et al., Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer, 2002 94(8): 2265\n\t\t\t\t\t2272.\n\t\t\t'},{id:"B83",body:'\n\t\t\t\t\n\t\t\t\t\tGaspar, L., et al., Recursive partitionaing analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys, 1997 37(4): 745\n\t\t\t\t\t751.\n\t\t\t'},{id:"B84",body:'\n\t\t\t\t\n\t\t\t\t\tGrant, F.C., Concerning intracranial malignant metastases: their frequency and the value of surgery in their treatment. Ann Surg, 1926 84(5): 635\n\t\t\t\t\t646.\n\t\t\t'},{id:"B85",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPatchell\n\t\t\t\t\t\t\tR. A.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\trandomized\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\ttrial\n\t\t\t\t\t\t\tof.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tsurgery\n\t\t\t\t\t\t\tin.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tthe\n\t\t\t\t\t\t\ttreatment.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tof\n\t\t\t\t\t\t\tsingle.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmetastases\n\t\t\t\t\t\t\tto.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tthe\n\t\t\t\t\t\t\tbrain.\n\t\t\t\t\t\t\n\t\t\t\t\t N Engl J Med, 1990 322(8): 494\n\t\t\t\t\t500.\n\t\t\t'},{id:"B86",body:'\n\t\t\t\t\n\t\t\t\t\tBrega, K., et al., Surgical treatment of brain metastases in malignant melanoma. Cancer, 1990 66(10): 2105\n\t\t\t\t\t2110.\n\t\t\t'},{id:"B87",body:'\n\t\t\t\t\n\t\t\t\t\tZacest, A.C., et al., Surgical management of cerebral metastases from melanoma: outcome\n\t\t\t\t\t147 147 patients treated at a single institution over two decades. J Neurosurg, 2002. 96(3): 552\n\t\t\t\t\t558.\n\t\t\t'},{id:"B88",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tAl-Shamy\n\t\t\t\t\t\t\tG.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSawaya\n\t\t\t\t\t\t\tR.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tManagement\n\t\t\t\t\t\t\tof.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tbrain\n\t\t\t\t\t\t\tmetases.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tthe\n\t\t\t\t\t\t\tindispensable.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\trole\n\t\t\t\t\t\t\tof.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tsurgery\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t J Neuroonc, 2009 92(3): 275\n\t\t\t\t\t282.\n\t\t\t'},{id:"B89",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMc Williams\n\t\t\t\t\t\t\tR. R.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMelanoma-induced\n\t\t\t\t\t\t\tbrain.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmetastases\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t Expert Rev Anticancer Ther, 2008 8(5): 742\n\t\t\t\t\t755.\n\t\t\t'},{id:"B90",body:'\n\t\t\t\t\n\t\t\t\t\tBindal, R.K., et al., Surgical treatment of multiple brain metastases. J Neurosurg, 1993 79(2): 210\n\t\t\t\t\t216.\n\t\t\t'},{id:"B91",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tIwadate\n\t\t\t\t\t\t\tY.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tNamba\n\t\t\t\t\t\t\tH.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tYamaura\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSignificance\n\t\t\t\t\t\t\tof.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tsurgical\n\t\t\t\t\t\t\tresection.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tfor\n\t\t\t\t\t\t\tthe.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\ttreatment\n\t\t\t\t\t\t\tof.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmultiple\n\t\t\t\t\t\t\tbrain.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmetastasis\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t Anticancer Res, 2000 20(1B): 573\n\t\t\t\t\t577.\n\t\t\t'},{id:"B92",body:'\n\t\t\t\t\n\t\t\t\t\tPaek, S.H., et al., Reevaluation\n\t\t\t\t\t208 surgery for the treatment of brain metastases: review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques. Neurosurgery, 2005. 56(5): 1021\n\t\t\t\t\t1034.\n\t\t\t'},{id:"B93",body:'\n\t\t\t\t\n\t\t\t\t\tVecht, C.J., et al., Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol,\n\t\t\t\t\t1993 33(6): 583\n\t\t\t\t\t590.\n\t\t\t'},{id:"B94",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMintz\n\t\t\t\t\t\t\tA. H.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\trandomized\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\ttrial\n\t\t\t\t\t\t\tto.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tassess\n\t\t\t\t\t\t\tthe.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tefficacy\n\t\t\t\t\t\t\tof.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tsurgery\n\t\t\t\t\t\t\tin.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\taddition\n\t\t\t\t\t\t\tto.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tradiotherapy\n\t\t\t\t\t\t\tin.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tpatients\n\t\t\t\t\t\t\twith. a.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tsingle\n\t\t\t\t\t\t\tcerebral.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmetastasis\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t Cancer, 1996 78(7): 1470\n\t\t\t\t\t1476.\n\t\t\t'},{id:"B95",body:'\n\t\t\t\t\n\t\t\t\t\tDosoretz, D.E., et al., Management of solitary metastasis to the brain: the role of elective brain irradiation following complete surgical resection. Int J Radiat Oncol Biol Phys, 1980 6(12): 1727\n\t\t\t\t\t1730.\n\t\t\t'},{id:"B96",body:'\n\t\t\t\t\n\t\t\t\t\tHagan, N.A., et al., The role of radiation therapy following resection of single brain metastasis from melanoma. Neurology, 1990 40(1): 158\n\t\t\t\t\t160.\n\t\t\t'},{id:"B97",body:'\n\t\t\t\t\n\t\t\t\t\tLeksell, L., The stereotaxic method and radiosurgery of the brain. Acta Chir Scand, 1951 102(4): 316\n\t\t\t\t\t319.\n\t\t\t'},{id:"B98",body:'\n\t\t\t\t\n\t\t\t\t\tNiranjan, A., et al., Experimental radiobiological investigations into radiosurgery: present understanding and future directions. Neurosurgery, 2004 55(3): 495\n\t\t\t\t\t504.\n\t\t\t'},{id:"B99",body:'\n\t\t\t\t\n\t\t\t\t\tSmith, M.L. and J.Y. Lee, Stereotactic radiosurgery in the management of brain metastases. Neurosurg Focus, 2007 22(3): E5\n\t\t\t\t\n\t\t\t'},{id:"B100",body:'\n\t\t\t\t\n\t\t\t\t\tMehta, M.P., et al., Defining the role of radiosurgery in the management of brain metastases. Int J Radiat Oncol Biol Phys, 1992 24(4): 619\n\t\t\t\t\t625.\n\t\t\t'},{id:"B101",body:'\n\t\t\t\t\n\t\t\t\t\tFlickinger, J.C., et al., Radiosurgery: Its role in brain metastasis management. Neurosurg Clin N Am, 1996 7(3): 497\n\t\t\t\t\t504.\n\t\t\t'},{id:"B102",body:'\n\t\t\t\t\n\t\t\t\t\tYoung, R.F., Radiosurgery for the treetment of brain metastases. Semin Surg Oncol, 1998 14(1): 70\n\t\t\t\t\t78.\n\t\t\t'},{id:"B103",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tDouglas\n\t\t\t\t\t\t\tJ. G.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMargolin\n\t\t\t\t\t\t\tK.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tThe\n\t\t\t\t\t\t\ttreatment.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tof\n\t\t\t\t\t\t\tbrain.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmetastases\n\t\t\t\t\t\t\tfrom.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmalignant\n\t\t\t\t\t\t\tmelanoma.\n\t\t\t\t\t\t\n\t\t\t\t\t Semin Oncol, 2002 29(5): 518\n\t\t\t\t\t524.\n\t\t\t'},{id:"B104",body:'\n\t\t\t\t\n\t\t\t\t\tMori, Y., et al., Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys, 1998 42(3): 581\n\t\t\t\t\t589.\n\t\t\t'},{id:"B105",body:'\n\t\t\t\t\n\t\t\t\t\tSomaza, S., et al., Stereotactic radiosurgery for cerebral metastatic melanoma. J Neurosurg, 1993 79(5): 661\n\t\t\t\t\t666.\n\t\t\t'},{id:"B106",body:'\n\t\t\t\t\n\t\t\t\t\tLavine, S.D., et al., Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications. Neurosurgery, 1999 44(1): 59\n\t\t\t\t\t64.\n\t\t\t'},{id:"B107",body:'\n\t\t\t\t\n\t\t\t\t\tBrown, P.D., et al., Stereotactic radiosurgery for patients with "radioresistant" brain metastases. Neurosurgery, 2002 51(3): 656\n\t\t\t\t\t665.\n\t\t\t'},{id:"B108",body:'\n\t\t\t\t\n\t\t\t\t\tMathieu, D., et al., Gamm knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery, 2007 80(3): 471\n\t\t\t\t\t481.\n\t\t\t'},{id:"B109",body:'\n\t\t\t\t\n\t\t\t\t\tMingione, V., et al., Gamma surgery for melanoma metastases in the brain. J Neurosurg, 2002 96(3): 544\n\t\t\t\t\t551.\n\t\t\t'},{id:"B110",body:'\n\t\t\t\t\n\t\t\t\t\tNam, T.K., et al., Gamma knife surgery for brain metastases in patients harboring four or more lesions: survival and prognostic factors. J Neurosurg, 2005 102(Suppl): 147\n\t\t\t\t\t150.\n\t\t\t'},{id:"B111",body:'\n\t\t\t\t\n\t\t\t\t\tAndrews, D.W., et al., Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG\n\t\t\t\t\t9508 randomised trial. Lancet, 2004. 363(9422): 1665\n\t\t\t\t\t1672.\n\t\t\t'},{id:"B112",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tAuchter\n\t\t\t\t\t\t\tR. M.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmultiinstituional\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\toutcome\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tprognostic\n\t\t\t\t\t\t\tfactor.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tanaylsis\n\t\t\t\t\t\t\tof.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tradiosurgery\n\t\t\t\t\t\t\tfor.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tresectable\n\t\t\t\t\t\t\tsingle.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tbrain\n\t\t\t\t\t\t\tmetastasis.\n\t\t\t\t\t\t\n\t\t\t\t\t Int J Radiat Oncol Biol Phys, 1996 35(1): 27\n\t\t\t\t\t35.\n\t\t\t'},{id:"B113",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tO’Neill\n\t\t\t\t\t\t\tB. P.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tcomparison\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tof\n\t\t\t\t\t\t\tsurgical.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tresection\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tstereotactic\n\t\t\t\t\t\t\tradiosurgery.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tin\n\t\t\t\t\t\t\tthe.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\ttreatment\n\t\t\t\t\t\t\tof.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tsolitary\n\t\t\t\t\t\t\tbrain.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmetastases\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t Int J Radiat Oncol Biol Phys, 2003 55(5): 1169\n\t\t\t\t\t1176.\n\t\t\t'},{id:"B114",body:'\n\t\t\t\t\n\t\t\t\t\tBindal, A.K., et al., Surgery versus radiosurgery in the treatment of brain metastasis. J Neurosurg, 1996 84(5): 748\n\t\t\t\t\t754.\n\t\t\t'},{id:"B115",body:'\n\t\t\t\t\n\t\t\t\t\tCho, K.H., et al., Stereotactic radiosurgery for patients with single brain metastasis. J Radiosurgol, 1998 1(2): 79\n\t\t\t\t\t85.\n\t\t\t'},{id:"B116",body:'\n\t\t\t\t\n\t\t\t\t\tKleeberg, U.R., et al., Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treamtnet effectiveness. A mutlicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma Res, 1995 5(3): 195\n\t\t\t\t\t200.\n\t\t\t'},{id:"B117",body:'\n\t\t\t\t\n\t\t\t\t\tJacquillat, C., et al., F153\n\t\t\t\t\tal report of the French multicenter phase II study of the nitrosurea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer, 1990. 66(9): 1873\n\t\t\t\t\t1878.\n\t\t\t'},{id:"B118",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSiena\n\t\t\t\t\t\t\tS.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tLandonio\n\t\t\t\t\t\t\tG.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBaietta\n\t\t\t\t\t\t\tE.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tTemozolomide\n\t\t\t\t\t\t\tfor.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tthe\n\t\t\t\t\t\t\ttreatment.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tof\n\t\t\t\t\t\t\tbrain.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmetastases\n\t\t\t\t\t\t\tassociated.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\twith\n\t\t\t\t\t\t\tmetastatic.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tmelanoma\n\t\t\t\t\t\t\ta.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tphase\n\t\t\t\t\t\t\tI. I.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tstudy\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t J Clin Oncol, 2003 22(11): 2101\n\t\t\t\t\t2107.\n\t\t\t'},{id:"B119",body:'\n\t\t\t\t\n\t\t\t\t\tMornex, F., et al., Randomized phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma [in French]. Cancer Radiother, 2003 7(1): 1\n\t\t\t\t\t8.\n\t\t\t'},{id:"B120",body:'\n\t\t\t\t\n\t\t\t\t\tAntonadou, D., et al., Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol, 2002 20(17): 3644\n\t\t\t\t\t3650.\n\t\t\t'},{id:"B121",body:'\n\t\t\t\t\n\t\t\t\t\tSavas, B., et al., Multidrug resistant malignant melanom with intracranial metastasis responding to immunotherapy. Anti-cancer Res, 1999 19(5C): 4413\n\t\t\t\t\t4420.\n\t\t\t'},{id:"B122",body:'\n\t\t\t\t\n\t\t\t\t\tSchartz, N.E.C., et al., Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res, 2010 20(3): 247\n\t\t\t\t\t250.\n\t\t\t'},{id:"B123",body:'\n\t\t\t\t\n\t\t\t\t\tDudley, M.E., et al., Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol, 2005 23(10): 2346\n\t\t\t\t\t2357.\n\t\t\t'},{id:"B124",body:'\n\t\t\t\t\n\t\t\t\t\tHong, J.J., et al., Succesful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res, 2010 16(19): 4892\n\t\t\t\t\t4898.\n\t\t\t'},{id:"B125",body:'\n\t\t\t\t\n\t\t\t\t\tMajer, M., et al., Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. Cancer, 2007 110(6): 1329\n\t\t\t\t\t1337.\n\t\t\t'}],footnotes:[],contributors:[{corresp:"yes",contributorFullName:"Khan K. Chaichana",address:null,affiliation:'
Johns Hopkins University School of Medicine, Department of Neurosurgery, Baltimore,, USA
'},{corresp:null,contributorFullName:"Kaisorn L. Chaichana",address:null,affiliation:'
Johns Hopkins University School of Medicine, Department of Neurosurgery, Baltimore,, USA
'}],corrections:null},book:{id:"523",type:"book",title:"Treatment of Metastatic Melanoma",subtitle:null,fullTitle:"Treatment of Metastatic Melanoma",slug:"treatment-of-metastatic-melanoma",publishedDate:"October 5th 2011",bookSignature:"Rachael Morton",coverURL:"https://cdn.intechopen.com/books/images_new/523.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",isbn:null,printIsbn:"978-953-307-574-7",pdfIsbn:"978-953-51-6513-2",reviewType:"peer-reviewed",numberOfWosCitations:19,isAvailableForWebshopOrdering:!0,editors:[{id:"52974",title:"Ms.",name:"Rachael",middleName:"L",surname:"Morton",slug:"rachael-morton",fullName:"Rachael Morton"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"1077"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"21334",type:"chapter",title:"Cutaneous Metastases from Malignant Melanoma: Clinical Features and New Therapeutic Perspectives",slug:"cutaneous-metastases-from-malignant-melanoma-clinical-features-and-new-therapeutic-perspectives",totalDownloads:6793,totalCrossrefCites:2,signatures:"Paola Savoia, Paolo Fava and Maria Grazia Bernengo",reviewType:"peer-reviewed",authors:[{id:"34125",title:"Dr.",name:"Paola",middleName:null,surname:"Savoia",fullName:"Paola Savoia",slug:"paola-savoia"},{id:"47285",title:"Dr.",name:"Paolo",middleName:null,surname:"Fava",fullName:"Paolo Fava",slug:"paolo-fava"},{id:"47286",title:"Prof.",name:"Maria Grazia",middleName:null,surname:"Bernengo",fullName:"Maria Grazia Bernengo",slug:"maria-grazia-bernengo"}]},{id:"21335",type:"chapter",title:"Impact of Sentinel Node Biopsy on Outcome in Melanoma",slug:"impact-of-sentinel-node-biopsy-on-outcome-in-melanoma",totalDownloads:2811,totalCrossrefCites:0,signatures:"Justin Kelly and MJ Kerin",reviewType:"peer-reviewed",authors:[{id:"36813",title:"Mr",name:"Justin",middleName:null,surname:"Kelly",fullName:"Justin Kelly",slug:"justin-kelly"}]},{id:"21336",type:"chapter",title:"Management of Head and Neck Melanoma",slug:"management-of-head-and-neck-melanoma",totalDownloads:2096,totalCrossrefCites:1,signatures:"James H F Shaw and Michael Fay",reviewType:"peer-reviewed",authors:[{id:"36622",title:"Prof.",name:"James",middleName:null,surname:"Shaw",fullName:"James Shaw",slug:"james-shaw"}]},{id:"21337",type:"chapter",title:"Diagnosis and Treatment Options for Brain Metastasis of Melanoma",slug:"diagnosis-and-treatment-options-for-brain-metastasis-of-melanoma",totalDownloads:11154,totalCrossrefCites:0,signatures:"Khan K. Chaichana and Kaisorn L. Chaichana",reviewType:"peer-reviewed",authors:[{id:"38678",title:"Prof.",name:"Kaisorn",middleName:null,surname:"Chaichana",fullName:"Kaisorn Chaichana",slug:"kaisorn-chaichana"},{id:"135687",title:"Prof.",name:"Khan",middleName:null,surname:"Chaichana",fullName:"Khan Chaichana",slug:"khan-chaichana"}]},{id:"21338",type:"chapter",title:"Chemotherapy",slug:"chemotherapy",totalDownloads:1435,totalCrossrefCites:0,signatures:"Aylin Türel Ermertcan, Ferdi Öztürk and Kamer Gündüz",reviewType:"peer-reviewed",authors:[{id:"36722",title:"Dr.",name:"Aylin",middleName:null,surname:"Türel Ermertcan",fullName:"Aylin Türel Ermertcan",slug:"aylin-turel-ermertcan"},{id:"39626",title:"Dr.",name:"Ferdi",middleName:null,surname:"Öztürk",fullName:"Ferdi Öztürk",slug:"ferdi-ozturk"},{id:"39627",title:"Prof.",name:"Kamer",middleName:null,surname:"Gündüz",fullName:"Kamer Gündüz",slug:"kamer-gunduz"}]},{id:"21339",type:"chapter",title:"Chemocentric Chemoimmunotherapy: A New Concept in Melanoma Immunotherapy",slug:"chemocentric-chemoimmunotherapy-a-new-concept-in-melanoma-immunotherapy",totalDownloads:1898,totalCrossrefCites:0,signatures:"Paul Howell, Soroosh Radfar, Yixiang Wang and Hung Khong",reviewType:"peer-reviewed",authors:[{id:"37156",title:"Prof.",name:"Hung",middleName:"T.",surname:"Khong",fullName:"Hung Khong",slug:"hung-khong"},{id:"51799",title:"Mr",name:"Paul",middleName:null,surname:"Howell",fullName:"Paul Howell",slug:"paul-howell"},{id:"51800",title:"Dr.",name:"Soroosh",middleName:null,surname:"Radfar",fullName:"Soroosh Radfar",slug:"soroosh-radfar"},{id:"51801",title:"Dr.",name:"Yixiang",middleName:null,surname:"Wang",fullName:"Yixiang Wang",slug:"yixiang-wang"}]},{id:"21340",type:"chapter",title:"Melanoma Immunomodulation: A War of Attrition",slug:"melanoma-immunomodulation-a-war-of-attrition",totalDownloads:1920,totalCrossrefCites:0,signatures:"Bently P. Doonan, Jessica D. Hathaway and Azizul Haque",reviewType:"peer-reviewed",authors:[{id:"32188",title:"Prof.",name:"Azizul",middleName:null,surname:"Haque",fullName:"Azizul Haque",slug:"azizul-haque"},{id:"51185",title:"Mr",name:"Bently",middleName:"Patrick",surname:"Doonan",fullName:"Bently Doonan",slug:"bently-doonan"},{id:"51186",title:"Ms",name:"Jessica",middleName:null,surname:"Hathaway",fullName:"Jessica Hathaway",slug:"jessica-hathaway"}]},{id:"21341",type:"chapter",title:"Simultaneous Knockdown of Mutant BRAF and Expression of INK4A in Melanoma Cells Leads to Potent Growth Inhibition and Apoptosis",slug:"simultaneous-knockdown-of-mutant-braf-and-expression-of-ink4a-in-melanoma-cells-leads-to-potent-grow",totalDownloads:2328,totalCrossrefCites:0,signatures:"Jianli Dong and Chet L. Schwab",reviewType:"peer-reviewed",authors:[{id:"32259",title:"Dr.",name:"Jianli",middleName:null,surname:"Dong",fullName:"Jianli Dong",slug:"jianli-dong"},{id:"73078",title:"Dr.",name:"Chet",middleName:null,surname:"Schwab",fullName:"Chet Schwab",slug:"chet-schwab"}]},{id:"21342",type:"chapter",title:"Promising Experimental Therapies for Metastatic Melanoma",slug:"promising-experimental-therapies-for-metastatic-melanoma",totalDownloads:1924,totalCrossrefCites:0,signatures:"Bao Lam, Patrick A. Ott and Anna C. Pavlick",reviewType:"peer-reviewed",authors:[{id:"33970",title:"Dr.",name:"Anna",middleName:null,surname:"Pavlick",fullName:"Anna Pavlick",slug:"anna-pavlick"},{id:"50458",title:"Dr.",name:"Patrick",middleName:null,surname:"Ott",fullName:"Patrick Ott",slug:"patrick-ott"},{id:"50459",title:"Dr.",name:"Bao",middleName:null,surname:"Lam",fullName:"Bao Lam",slug:"bao-lam"}]},{id:"21343",type:"chapter",title:"The Role of Electrochemotherapy in the Treatment of Malignant Melanoma",slug:"the-role-of-electrochemotherapy-in-the-treatment-of-malignant-melanoma",totalDownloads:2854,totalCrossrefCites:0,signatures:"Mecker G. Möller, Slawomir Salwa, Declan M. Soden and Gerald C. O’Sullivan",reviewType:"peer-reviewed",authors:[{id:"41241",title:"Prof.",name:"Gerald C",middleName:null,surname:"O'Sullivan",fullName:"Gerald C O'Sullivan",slug:"gerald-c-o'sullivan"},{id:"49625",title:"Dr.",name:"Mecker",middleName:null,surname:"Moller",fullName:"Mecker Moller",slug:"mecker-moller"},{id:"104084",title:"Dr.",name:"Declan",middleName:null,surname:"Soden",fullName:"Declan Soden",slug:"declan-soden"},{id:"104130",title:"Dr.",name:"Slawomir",middleName:null,surname:"Salwa",fullName:"Slawomir Salwa",slug:"slawomir-salwa"}]},{id:"21344",type:"chapter",title:"Pulse Power Ablation of Melanoma with Nanosecond Pulsed Electric Fields",slug:"pulse-power-ablation-of-melanoma-with-nanosecond-pulsed-electric-fields",totalDownloads:2697,totalCrossrefCites:1,signatures:"Stephen J. Beebe, Wentia E. Ford, Wei Ren and Xinhua Chen",reviewType:"peer-reviewed",authors:[{id:"49481",title:"Prof.",name:"Stephen",middleName:"J.",surname:"Beebe",fullName:"Stephen Beebe",slug:"stephen-beebe"},{id:"51064",title:"Dr.",name:"Wentia",middleName:null,surname:"Ford",fullName:"Wentia Ford",slug:"wentia-ford"},{id:"51065",title:"Dr.",name:"Xinhua",middleName:null,surname:"Chen",fullName:"Xinhua Chen",slug:"xinhua-chen"},{id:"89381",title:"Dr.",name:"Wei",middleName:null,surname:"Ren",fullName:"Wei Ren",slug:"wei-ren"}]},{id:"21345",type:"chapter",title:"Can Photodynamic Therapy Be an Alternative Method in Melanoma Treatment?",slug:"can-photodynamic-therapy-be-an-alternative-method-in-melanoma-treatment-",totalDownloads:2501,totalCrossrefCites:1,signatures:"Anna Choromańska, Julita Kulbacka, Agnieszka Chwiłkowska, Nina Skołucka, Andrzej Gamian and Jolanta Saczko",reviewType:"peer-reviewed",authors:[{id:"37665",title:"MSc",name:"Anna",middleName:"Malgorzata",surname:"Choromanska",fullName:"Anna Choromanska",slug:"anna-choromanska"},{id:"49376",title:"Dr.",name:"Jolanta",middleName:null,surname:"Saczko",fullName:"Jolanta Saczko",slug:"jolanta-saczko"},{id:"49377",title:"Dr.",name:"Julita",middleName:null,surname:"Kulbacka",fullName:"Julita Kulbacka",slug:"julita-kulbacka"},{id:"49378",title:"Dr.",name:"Agnieszka",middleName:null,surname:"Chwilkowska",fullName:"Agnieszka Chwilkowska",slug:"agnieszka-chwilkowska"},{id:"66602",title:"MSc",name:"Nina",middleName:null,surname:"Skolucka",fullName:"Nina Skolucka",slug:"nina-skolucka"},{id:"75576",title:"Prof.",name:"Andrzej",middleName:null,surname:"Gamian",fullName:"Andrzej Gamian",slug:"andrzej-gamian"}]},{id:"21346",type:"chapter",title:"Update on Clinical Trials for Malignant Melanoma",slug:"update-on-clinical-trials-for-malignant-melanoma",totalDownloads:2338,totalCrossrefCites:0,signatures:"Raffaele Califano, Ruth Board, Aidalena Z Abidin, Louise Carter, Laura Cove-Smith, Bihani Kularatne and Paul Lorigan",reviewType:"peer-reviewed",authors:[{id:"33934",title:"Dr.",name:"Paul",middleName:null,surname:"Lorigan",fullName:"Paul Lorigan",slug:"paul-lorigan"},{id:"33938",title:"Dr.",name:"Raffaele",middleName:null,surname:"Califano",fullName:"Raffaele Califano",slug:"raffaele-califano"},{id:"33939",title:"Dr.",name:"Bihani",middleName:null,surname:"Kularatne",fullName:"Bihani Kularatne",slug:"bihani-kularatne"},{id:"33940",title:"Dr.",name:"Laura",middleName:null,surname:"Cove-Smith",fullName:"Laura Cove-Smith",slug:"laura-cove-smith"},{id:"105950",title:"Dr.",name:"Ruth",middleName:null,surname:"Board",fullName:"Ruth Board",slug:"ruth-board"},{id:"105951",title:"Dr.",name:"Aidalena",middleName:"Zainal",surname:"Abidin",fullName:"Aidalena Abidin",slug:"aidalena-abidin"},{id:"108779",title:"Dr.",name:"Louise",middleName:null,surname:"Carter",fullName:"Louise Carter",slug:"louise-carter"}]},{id:"21347",type:"chapter",title:"Oral Malignant Melanoma",slug:"oral-malignant-melanoma",totalDownloads:5629,totalCrossrefCites:0,signatures:"Thomas Mücke, Anna Borgmann, Klaus-Dietrich Wolff and David Andrew Mitchell",reviewType:"peer-reviewed",authors:[{id:"44046",title:"Dr.",name:"Thomas",middleName:null,surname:"Mücke",fullName:"Thomas Mücke",slug:"thomas-mucke"},{id:"51405",title:"Mr.",name:"Klaus-Dietrich",middleName:null,surname:"Wolff",fullName:"Klaus-Dietrich Wolff",slug:"klaus-dietrich-wolff"},{id:"87253",title:"Ms.",name:"Anna",middleName:null,surname:"Borgmann",fullName:"Anna Borgmann",slug:"anna-borgmann"},{id:"87257",title:"BSc.",name:"David",middleName:null,surname:"Mitchell",fullName:"David Mitchell",slug:"david-mitchell"}]},{id:"21348",type:"chapter",title:"Choroidal Melanoma",slug:"choroidal-melanoma",totalDownloads:1936,totalCrossrefCites:0,signatures:"Raquel Correa, Mario Lobato and José Antonio Medina",reviewType:"peer-reviewed",authors:[{id:"38234",title:"Dr.",name:"Raquel",middleName:null,surname:"Correa",fullName:"Raquel Correa",slug:"raquel-correa"},{id:"135662",title:"Dr.",name:"Mario",middleName:null,surname:"Lobato",fullName:"Mario Lobato",slug:"mario-lobato"},{id:"137239",title:"Dr.",name:"Jose Antonio",middleName:null,surname:"Medina Carmona",fullName:"Jose Antonio Medina Carmona",slug:"jose-antonio-medina-carmona"}]}]},relatedBooks:[{type:"book",id:"273",title:"Research on Melanoma",subtitle:"A Glimpse into Current Directions and Future Trends",isOpenForSubmission:!1,hash:"03dcadf8ca228b0a39a14c7614a712f2",slug:"research-on-melanoma-a-glimpse-into-current-directions-and-future-trends",bookSignature:"Mandi Murph",coverURL:"https://cdn.intechopen.com/books/images_new/273.jpg",editedByType:"Edited by",editors:[{id:"32293",title:"Prof.",name:"Mandi",surname:"Murph",slug:"mandi-murph",fullName:"Mandi Murph"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"19089",title:"Predictive Capacity and Functional Significance of MicroRNA in Human Melanoma",slug:"predictive-capacity-and-functional-significance-of-microrna-in-human-melanoma",signatures:"Xiaobo Li and Yaguang Xi",authors:[{id:"32242",title:"Dr.",name:"Yaguang",middleName:null,surname:"Xi",fullName:"Yaguang Xi",slug:"yaguang-xi"},{id:"51393",title:"Dr.",name:"Xiaobo",middleName:null,surname:"Li",fullName:"Xiaobo Li",slug:"xiaobo-li"}]},{id:"19090",title:"Epigenetic Changes in Melanoma and the Development of Epigenetic Therapy for Melanoma",slug:"epigenetic-changes-in-melanoma-and-the-development-of-epigenetic-therapy-for-melanoma",signatures:"Duc P. Do and Syed A.A. Rizvi",authors:[{id:"33548",title:"Dr.",name:"Duc",middleName:"P.",surname:"Do",fullName:"Duc Do",slug:"duc-do"},{id:"60880",title:"Dr.",name:"Syed",middleName:"A",surname:"Rizvi",fullName:"Syed Rizvi",slug:"syed-rizvi"}]},{id:"19091",title:"Genetic, Epigenetic and Molecular Changes in Melanoma: A New Paradigm for Biological Classification",slug:"genetic-epigenetic-and-molecular-changes-in-melanoma-a-new-paradigm-for-biological-classification",signatures:"Stefania Staibano, Massimo Mascolo, Maria Siano, Gennaro Ilardi and Gaetano De Rosa",authors:[{id:"36959",title:"Prof.",name:"Stefania",middleName:null,surname:"Staibano",fullName:"Stefania Staibano",slug:"stefania-staibano"},{id:"36990",title:"Prof.",name:"Gaetano",middleName:null,surname:"De Rosa",fullName:"Gaetano De Rosa",slug:"gaetano-de-rosa"},{id:"48394",title:"Dr.",name:"Massimo",middleName:null,surname:"Mascolo",fullName:"Massimo Mascolo",slug:"massimo-mascolo"},{id:"48395",title:"Dr.",name:"Maria",middleName:null,surname:"Siano",fullName:"Maria Siano",slug:"maria-siano"},{id:"93383",title:"Dr.",name:"Gennaro",middleName:null,surname:"Ilardi",fullName:"Gennaro Ilardi",slug:"gennaro-ilardi"}]},{id:"19958",title:"A Bromophosphonate Analogue of Lysophosphatidic Acid Surpasses Dacarbazine in Reducing Cell Proliferation and Viability of MeWo Melanoma Cells",slug:"a-bromophosphonate-analogue-of-lysophosphatidic-acid-surpasses-dacarbazine-in-reducing-cell-prolifer",signatures:"Duy Nguyen, Oanh Nguyen, Honglu Zhang, Glenn D. Prestwich and Mandi M. Murph",authors:[{id:"32293",title:"Prof.",name:"Mandi",middleName:null,surname:"Murph",fullName:"Mandi Murph",slug:"mandi-murph"},{id:"50335",title:"Prof.",name:"Glenn",middleName:null,surname:"Prestwich",fullName:"Glenn Prestwich",slug:"glenn-prestwich"},{id:"53495",title:"Mr.",name:"Duy",middleName:null,surname:"Nguyen",fullName:"Duy Nguyen",slug:"duy-nguyen"},{id:"53496",title:"Ms.",name:"Oanh",middleName:null,surname:"Nguyen",fullName:"Oanh Nguyen",slug:"oanh-nguyen"},{id:"77500",title:"Dr.",name:"Honglu",middleName:null,surname:"Zhang",fullName:"Honglu Zhang",slug:"honglu-zhang"}]},{id:"19093",title:"Low-Anticoagulant Heparins in the Treatment of Metastasis",slug:"low-anticoagulant-heparins-in-the-treatment-of-metastasis",signatures:"Narayanam V. Rao, Glenn D. Prestwich, John R. Hoidal and Thomas P. Kennedy",authors:[{id:"50335",title:"Prof.",name:"Glenn",middleName:null,surname:"Prestwich",fullName:"Glenn Prestwich",slug:"glenn-prestwich"},{id:"36545",title:"Dr.",name:"Narayanam",middleName:null,surname:"Rao",fullName:"Narayanam Rao",slug:"narayanam-rao"},{id:"50336",title:"Prof.",name:"John",middleName:null,surname:"Hoidal",fullName:"John Hoidal",slug:"john-hoidal"},{id:"50337",title:"Prof.",name:"Thomas",middleName:null,surname:"Kennedy",fullName:"Thomas Kennedy",slug:"thomas-kennedy"}]},{id:"19094",title:"Novel Antifolates as Produgs for the Treatment of Melanoma",slug:"novel-antifolates-as-produgs-for-the-treatment-of-melanoma",signatures:"Jose Neptuno Rodriguez-Lopez, Luis Sanchez-del-Campo, Magali Saez-Ayala, Maria F. Montenegro and Juan Cabezas-Herrera",authors:[{id:"35809",title:"Dr.",name:"Jose Neptuno",middleName:null,surname:"Rodriguez-Lopez",fullName:"Jose Neptuno Rodriguez-Lopez",slug:"jose-neptuno-rodriguez-lopez"},{id:"35830",title:"Dr.",name:"Luis",middleName:null,surname:"Sanchez-del-Campo",fullName:"Luis Sanchez-del-Campo",slug:"luis-sanchez-del-campo"},{id:"35831",title:"Dr.",name:"Magali",middleName:null,surname:"Saez-Ayala",fullName:"Magali Saez-Ayala",slug:"magali-saez-ayala"},{id:"35832",title:"Prof.",name:"Juan",middleName:null,surname:"Cabezas-Herrera",fullName:"Juan Cabezas-Herrera",slug:"juan-cabezas-herrera"},{id:"35833",title:"Dr.",name:"Maria F.",middleName:null,surname:"Montenegro",fullName:"Maria F. Montenegro",slug:"maria-f.-montenegro"}]},{id:"19095",title:"The Potential of Triterpenoids in the Treatment of Melanoma",slug:"the-potential-of-triterpenoids-in-the-treatment-of-melanoma",signatures:"J. Sarek, M. Kvasnica, M. Vlk, M. Urban, P. Dzubak and M. Hajduch",authors:[{id:"35431",title:"Dr.",name:"Jan",middleName:null,surname:"Sarek",fullName:"Jan Sarek",slug:"jan-sarek"},{id:"52759",title:"Dr.",name:"Miroslav",middleName:null,surname:"Kvasnica",fullName:"Miroslav Kvasnica",slug:"miroslav-kvasnica"},{id:"52760",title:"Dr.",name:"Martin",middleName:null,surname:"Vlk",fullName:"Martin Vlk",slug:"martin-vlk"},{id:"52761",title:"Dr.",name:"Petr",middleName:null,surname:"Dzubak",fullName:"Petr Dzubak",slug:"petr-dzubak"},{id:"67647",title:"Dr.",name:"Milan",middleName:null,surname:"Urban",fullName:"Milan Urban",slug:"milan-urban"},{id:"67649",title:"Dr.",name:"Marian",middleName:null,surname:"Hajduch",fullName:"Marian Hajduch",slug:"marian-hajduch"}]},{id:"19096",title:"New Molecular Targets for the Systemic Therapy of Melanoma",slug:"new-molecular-targets-for-the-systemic-therapy-of-melanoma",signatures:"Kausar Begam Riaz Ahmed and Michael A. Davies",authors:[{id:"38597",title:"Dr.",name:"Michael",middleName:null,surname:"Davies",fullName:"Michael Davies",slug:"michael-davies"},{id:"38611",title:"Ms",name:"Kausar Begam",middleName:null,surname:"Riaz Ahmed",fullName:"Kausar Begam Riaz Ahmed",slug:"kausar-begam-riaz-ahmed"}]},{id:"19097",title:"BRAF V600E Mutated Gene Variant as a Circulating Molecular Marker in Metastatic Melanoma Patients",slug:"braf-v600e-mutated-gene-variant-as-a-circulating-molecular-marker-in-metastatic-melanoma-patients",signatures:"Viviana Vallacchi, Licia Rivoltini and Monica Rodolfo",authors:[{id:"40489",title:"Dr.",name:"Monica",middleName:null,surname:"Rodolfo",fullName:"Monica Rodolfo",slug:"monica-rodolfo"},{id:"51700",title:"Dr.",name:"Viviana",middleName:null,surname:"Vallacchi",fullName:"Viviana Vallacchi",slug:"viviana-vallacchi"},{id:"51701",title:"Dr.",name:"Licia",middleName:null,surname:"Rivoltini",fullName:"Licia Rivoltini",slug:"licia-rivoltini"}]},{id:"19098",title:"Ultraviolet Light as a Modulator of Melanoma Development",slug:"ultraviolet-light-as-a-modulator-of-melanoma-development",signatures:"Graeme Walker and Elke Hacker",authors:[{id:"49832",title:"Dr.",name:"Graeme",middleName:null,surname:"Walker",fullName:"Graeme Walker",slug:"graeme-walker"},{id:"49836",title:"Dr.",name:"Elke",middleName:null,surname:"Hacker",fullName:"Elke Hacker",slug:"elke-hacker"}]},{id:"19099",title:"Dual Roles of the Melanoma CAM (MelCAM/METCAM) in Malignant Progression of Melanoma",slug:"dual-roles-of-the-melanoma-cam-melcam-metcam-in-malignant-progression-of-melanoma",signatures:"Guang-Jer Wu",authors:[{id:"217323",title:"Prof.",name:"Guang-Jer",middleName:null,surname:"Wu",fullName:"Guang-Jer Wu",slug:"guang-jer-wu"}]},{id:"19100",title:"Dual Function of Wnts in Human Cutaneous Melanoma",slug:"dual-function-of-wnts-in-human-cutaneous-melanoma",signatures:"Ksenia Kulikova, Alexey Kibardin, Nikolay Gnuchev, Georgii Georgiev and Sergey Larin",authors:[{id:"51676",title:"Dr.",name:"Ksenia",middleName:null,surname:"Kulikova",fullName:"Ksenia Kulikova",slug:"ksenia-kulikova"},{id:"51690",title:"Dr.",name:"Alexey",middleName:null,surname:"Kibardin",fullName:"Alexey Kibardin",slug:"alexey-kibardin"},{id:"51691",title:"Prof.",name:"Gnuchev",middleName:null,surname:"Nikolay",fullName:"Gnuchev Nikolay",slug:"gnuchev-nikolay"},{id:"51692",title:"Prof.",name:"Georgiev",middleName:null,surname:"Georgii",fullName:"Georgiev Georgii",slug:"georgiev-georgii"},{id:"51693",title:"Dr.",name:"Sergey",middleName:null,surname:"Larin",fullName:"Sergey Larin",slug:"sergey-larin"}]},{id:"19101",title:"A POU3F2-MITF-SHC4 Axis in Phenotype Switching of Melanoma Cells",slug:"a-pou3f2-mitf-shc4-axis-in-phenotype-switching-of-melanoma-cells",signatures:"Thomas Strub, Dominique Kobi, Dana Koludrovic and Irwin Davidson",authors:[{id:"36137",title:"Dr.",name:"Irwin",middleName:null,surname:"Davidson",fullName:"Irwin Davidson",slug:"irwin-davidson"},{id:"46090",title:"Prof.",name:"Thomas",middleName:null,surname:"Strub",fullName:"Thomas Strub",slug:"thomas-strub"},{id:"46091",title:"Prof.",name:"Dana",middleName:null,surname:"Koludrovic",fullName:"Dana Koludrovic",slug:"dana-koludrovic"}]},{id:"19102",title:"The Role of Cellular Differentiation and Cell Fate in Malignant Melanoma",slug:"the-role-of-cellular-differentiation-and-cell-fate-in-malignant-melanoma",signatures:"Paul Kuzel and Andy J. Chien",authors:[{id:"37120",title:"Prof.",name:"Andy",middleName:null,surname:"Chien",fullName:"Andy Chien",slug:"andy-chien"}]},{id:"19103",title:"Role of Angiogenesis and Microenvironment in Melanoma Progression",slug:"role-of-angiogenesis-and-microenvironment-in-melanoma-progression",signatures:"Roberto Ria, Antonia Reale and Angelo Vacca",authors:[{id:"38835",title:"Dr.",name:"Roberto",middleName:null,surname:"Ria",fullName:"Roberto Ria",slug:"roberto-ria"},{id:"41824",title:"Dr.",name:"Antonia",middleName:null,surname:"Reale",fullName:"Antonia Reale",slug:"antonia-reale"},{id:"41825",title:"Prof.",name:"Angelo",middleName:null,surname:"Vacca",fullName:"Angelo Vacca",slug:"angelo-vacca"}]},{id:"19104",title:"Stromal Microenvironment Alterations in Malignant Melanoma",slug:"stromal-microenvironment-alterations-in-malignant-melanoma",signatures:"Svetlana Brychtova, Michala Bezdekova, Jaroslav Hirnak, Eva Sedlakova, Martin Tichy and Tomas Brychta",authors:[{id:"49772",title:"Dr.",name:"Svetlana",middleName:null,surname:"Brychtova",fullName:"Svetlana Brychtova",slug:"svetlana-brychtova"},{id:"49816",title:"MSc.",name:"Michala",middleName:null,surname:"Bezdekova",fullName:"Michala Bezdekova",slug:"michala-bezdekova"},{id:"49817",title:"Dr.",name:"Jaroslav",middleName:null,surname:"Hirnak",fullName:"Jaroslav Hirnak",slug:"jaroslav-hirnak"},{id:"49819",title:"MSc.",name:"Eva",middleName:null,surname:"Sedlakova",fullName:"Eva Sedlakova",slug:"eva-sedlakova"},{id:"49820",title:"Dr.",name:"Martin",middleName:null,surname:"Tichy",fullName:"Martin Tichy",slug:"martin-tichy"},{id:"49821",title:"Dr.",name:"Tomas",middleName:null,surname:"Brychta",fullName:"Tomas Brychta",slug:"tomas-brychta"}]},{id:"19105",title:"Current Insight Into the Metastatic Process and Melanoma Cell Dissemination",slug:"current-insight-into-the-metastatic-process-and-melanoma-cell-dissemination",signatures:"Isabelle Bourgault-Villada, Michelle Hong, Karen Khoo, Muly Tham, Benjamin Toh,Lu-En Wai and Jean-Pierre Abastado",authors:[{id:"34324",title:"Dr.",name:"Jean-Pierre",middleName:null,surname:"Abastado",fullName:"Jean-Pierre Abastado",slug:"jean-pierre-abastado"},{id:"72150",title:"Prof.",name:"Isabelle",middleName:null,surname:"Bourgault-Villada",fullName:"Isabelle Bourgault-Villada",slug:"isabelle-bourgault-villada"},{id:"83524",title:"Mrs.",name:"Michelle",middleName:null,surname:"Hong",fullName:"Michelle Hong",slug:"michelle-hong"},{id:"83525",title:"Ms.",name:"Karen",middleName:null,surname:"Khoo",fullName:"Karen Khoo",slug:"karen-khoo"},{id:"83526",title:"Dr.",name:"Muly",middleName:null,surname:"Tham",fullName:"Muly Tham",slug:"muly-tham"},{id:"83527",title:"Mr.",name:"Benjamin",middleName:null,surname:"Toh",fullName:"Benjamin Toh",slug:"benjamin-toh"},{id:"83529",title:"Dr.",name:"Lu-En",middleName:null,surname:"Wai",fullName:"Lu-En Wai",slug:"lu-en-wai"}]},{id:"19106",title:"Increased Resistance of Vasculogenic Mimicry-Forming Uveal Melanoma Cells against Cytotoxic Agents in Three-Dimensional Cultures",slug:"increased-resistance-of-vasculogenic-mimicry-forming-uveal-melanoma-cells-against-cytotoxic-agents-i",signatures:"Klara Valyi-Nagy, Andras Voros, Eva Gagyi and Tibor Valyi-Nagy",authors:[{id:"34115",title:"Prof.",name:"Tibor",middleName:null,surname:"Valyi-Nagy",fullName:"Tibor Valyi-Nagy",slug:"tibor-valyi-nagy"},{id:"45508",title:"Prof.",name:"Klara",middleName:null,surname:"Valyi-Nagy",fullName:"Klara Valyi-Nagy",slug:"klara-valyi-nagy"},{id:"45509",title:"Dr.",name:"Andras",middleName:null,surname:"Voros",fullName:"Andras Voros",slug:"andras-voros"},{id:"94070",title:"Dr.",name:"Eva",middleName:null,surname:"Gagyi",fullName:"Eva Gagyi",slug:"eva-gagyi"}]},{id:"19107",title:"The Role of Adhesion Receptors in Melanoma Metastasis and Therapeutic Intervention Thereof",slug:"the-role-of-adhesion-receptors-in-melanoma-metastasis-and-therapeutic-intervention-thereof",signatures:"Michael Alexander and Gerd Bendas",authors:[{id:"32941",title:"Dr.",name:"Michael",middleName:null,surname:"Alexander",fullName:"Michael Alexander",slug:"michael-alexander"},{id:"50037",title:"Prof.",name:"Gerd",middleName:null,surname:"Bendas",fullName:"Gerd Bendas",slug:"gerd-bendas"}]}]}],publishedBooks:[{type:"book",id:"273",title:"Research on Melanoma",subtitle:"A Glimpse into Current Directions and Future Trends",isOpenForSubmission:!1,hash:"03dcadf8ca228b0a39a14c7614a712f2",slug:"research-on-melanoma-a-glimpse-into-current-directions-and-future-trends",bookSignature:"Mandi Murph",coverURL:"https://cdn.intechopen.com/books/images_new/273.jpg",editedByType:"Edited by",editors:[{id:"32293",title:"Prof.",name:"Mandi",surname:"Murph",slug:"mandi-murph",fullName:"Mandi Murph"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"520",title:"Melanoma in the Clinic",subtitle:"Diagnosis, Management and Complications of Malignancy",isOpenForSubmission:!1,hash:"1d46978920ee70714be6f18821b032ec",slug:"melanoma-in-the-clinic-diagnosis-management-and-complications-of-malignancy",bookSignature:"Prof. Mandi Murph",coverURL:"https://cdn.intechopen.com/books/images_new/520.jpg",editedByType:"Edited by",editors:[{id:"32293",title:"Prof.",name:"Mandi",surname:"Murph",slug:"mandi-murph",fullName:"Mandi Murph"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"523",title:"Treatment of Metastatic Melanoma",subtitle:null,isOpenForSubmission:!1,hash:"2cd3cbc443f75eb4ccd3664349adeab7",slug:"treatment-of-metastatic-melanoma",bookSignature:"Rachael Morton",coverURL:"https://cdn.intechopen.com/books/images_new/523.jpg",editedByType:"Edited by",editors:[{id:"52974",title:"Ms.",name:"Rachael",surname:"Morton",slug:"rachael-morton",fullName:"Rachael Morton"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"524",title:"Advances in Malignant Melanoma",subtitle:"Clinical and Research Perspectives",isOpenForSubmission:!1,hash:"529a20a7c31a8caebb49d5ce7beb7eb8",slug:"advances-in-malignant-melanoma-clinical-and-research-perspectives",bookSignature:"April W. Armstrong",coverURL:"https://cdn.intechopen.com/books/images_new/524.jpg",editedByType:"Edited by",editors:[{id:"32510",title:"Dr.",name:"April",surname:"Armstrong",slug:"april-armstrong",fullName:"April Armstrong"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"992",title:"Skin Cancers",subtitle:"Risk Factors, Prevention and Therapy",isOpenForSubmission:!1,hash:"23a6e5be04656e2ea63fb12f604c856e",slug:"skin-cancers-risk-factors-prevention-and-therapy",bookSignature:"Caterina AM La Porta",coverURL:"https://cdn.intechopen.com/books/images_new/992.jpg",editedByType:"Edited by",editors:[{id:"64852",title:"Prof.",name:"Caterina",surname:"La Porta",slug:"caterina-la-porta",fullName:"Caterina La Porta"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],publishedBooksByAuthor:[{type:"book",id:"523",title:"Treatment of Metastatic Melanoma",subtitle:null,isOpenForSubmission:!1,hash:"2cd3cbc443f75eb4ccd3664349adeab7",slug:"treatment-of-metastatic-melanoma",bookSignature:"Rachael Morton",coverURL:"https://cdn.intechopen.com/books/images_new/523.jpg",editedByType:"Edited by",editors:[{id:"52974",title:"Ms.",name:"Rachael",surname:"Morton",slug:"rachael-morton",fullName:"Rachael Morton"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},onlineFirst:{chapter:{type:"chapter",id:"71547",title:"Dipolar Interactions: Hyperfine Structure Interaction and Fine Structure Interactions",doi:"10.5772/intechopen.91791",slug:"dipolar-interactions-hyperfine-structure-interaction-and-fine-structure-interactions",body:'
1. Dipolar interactions
Dipolar interaction occurs due to the interaction between the two spins. If one spin becomes an electron spin and the other spin becomes a nucleus spin, this interaction is called a hyperfine structure interaction. If two of the spins are electron spin or both are nucleus spin, this interaction is called fine structure interaction. The dipolar interaction Hamiltonian is expressed as
ϰ=μ1→.μ2→r3−3μ1→.r→μ2→.r→r5E1
where μ1→ and μ2→ are the magnetic dipole moments for each spin (electron spin or nucleus spin).
1.1 Hyperfine structure interaction
The interaction between the magnetic dipole moment of the nucleus and the magnetic dipole moment of the electron gives the hyperfine structure interaction. There are two types of hyperfine structure interaction. These are isotropic hyperfine interaction and anisotropic hyperfine interaction.
1.1.1 Isotropic hyperfine structure
Isotropic superfine interaction is also known as Fermi contact interaction. The Hamiltonian term of isotropic hyperfine structure interaction is expressed as
ϰ=gegNβeβN8π3S→.I→.δrE2
where ge= g-value of the electron, gN= g-value of the nucleus, βe = Bohr magneton, βN= nuclear magneton, S→= electron spin operator, I→ = nuclear spin operator, and δr = Dirac delta function for the distance between the electron and the nucleus.
In a shorter way, it is expressed as
ϰ=aS→.I→E3
The isotropic hyperfine constant is written as
a=8π3gegNβeβNδrE4
Here a is called the isotropic hyperfine constant, S→ is the spin angular momentum of the electron, and I→ is the spin angular momentum of the nucleus.
1.1.2 Anisotropic hyperfine structure
Anisotropic hyperfine interaction is also called dipolar interaction or dipole–dipole interaction. The Hamiltonian term of anisotropic hyperfine structure interaction is expressed as
ϰ=gegNβeβN3S→.r→I→.r→r5−S→.I→r3E5
More specifically, the expression of the anisotropic hyperfine interaction in the Cartesian coordinate is written as
where A0→→ is called the anisotropic hyperfine coupling tensor. The tensor is expressed in two ways as diagonal elements and non-diagonal elements. The diagonal elements of the tensor is expressed as
Aii0=gegNβeβN3i2−r2r5,i=x,y,zE8
The non-diagonal elements of the tensor is expressed as
Aij0=gegNβeβN3ijr5,i,j=x,y,zE9
The sum of the isotropic and anisotropic terms fully expresses the hyperfine structure interaction Hamiltonian and is expressed as
ϰ=aS→.I→+S→.A0→→.I→=S→.A→→.I→E10
where A→→ is the general hyperfine structure tensor.
Figure 1 shows the formation of the hyperfine structure splittings. Figure 2 shows the formation of an EPR spectrum due to the hyperfine structure splittings.
Figure 1.
The formation of the hyperfine structure splittings.
Figure 2.
The formation of an EPR spectrum due to the hyperfine structure splittings.
1.2 Fine structure interaction
The fine structure is seen in two ways. The first is the fine structure interaction between two electron spins. The second is the fine structure interaction between the two nucleus spins. The fine structure interaction between two electron spin is also referred to as zero-field interaction or zero-field splitting. The interaction between two nuclear spin is called nuclear quadrupole interaction.
1.2.1 Zero-field splitting (interaction)
This interaction between two electron spins is the dipolar interaction. When writing Hamiltonian for zero-field interaction, the magnetic dipole moments in Eq. (1) are arranged for two electron spins. In this case, the Hamiltonian of the zero-field splitting is written as
ϰ=ge2βe2S1→.S2→r3−3S1→.r→S2→.r→r5E11
More specifically, the expression of the anisotropic hyperfine interaction in the Cartesian coordinate is written as
In general, the Hamiltonian of the zero-field splitting is written as
ϰ=S→.D→→.S→E14
where D→→ is called the zero-field splitting tensor or the spin–spin coupling tensor. The tensor is expressed in two ways as diagonal elements and non-diagonal elements. The diagonal elements of the tensor is expressed as
Dii=ge2βe2r2−3i2r5,i=x,y,zE15
The non-diagonal elements of the tensor is expressed as.
Dij=ge2βe23ijr5,i,j=x,y,zE16
The zero-field splittings for s = 1/2, s = 1, and s = 3/2 are shown in Figure 3.
Figure 3.
The zero-field splittings for (a) s = 1/2, (b) s = 1, and (c) s = 3/2.
1.2.2 Nuclear quadrupole interaction
The interaction between the nucleus spins is known as the nuclear quadrupole interaction. The effects of nuclear quadrupole interaction can be observed on the energy levels of the hyperfine structure for a nucleus with I≥1. The Hamiltonian of the nuclear quadrupole interaction is expressed as
ϰ=eQ6I2I−1∑α,β=x,y,zVαβ32IαIβ+IβIα−δαβI2E17
where Vαβ is the component of the field gradient tensor and eQ is the nuclear quadrupole moment, and it is a measure of the deviation of charge distribution from spherical symmetry. The nuclear quadrupole moment is expressed as
eQ=∫ρN3z2−r2dVE18
where e is the proton charge,ρN is the distribution function of the nuclear charge, z is the z-coordinate of the charge element a distance r from the origin. The integral was taken over the volume of the nucleus.
In general, the nuclear quadrupole interaction Hamiltonian is written as
ϰ=I→.P→→.I→E19
where P→→ is called the nuclear quadrupole coupling tensor.
The nuclear quadrupole splittings are shown in Figure 4.
Figure 4.
The nuclear quadrupole splittings for (a) Hquadrupole ≠ 0, H = 0 and (b) for HZeeman≫ Hquadrupole.
2. Effective Hamiltonian terms in electron paramagnetic resonance spectroscopy
The hyperfine structure Hamiltonian term, electron Zeeman Hamiltonian term, nuclear Zeeman Hamiltonian term, the term of the zero-field splitting, and the term of the nuclear quadrupole interaction are Hamiltonian terms in EPR Spectroscopy. However, in EPR spectroscopy, the electron Zeeman term and the hyperfine structure term are effective Hamiltonian terms. Therefore, the effect of the terms other than the electron Zeeman term and the hyperfine structure term is not taken into account, since the effect is minimal compared to these two terms. The electron Zeeman term and the nuclear Zeeman term have not been mentioned before. Therefore, it will be explained briefly below.
The electron Zeeman interaction occurs as a result of the interaction of the magnetic dipole moment caused by the spin of the electron with the applied magnetic field:
ϰ=−μs→.H→E20
ϰ=−γsS→.H→E21
where γs is the gyromagnetic ratio of electron spin and is written as.
γs=−gsβeℏ=−gsβein the atomic unit systemℏ=1E22
where gs is the spectroscopic splitting factor of the electron spin and is written as
gs=2E23
ϰ=−−gsβeS→.H→E24
ϰ=gsβeS→.H→E25
The nuclear Zeeman interaction occurs as a result of the interaction of the magnetic dipole moment caused by the spin of the nucleus with the applied magnetic field:
ϰ=−μI→.H→E26
ϰ=−γII→.H→E27
where γI is the nuclear gyromagnetic ratio and is written as.
γI=gIβNℏ=gIβNin the atomic unit systemℏ=1E28
where gI is the spectroscopic splitting factor of the nucleus spin and is written as
gI=1E29
ϰ=−gIβNI→.H→E30
ϰ=−gIβNI→.H→E31
The general spin Hamiltonian for EPR spectroscopy can be written as
The effective spin Hamiltonian for EPR spectroscopy can be written as [1, 2, 3, 4, 5, 6, 7, 8, 9].
ϰ=gsβeS→.H→+S→.A→→.I→E33
3. Conclusion
Dipolar interaction can be seen in three ways. These are the hyperfine structure interaction, the zero-field splitting interaction, and the nuclear quadrupole interaction. Each interaction involves the interaction of two spins. The interaction between a nucleus spin and an electron spin is mentioned in the hyperfine structure interaction. The interaction of two electron spins is mentioned in the zero-field splitting interaction. The interaction of two nuclear spins is mentioned in the nuclear quadrupole interaction. The last two interactions are also known as fine structure interactions.
The hyperfine structure interaction is an important interaction for EPR spectroscopy. In EPR spectroscopy, the effect of the hyperfine structure interaction is taken into account together with the electron Zeeman interaction [10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24]. In addition, nuclear Zeeman interaction, the zero-field interaction, and the nuclear quadrupole interaction have an effect on EPR spectroscopy. However, their effects are negligible.
\n',keywords:"dipolar interaction hyperfine structure, isotropic hyperfine structure, anisotropic hyperfine structure, the zero-field splitting, the nuclear quadrupole interaction, the electronic Zeeman interaction, the nuclear Zeeman term, EPR",chapterPDFUrl:"https://cdn.intechopen.com/pdfs/71547.pdf",chapterXML:"https://mts.intechopen.com/source/xml/71547.xml",downloadPdfUrl:"/chapter/pdf-download/71547",previewPdfUrl:"/chapter/pdf-preview/71547",totalDownloads:613,totalViews:0,totalCrossrefCites:0,dateSubmitted:"October 10th 2019",dateReviewed:"February 23rd 2020",datePrePublished:"March 25th 2020",datePublished:"October 14th 2020",dateFinished:"March 25th 2020",readingETA:"0",abstract:"The interaction between the nuclear spin and the electron spin creates a hyperfine structure. Hyperfine structure interaction occurs in paramagnetic structures with unpaired electrons. Therefore, hyperfine structure interaction is the most important of the fundamental parameters investigated by electron paramagnetic resonance (EPR) spectroscopy. For EPR spectroscopy the two effective Hamiltonian terms are the hyperfine structure interaction and the electronic Zeeman interaction. The hyperfine structure interaction has two types as isotropic and anisotropic hyperfine structure interactions. The zero-field splitting term (electronic quadrupole fine structure), the nuclear Zeeman term, and the nuclear quadrupole interaction term are among the Hamiltonian terms used in EPR. However, their effects are not as much as the term of the hyperfine structure interaction. The zero-field splitting term and the nuclear quadrupole interaction term are the fine structure terms. The interaction of two electron spins create a zero-field splitting, the interaction between the two nucleus spins form the nuclear quadrupole interaction. Hyperfine structure interaction, zero-field interaction, and nuclear quadrupole interaction are subclasses of dipolar interaction. Interaction tensors are available for all three interactions.",reviewType:"peer-reviewed",bibtexUrl:"/chapter/bibtex/71547",risUrl:"/chapter/ris/71547",signatures:"Betül Çalişkan and Ali Cengiz Çalişkan",book:{id:"10076",type:"book",title:"Quantum Mechanics",subtitle:null,fullTitle:"Quantum Mechanics",slug:"quantum-mechanics",publishedDate:"October 14th 2020",bookSignature:"Paul Bracken",coverURL:"https://cdn.intechopen.com/books/images_new/10076.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",isbn:"978-1-83968-045-8",printIsbn:"978-1-83968-044-1",pdfIsbn:"978-1-83968-046-5",isAvailableForWebshopOrdering:!0,editors:[{id:"92883",title:"Prof.",name:"Paul",middleName:null,surname:"Bracken",slug:"paul-bracken",fullName:"Paul Bracken"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"199110",title:"Dr.",name:"Betül",middleName:null,surname:"Çalişkan",fullName:"Betül Çalişkan",slug:"betul-caliskan",email:"bcaliska@gmail.com",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/199110/images/system/199110.jpg",institution:{name:"Pamukkale University",institutionURL:null,country:{name:"Turkey"}}},{id:"208732",title:"Dr.",name:"Ali Cengiz",middleName:null,surname:"Çalişkan",fullName:"Ali Cengiz Çalişkan",slug:"ali-cengiz-caliskan",email:"alicengizcaliskan@gmail.com",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:{name:"Gazi University",institutionURL:null,country:{name:"Turkey"}}}],sections:[{id:"sec_1",title:"1. Dipolar interactions",level:"1"},{id:"sec_1_2",title:"1.1 Hyperfine structure interaction",level:"2"},{id:"sec_1_3",title:"1.1.1 Isotropic hyperfine structure",level:"3"},{id:"sec_2_3",title:"1.1.2 Anisotropic hyperfine structure",level:"3"},{id:"sec_4_2",title:"1.2 Fine structure interaction",level:"2"},{id:"sec_4_3",title:"1.2.1 Zero-field splitting (interaction)",level:"3"},{id:"sec_5_3",title:"1.2.2 Nuclear quadrupole interaction",level:"3"},{id:"sec_8",title:"2. Effective Hamiltonian terms in electron paramagnetic resonance spectroscopy",level:"1"},{id:"sec_9",title:"3. Conclusion",level:"1"}],chapterReferences:[{id:"B1",body:'Atherton NM. Electron Spin Resonance Theory and Applications. New York: John Wiley & Sons Inc.; 1993'},{id:"B2",body:'Weil JA, Bolton JR, Wertz JE. Electron Paramagnetic Resonance Elementary Theory and Practical Applications. New York: John Wiley & Sons Inc.; 1994'},{id:"B3",body:'Gordy W. Theory and Applications of Electron Spin Resonance. New York: John Wiley & Sons Inc.; 1980'},{id:"B4",body:'Symons M. Chemical and Biochemical Aspects of Electron-Spin Resonance Spectroscopy. New York: Van Nostrand Reinhold Company; 1978'},{id:"B5",body:'Bersohn M, Baird JC. An Introduction to Electron Paramagnetic Resonance. New York: W.A. Benjamin, Inc.; 1966'},{id:"B6",body:'Assenheim HM. Introduction to Electron Spin Resonance. New York: Plenum Press; 1967'},{id:"B7",body:'Ingram DJE. Free Radicals as Studied by Electron Spin Resonance. Butterworth’s Scientific Publications; 1958'},{id:"B8",body:'Ranby B, Rabek JF. ESR Spectroscopy in Polymer Research. Berlin: Springer-Verlag; 1977'},{id:"B9",body:'Roylance DK. An EPR investigation of polymer fracture, PhD Dissertation, Department of Mechanical Engineering, University of Utah, Salt Lake City, Utah. August 1968'},{id:"B10",body:'Caliskan B, Caliskan AC, Er E. Electron paramagnetic resonance study of gamma-irradiated potassium hydroquinone monosulfonate single crystal. Radiation Effects and Defects in Solids. 2016;171(5–6):440-450. DOI: 10.1080/10420150.2016.1203924'},{id:"B11",body:'Caliskan B. EPR study of gamma irradiated cholestanone single crystal. Acta Physica Polonica A. 2014;125(1):135-138. DOI: 10.12693/APhysPolA.125.135'},{id:"B12",body:'Caliskan B, Caliskan AC, Yerli R. Electron paramagnetic resonance study of radiation damage in isonipecotic acid single crystal. Journal of Molecular Structure. 2014;1075:12-16. DOI: 10.1016/j.mol.struc.2014.06.030'},{id:"B13",body:'Caliskan B, Caliskan AC. EPR study of radiation damage in gamma irradiated 3-nitroacetophenone single crystal. Radiation Effects and Defects in Solids. 2017;172(5–6):398-410. DOI: 10.1080/10420150.2017.1320800'},{id:"B14",body:'Caliskan B, Caliskan AC, Er E. Electron paramagnetic resonance study of radiation-induced paramagnetic centers in succinic anhydride single crystal. Journal of Molecular Structure. 2017;1144:421-431. DOI: 10.1016/j.molstruc.2017.05.039'},{id:"B15",body:'Caliskan B, Caliskan AC. EPR study of free radical in gamma-irradiated bis(cyclopentadienyl)zirconium dichloride single crystal. Radiation Effects and Defects in Solids. 2017;172(5–6):507-516. DOI: 10.1080/10420150.2017.1346652'},{id:"B16",body:'Caliskan B, Aras E, Asik B, Buyum M, Birey M. EPR of gamma irradiated single crystals of cholesteryl benzoate. Radiation Effects and Defects in Solids. 2004;159(1):1-5. DOI: 10.1080/10420150310001604101'},{id:"B17",body:'Caliskan B, Tokgoz H. Electron paramagnetic resonance study of gamma-irradiated phenidone single crystal. Radiation Effects and Defects in Solids. 2014;169(3):225-231. DOI: 10.1080/10420150.2013.834903'},{id:"B18",body:'Caliskan B, Civi M, Birey M. Electron paramagnetic resonance analysis of gamma irradiated 4-nitropyridine N-oxide single crystal. Radiation Effects and Defects in Solids. 2006;161(5):313-317. DOI: 10.1080/10420150600576049'},{id:"B19",body:'Caliskan B, Caliskan AC. Electron paramagnetic resonance study of the paramagnetic center in gamma-irradiated sulfanilic acid single crystal. Acta Physica Polonica A. 2019;135(3):480-484. DOI: 10.12693/APhysPolA.135.480'},{id:"B20",body:'Caliskan B, Civi M, Birey M. Electron paramagnetic resonance characterization of gamma irradiation damage centers in S-butyrylthiocholine iodide single crystal. Radiation Effects and Defects in Solids. 2007;162(2):87-93. DOI: 10.1080/10420150600907632'},{id:"B21",body:'Aras E, Asik B, Caliskan B, Buyum M, Birey M. Electron paramagnetic resonance study of irradiated tetramethyl-4-piperidion. Radiation Effects and Defects in Solids. 2004;159(6):353-358. DOI: 10.1080/10420150410001731820'},{id:"B22",body:'Asik B, Aras E, Caliskan B, Eken M, Birey M. EPR study of irradiated 4-chloromethyl pyridinium chloride. Radiation Effects and Defects in Solids. 2004;159(1):55-60. DOI: 10.1080/10420150310001639770'},{id:"B23",body:'Caliskan B, Caliskan AC. Electron paramagnetic resonance study of the radiation damage in phosphoryethanolamine single crystal. Journal of Molecular Structure. 2018;1173:781-791. DOI: 10.1016/j.molstruc.2018.07.045'},{id:"B24",body:'Caliskan B, Caliskan AC. Electron paramagnetic resonance study of the radiation damage in trans-chalcone single crystal. Acta Physica Polonica A. 2019;136(1):92-100. DOI: 10.12693/APhysPolA.136.92'}],footnotes:[],contributors:[{corresp:"yes",contributorFullName:"Betül Çalişkan",address:"bcaliska@gmail.com",affiliation:'
Faculty of Arts and Science, Department of Physics, Pamukkale University, Kinikli, Turkey
Faculty of Science, Department of Chemistry, Gazi University, Turkey
'}],corrections:null},book:{id:"10076",type:"book",title:"Quantum Mechanics",subtitle:null,fullTitle:"Quantum Mechanics",slug:"quantum-mechanics",publishedDate:"October 14th 2020",bookSignature:"Paul Bracken",coverURL:"https://cdn.intechopen.com/books/images_new/10076.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",isbn:"978-1-83968-045-8",printIsbn:"978-1-83968-044-1",pdfIsbn:"978-1-83968-046-5",isAvailableForWebshopOrdering:!0,editors:[{id:"92883",title:"Prof.",name:"Paul",middleName:null,surname:"Bracken",slug:"paul-bracken",fullName:"Paul Bracken"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}}},profile:{item:{id:"353922",title:"Dr.",name:"Yujing",middleName:null,surname:"BI",email:"biyujing15@hotmail.com",fullName:"Yujing BI",slug:"yujing-bi",position:null,biography:null,institutionString:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",totalCites:0,totalChapterViews:"0",outsideEditionCount:0,totalAuthoredChapters:"1",totalEditedBooks:"0",personalWebsiteURL:null,twitterURL:null,linkedinURL:null,institution:null},booksEdited:[],chaptersAuthored:[{id:"78388",title:"Revisiting Olivine Phosphate and Blend Cathodes in Lithium Ion Batteries for Electric Vehicles",slug:"revisiting-olivine-phosphate-and-blend-cathodes-in-lithium-ion-batteries-for-electric-vehicles",abstract:"As electric vehicle market growing fast, lithium ion batteries demand is increasing rapidly. Sufficient battery materials supplies including cathode, anode, electrolyte, additives, et al. are required accordingly. Although layered cathode is welcome in high energy density batteries, it is challenging to balance the high energy density and safety beside cost. As consequence, olivine phosphate cathode is coming to the stage center again along with battery technology development. It is important and necessary to revisit the olivine phosphate cathode to understand and support the development of electric vehicles utilized lithium ion batteries. In addition, blend cathode is a good strategy to tailor and balance cathode property and performance. In this chapter, blend cathode using olivine phosphate cathode will be discussed as well as olivine phosphate cathode.",signatures:"Yujing Bi and Deyu Wang",authors:[{id:"353922",title:"Dr.",name:"Yujing",surname:"BI",fullName:"Yujing BI",slug:"yujing-bi",email:"biyujing15@hotmail.com"},{id:"427192",title:"Prof.",name:"Deyu",surname:"Wang",fullName:"Deyu Wang",slug:"deyu-wang",email:"wangdeyu@jhun.edu.cn"}],book:{id:"10969",title:"New Perspectives on Electric Vehicles",slug:"new-perspectives-on-electric-vehicles",productType:{id:"1",title:"Edited Volume"}}}],collaborators:[{id:"22357",title:"Dr.",name:"Abdelaziz",surname:"Sahbani",slug:"abdelaziz-sahbani",fullName:"Abdelaziz Sahbani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"190371",title:"Dr.",name:"Mircea",surname:"Ruba",slug:"mircea-ruba",fullName:"Mircea Ruba",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/190371/images/system/190371.png",biography:"Dr. Mircea Ruba is currently a lecturer with the Technical University of Cluj-Napoca (TUCN), Department of Electrical Machines\nand Drives and is a member of CAREESD, being in charge of the\nReal-Time System Modelling and Testing Laboratory (RTsymLab). His scientific interests are focused on electric vehicle (EV)\npropulsion drives and on their real-time FPGA based simulation\nand Hardware in the Loop (HiL) testing. He has been a researcher\nin over 20 projects and in most he worked to develop electrical motors, power inverters, controllers and battery supply units for EVs. His skills in designing, simulation\nand controlling propulsion motors for EVs have been proved in a large number of\npublications, creating real-time (RT) FPGA based simulators for their realistic analysis and control. Investigation of LiIon battery identification, simulation and testing\nwas also a consistent research direction for Dr Ruba including patenting a novel, ultra-fast and efficient BMS. He invested several years and his PhD thesis in the study\nof fault tolerant machines, converters, and controllers outcome in many publications\npatenting a novel fault detection and compensation strategy and a modular fault\ntolerant motor design. His patents were awarded in 13 international exhibitions, his\npublications were cited in hundreds of papers, especially in 97 ISI journals and since\n2018 he was invited to be an editor for “Devices and machines applied for electric\nmobility solutions” published by IntechOpen. He has published over 80 conference\npapers, 6 ISI journal papers, 4 books, and 6 patents (3 still pending)",institutionString:"Technical University of Cluj Napoca",institution:{name:"Technical University of Cluj-Napoca",institutionURL:null,country:{name:"Romania"}}},{id:"240170",title:"Dr.",name:"Muhammet Tahir",surname:"Güneşer",slug:"muhammet-tahir-guneser",fullName:"Muhammet Tahir Güneşer",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Acıbadem University",institutionURL:null,country:{name:"Turkey"}}},{id:"352834",title:"Mr.",name:"Raul Octavian",surname:"Nemeș",slug:"raul-octavian-nemes",fullName:"Raul Octavian Nemeș",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Technical University of Cluj-Napoca",institutionURL:null,country:{name:"Romania"}}},{id:"352835",title:"Ms.",name:"Sorina Maria",surname:"Ciornei",slug:"sorina-maria-ciornei",fullName:"Sorina Maria Ciornei",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Technical University of Cluj-Napoca",institutionURL:null,country:{name:"Romania"}}},{id:"352836",title:"Ph.D. Student",name:"Raluca Maria",surname:"Raia",slug:"raluca-maria-raia",fullName:"Raluca Maria Raia",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Technical University of Cluj-Napoca",institutionURL:null,country:{name:"Romania"}}},{id:"355074",title:"Assistant Prof.",name:"Murat",surname:"Furat",slug:"murat-furat",fullName:"Murat Furat",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"355138",title:"BSc.",name:"Senem",surname:"Kocaoğlu",slug:"senem-kocaoglu",fullName:"Senem Kocaoğlu",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"İskenderun Technical University",institutionURL:null,country:{name:"Turkey"}}},{id:"419585",title:"MSc.",name:"İsra",surname:"Karabiber",slug:"isra-karabiber",fullName:"İsra Karabiber",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"İskenderun Technical University",institutionURL:null,country:{name:"Turkey"}}},{id:"420879",title:"Dr.",name:"Hela",surname:"Mahersia",slug:"hela-mahersia",fullName:"Hela Mahersia",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"National Engineering School of Tunis",institutionURL:null,country:{name:"Tunisia"}}}]},generic:{page:{slug:"unsubscribe-successful",title:"Unsubscribe Successful",intro:"
You have been successfully unsubscribed.
",metaTitle:"Unsubscribe Successful",metaDescription:"You have been successfully unsubscribed.",metaKeywords:null,canonicalURL:"/page/unsubscribe-successful",contentRaw:'[{"type":"htmlEditorComponent","content":""}]'},components:[{type:"htmlEditorComponent",content:""}]},successStories:{items:[]},authorsAndEditors:{filterParams:{},profiles:[{id:"396",title:"Dr.",name:"Vedran",middleName:null,surname:"Kordic",slug:"vedran-kordic",fullName:"Vedran Kordic",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/396/images/7281_n.png",biography:"After obtaining his Master's degree in Mechanical Engineering he continued his education at the Vienna University of Technology where he obtained his PhD degree in 2004. He worked as a researcher at the Automation and Control Institute, Faculty of Electrical Engineering, Vienna University of Technology until 2008. His studies in robotics lead him not only to a PhD degree but also inspired him to co-found and build the International Journal of Advanced Robotic Systems - world's first Open Access journal in the field of robotics.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"441",title:"Ph.D.",name:"Jaekyu",middleName:null,surname:"Park",slug:"jaekyu-park",fullName:"Jaekyu Park",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/441/images/1881_n.jpg",biography:null,institutionString:null,institution:{name:"LG Corporation (South Korea)",country:{name:"Korea, South"}}},{id:"465",title:"Dr",name:"Christian",middleName:null,surname:"Martens",slug:"christian-martens",fullName:"Christian Martens",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"479",title:"Dr.",name:"Valentina",middleName:null,surname:"Colla",slug:"valentina-colla",fullName:"Valentina Colla",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/479/images/358_n.jpg",biography:null,institutionString:null,institution:{name:"Sant'Anna School of Advanced Studies",country:{name:"Italy"}}},{id:"494",title:"PhD",name:"Loris",middleName:null,surname:"Nanni",slug:"loris-nanni",fullName:"Loris Nanni",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/494/images/system/494.jpg",biography:"Loris Nanni received his Master Degree cum laude on June-2002 from the University of Bologna, and the April 26th 2006 he received his Ph.D. in Computer Engineering at DEIS, University of Bologna. On September, 29th 2006 he has won a post PhD fellowship from the university of Bologna (from October 2006 to October 2008), at the competitive examination he was ranked first in the industrial engineering area. He extensively served as referee for several international journals. He is author/coauthor of more than 100 research papers. He has been involved in some projects supported by MURST and European Community. His research interests include pattern recognition, bioinformatics, and biometric systems (fingerprint classification and recognition, signature verification, face recognition).",institutionString:null,institution:null},{id:"496",title:"Dr.",name:"Carlos",middleName:null,surname:"Leon",slug:"carlos-leon",fullName:"Carlos Leon",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Seville",country:{name:"Spain"}}},{id:"512",title:"Dr.",name:"Dayang",middleName:null,surname:"Jawawi",slug:"dayang-jawawi",fullName:"Dayang Jawawi",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Technology Malaysia",country:{name:"Malaysia"}}},{id:"528",title:"Dr.",name:"Kresimir",middleName:null,surname:"Delac",slug:"kresimir-delac",fullName:"Kresimir Delac",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/528/images/system/528.jpg",biography:"K. Delac received his B.Sc.E.E. degree in 2003 and is currentlypursuing a Ph.D. degree at the University of Zagreb, Faculty of Electrical Engineering andComputing. His current research interests are digital image analysis, pattern recognition andbiometrics.",institutionString:null,institution:{name:"University of Zagreb",country:{name:"Croatia"}}},{id:"557",title:"Dr.",name:"Andon",middleName:"Venelinov",surname:"Topalov",slug:"andon-topalov",fullName:"Andon Topalov",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/557/images/1927_n.jpg",biography:"Dr. Andon V. Topalov received the MSc degree in Control Engineering from the Faculty of Information Systems, Technologies, and Automation at Moscow State University of Civil Engineering (MGGU) in 1979. He then received his PhD degree in Control Engineering from the Department of Automation and Remote Control at Moscow State Mining University (MGSU), Moscow, in 1984. From 1985 to 1986, he was a Research Fellow in the Research Institute for Electronic Equipment, ZZU AD, Plovdiv, Bulgaria. In 1986, he joined the Department of Control Systems, Technical University of Sofia at the Plovdiv campus, where he is presently a Full Professor. He has held long-term visiting Professor/Scholar positions at various institutions in South Korea, Turkey, Mexico, Greece, Belgium, UK, and Germany. And he has coauthored one book and authored or coauthored more than 80 research papers in conference proceedings and journals. His current research interests are in the fields of intelligent control and robotics.",institutionString:null,institution:{name:"Technical University of Sofia",country:{name:"Bulgaria"}}},{id:"585",title:"Prof.",name:"Munir",middleName:null,surname:"Merdan",slug:"munir-merdan",fullName:"Munir Merdan",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/585/images/system/585.jpg",biography:"Munir Merdan received the M.Sc. degree in mechanical engineering from the Technical University of Sarajevo, Bosnia and Herzegovina, in 2001, and the Ph.D. degree in electrical engineering from the Vienna University of Technology, Vienna, Austria, in 2009.Since 2005, he has been at the Automation and Control Institute, Vienna University of Technology, where he is currently a Senior Researcher. His research interests include the application of agent technology for achieving agile control in the manufacturing environment.",institutionString:null,institution:null},{id:"605",title:"Prof",name:"Dil",middleName:null,surname:"Hussain",slug:"dil-hussain",fullName:"Dil Hussain",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/605/images/system/605.jpg",biography:"Dr. Dil Muhammad Akbar Hussain is a professor of Electronics Engineering & Computer Science at the Department of Energy Technology, Aalborg University Denmark. Professor Akbar has a Master degree in Digital Electronics from Govt. College University, Lahore Pakistan and a P-hD degree in Control Engineering from the School of Engineering and Applied Sciences, University of Sussex United Kingdom. Aalborg University has Two Satellite Campuses, one in Copenhagen (Aalborg University Copenhagen) and the other in Esbjerg (Aalborg University Esbjerg).\n· He is a member of prestigious IEEE (Institute of Electrical and Electronics Engineers), and IAENG (International Association of Engineers) organizations. \n· He is the chief Editor of the Journal of Software Engineering.\n· He is the member of the Editorial Board of International Journal of Computer Science and Software Technology (IJCSST) and International Journal of Computer Engineering and Information Technology. \n· He is also the Editor of Communication in Computer and Information Science CCIS-20 by Springer.\n· Reviewer For Many Conferences\nHe is the lead person in making collaboration agreements between Aalborg University and many universities of Pakistan, for which the MOU’s (Memorandum of Understanding) have been signed.\nProfessor Akbar is working in Academia since 1990, he started his career as a Lab demonstrator/TA at the University of Sussex. After finishing his P. hD degree in 1992, he served in the Industry as a Scientific Officer and continued his academic career as a visiting scholar for a number of educational institutions. In 1996 he joined National University of Science & Technology Pakistan (NUST) as an Associate Professor; NUST is one of the top few universities in Pakistan. In 1999 he joined an International Company Lineo Inc, Canada as Manager Compiler Group, where he headed the group for developing Compiler Tool Chain and Porting of Operating Systems for the BLACKfin processor. The processor development was a joint venture by Intel and Analog Devices. In 2002 Lineo Inc., was taken over by another company, so he joined Aalborg University Denmark as an Assistant Professor.\nProfessor Akbar has truly a multi-disciplined career and he continued his legacy and making progress in many areas of his interests both in teaching and research. He has contributed in stochastic estimation of control area especially, in the Multiple Target Tracking and Interactive Multiple Model (IMM) research, Ball & Beam Control Problem, Robotics, Levitation Control. He has contributed in developing Algorithms for Fingerprint Matching, Computer Vision and Face Recognition. He has been supervising Pattern Recognition, Formal Languages and Distributed Processing projects for several years. He has reviewed many books on Management, Computer Science. Currently, he is an active and permanent reviewer for many international conferences and symposia and the program committee member for many international conferences.\nIn teaching he has taught the core computer science subjects like, Digital Design, Real Time Embedded System Programming, Operating Systems, Software Engineering, Data Structures, Databases, Compiler Construction. In the Engineering side, Digital Signal Processing, Computer Architecture, Electronics Devices, Digital Filtering and Engineering Management.\nApart from his Academic Interest and activities he loves sport especially, Cricket, Football, Snooker and Squash. He plays cricket for Esbjerg city in the second division team as an opener wicket keeper batsman. He is a very good player of squash but has not played squash since his arrival in Denmark.",institutionString:null,institution:null},{id:"611",title:"Prof.",name:"T",middleName:null,surname:"Nagarajan",slug:"t-nagarajan",fullName:"T Nagarajan",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universiti Teknologi Petronas",country:{name:"Malaysia"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:6581},{group:"region",caption:"Middle and South America",value:2,count:5888},{group:"region",caption:"Africa",value:3,count:2381},{group:"region",caption:"Asia",value:4,count:12507},{group:"region",caption:"Australia and Oceania",value:5,count:1006},{group:"region",caption:"Europe",value:6,count:17528}],offset:12,limit:12,total:132501},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{sort:"dateEndThirdStepPublish",topicId:"23"},books:[{type:"book",id:"11438",title:"Fake News in the Era of Pandemics",subtitle:null,isOpenForSubmission:!0,hash:"bc9e4cab86c76f35cd70b39086d9b69e",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/11438.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11472",title:"21st Century Slavery",subtitle:null,isOpenForSubmission:!0,hash:"b341f3fc3411ced881e43ce007a892b8",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/11472.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11473",title:"Social Inequality",subtitle:null,isOpenForSubmission:!0,hash:"20307129f7fb39aa443d5449acb6a784",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/11473.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11770",title:"Feminism",subtitle:null,isOpenForSubmission:!0,hash:"008be465c708a6fde48c8468757a40af",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/11770.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11771",title:"Photography",subtitle:null,isOpenForSubmission:!0,hash:"466454ffeb31a0953c5120379ffece18",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/11771.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11773",title:"Archaeology - Challenges and Updates",subtitle:null,isOpenForSubmission:!0,hash:"17d91462fa926279f65164ac0d5641cd",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/11773.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11481",title:"Active Learning - Research and Practice",subtitle:null,isOpenForSubmission:!0,hash:"3aba1eb3600a8c9ff880c628f70b3298",slug:null,bookSignature:"Ph.D. Delfín Ortega-Sánchez",coverURL:"https://cdn.intechopen.com/books/images_new/11481.jpg",editedByType:null,editors:[{id:"302925",title:"Ph.D.",name:"Delfín",surname:"Ortega-Sánchez",slug:"delfin-ortega-sanchez",fullName:"Delfín Ortega-Sánchez"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12123",title:"Heritage",subtitle:null,isOpenForSubmission:!0,hash:"cd87c7c1fb6a01f377378713388b9fd6",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12123.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12124",title:"Criminal Behavior",subtitle:null,isOpenForSubmission:!0,hash:"b0c407228070f8876b24ceb718516ed7",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12124.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12115",title:"European Politics",subtitle:null,isOpenForSubmission:!0,hash:"274a7fe06bb1c3cf128bf7ad081c7c12",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12115.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12116",title:"Youth and Youth Work",subtitle:null,isOpenForSubmission:!0,hash:"5fcd245b25b23db90b3fd0430d61e168",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12116.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12117",title:"Terrorism",subtitle:null,isOpenForSubmission:!0,hash:"6e88a48205eb81b8374e9e8efac25f6e",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12117.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:41},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:11},{group:"topic",caption:"Business, Management and Economics",value:7,count:6},{group:"topic",caption:"Chemistry",value:8,count:21},{group:"topic",caption:"Computer and Information Science",value:9,count:21},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:15},{group:"topic",caption:"Engineering",value:11,count:59},{group:"topic",caption:"Environmental Sciences",value:12,count:8},{group:"topic",caption:"Immunology and Microbiology",value:13,count:10},{group:"topic",caption:"Materials Science",value:14,count:27},{group:"topic",caption:"Mathematics",value:15,count:9},{group:"topic",caption:"Medicine",value:16,count:124},{group:"topic",caption:"Nanotechnology and Nanomaterials",value:17,count:9},{group:"topic",caption:"Neuroscience",value:18,count:3},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:6},{group:"topic",caption:"Physics",value:20,count:11},{group:"topic",caption:"Psychology",value:21,count:10},{group:"topic",caption:"Robotics",value:22,count:4},{group:"topic",caption:"Social Sciences",value:23,count:9},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:4}],offset:12,limit:12,total:34},popularBooks:{featuredBooks:[{type:"book",id:"10584",title:"Engineered Wood Products for Construction",subtitle:null,isOpenForSubmission:!1,hash:"421757c56a3735986055250821275a51",slug:"engineered-wood-products-for-construction",bookSignature:"Meng Gong",coverURL:"https://cdn.intechopen.com/books/images_new/10584.jpg",editors:[{id:"274242",title:"Dr.",name:"Meng",middleName:null,surname:"Gong",slug:"meng-gong",fullName:"Meng Gong"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10222",title:"Demyelination Disorders",subtitle:null,isOpenForSubmission:!1,hash:"b6c26ceccacdde70c41c587361bd5558",slug:"demyelination-disorders",bookSignature:"Stavros J. Baloyannis, Fabian H. Rossi and Welwin Liu",coverURL:"https://cdn.intechopen.com/books/images_new/10222.jpg",editors:[{id:"156098",title:"Emeritus Prof.",name:"Stavros J.",middleName:"J.",surname:"Baloyannis",slug:"stavros-j.-baloyannis",fullName:"Stavros J. Baloyannis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9544",title:"Global Trade in the Emerging Business Environment",subtitle:null,isOpenForSubmission:!1,hash:"fb8cb09b9599246add78d508a98273d5",slug:"global-trade-in-the-emerging-business-environment",bookSignature:"Muhammad Mohiuddin, Jingbin Wang , Md. Samim Al Azad and Selim Ahmed",coverURL:"https://cdn.intechopen.com/books/images_new/9544.jpg",editors:[{id:"418514",title:"Dr.",name:"Muhammad",middleName:null,surname:"Mohiuddin",slug:"muhammad-mohiuddin",fullName:"Muhammad Mohiuddin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10979",title:"Parenting",subtitle:"Challenges of Child Rearing in a Changing Society",isOpenForSubmission:!1,hash:"6f345ebcf4fd61e73643c69063a12c7b",slug:"parenting-challenges-of-child-rearing-in-a-changing-society",bookSignature:"Sayyed Ali Samadi",coverURL:"https://cdn.intechopen.com/books/images_new/10979.jpg",editors:[{id:"52145",title:"Dr.",name:"Sayyed Ali",middleName:null,surname:"Samadi",slug:"sayyed-ali-samadi",fullName:"Sayyed Ali Samadi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9808",title:"Contemporary Topics in Patient Safety",subtitle:"Volume 1",isOpenForSubmission:!1,hash:"fb6371607c2c6c02c6a2af8892765aba",slug:"contemporary-topics-in-patient-safety-volume-1",bookSignature:"Stanislaw P. Stawicki and Michael S. Firstenberg",coverURL:"https://cdn.intechopen.com/books/images_new/9808.jpg",editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10681",title:"Biodegradation Technology of Organic and Inorganic Pollutants",subtitle:null,isOpenForSubmission:!1,hash:"9a6e10e02788092872fd249436898e97",slug:"biodegradation-technology-of-organic-and-inorganic-pollutants",bookSignature:"Kassio Ferreira Mendes, Rodrigo Nogueira de Sousa and Kamila Cabral Mielke",coverURL:"https://cdn.intechopen.com/books/images_new/10681.jpg",editors:[{id:"197720",title:"Ph.D.",name:"Kassio",middleName:null,surname:"Ferreira Mendes",slug:"kassio-ferreira-mendes",fullName:"Kassio Ferreira Mendes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10764",title:"Antenna Systems",subtitle:null,isOpenForSubmission:!1,hash:"2fbf1c7a5d92723f08198fc9b526a8ad",slug:"antenna-systems",bookSignature:"Hussain Al-Rizzo and Said Abushamleh",coverURL:"https://cdn.intechopen.com/books/images_new/10764.jpg",editors:[{id:"153384",title:"Prof.",name:"Hussain",middleName:null,surname:"Al-Rizzo",slug:"hussain-al-rizzo",fullName:"Hussain Al-Rizzo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10668",title:"Sustainability of Concrete With Synthetic and Recycled Aggregates",subtitle:null,isOpenForSubmission:!1,hash:"55856c6a8bc3a5b21dae5a1af09a56b6",slug:"sustainability-of-concrete-with-synthetic-and-recycled-aggregates",bookSignature:"Hosam M. Saleh",coverURL:"https://cdn.intechopen.com/books/images_new/10668.jpg",editors:[{id:"144691",title:"Prof.",name:"Hosam",middleName:null,surname:"Saleh",slug:"hosam-saleh",fullName:"Hosam Saleh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10803",title:"Reactive Oxygen Species",subtitle:null,isOpenForSubmission:!1,hash:"176adcf090fdd1f93cb8ce3146e79ca1",slug:"reactive-oxygen-species",bookSignature:"Rizwan Ahmad",coverURL:"https://cdn.intechopen.com/books/images_new/10803.jpg",editors:[{id:"40482",title:null,name:"Rizwan",middleName:null,surname:"Ahmad",slug:"rizwan-ahmad",fullName:"Rizwan Ahmad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9032",title:"Corporate Social Responsibility",subtitle:null,isOpenForSubmission:!1,hash:"f609bf3251d7cc7bae0099a4374adfc3",slug:"corporate-social-responsibility",bookSignature:"Beatrice Orlando",coverURL:"https://cdn.intechopen.com/books/images_new/9032.jpg",editors:[{id:"232969",title:"Prof.",name:"Beatrice",middleName:null,surname:"Orlando",slug:"beatrice-orlando",fullName:"Beatrice Orlando"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10351",title:"Enhanced Liposuction",subtitle:"New Perspectives and Techniques",isOpenForSubmission:!1,hash:"f08ed6de16da357614586c5b58ed4dfa",slug:"enhanced-liposuction-new-perspectives-and-techniques",bookSignature:"Diane Irvine Duncan",coverURL:"https://cdn.intechopen.com/books/images_new/10351.jpg",editors:[{id:"279869",title:"Dr.",name:"Diane Irvine",middleName:null,surname:"Duncan",slug:"diane-irvine-duncan",fullName:"Diane Irvine Duncan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10779",title:"21st Century Nanostructured Materials",subtitle:"Physics, Chemistry, Classification, and Emerging Applications in Industry, Biomedicine, and Agriculture",isOpenForSubmission:!1,hash:"72c67f97f9bef68200df115b5fd79884",slug:"21st-century-nanostructured-materials-physics-chemistry-classification-and-emerging-applications-in-industry-biomedicine-and-agriculture",bookSignature:"Phuong V. Pham",coverURL:"https://cdn.intechopen.com/books/images_new/10779.jpg",editors:[{id:"236073",title:"Dr.",name:"Phuong",middleName:"Viet",surname:"Pham",slug:"phuong-pham",fullName:"Phuong Pham"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:4386},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"10584",title:"Engineered Wood Products for Construction",subtitle:null,isOpenForSubmission:!1,hash:"421757c56a3735986055250821275a51",slug:"engineered-wood-products-for-construction",bookSignature:"Meng Gong",coverURL:"https://cdn.intechopen.com/books/images_new/10584.jpg",publishedDate:"April 28th 2022",numberOfDownloads:3665,editors:[{id:"274242",title:"Dr.",name:"Meng",middleName:null,surname:"Gong",slug:"meng-gong",fullName:"Meng Gong"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10222",title:"Demyelination Disorders",subtitle:null,isOpenForSubmission:!1,hash:"b6c26ceccacdde70c41c587361bd5558",slug:"demyelination-disorders",bookSignature:"Stavros J. Baloyannis, Fabian H. Rossi and Welwin Liu",coverURL:"https://cdn.intechopen.com/books/images_new/10222.jpg",publishedDate:"May 4th 2022",numberOfDownloads:1713,editors:[{id:"156098",title:"Emeritus Prof.",name:"Stavros J.",middleName:"J.",surname:"Baloyannis",slug:"stavros-j.-baloyannis",fullName:"Stavros J. Baloyannis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9544",title:"Global Trade in the Emerging Business Environment",subtitle:null,isOpenForSubmission:!1,hash:"fb8cb09b9599246add78d508a98273d5",slug:"global-trade-in-the-emerging-business-environment",bookSignature:"Muhammad Mohiuddin, Jingbin Wang , Md. Samim Al Azad and Selim Ahmed",coverURL:"https://cdn.intechopen.com/books/images_new/9544.jpg",publishedDate:"April 28th 2022",numberOfDownloads:2481,editors:[{id:"418514",title:"Dr.",name:"Muhammad",middleName:null,surname:"Mohiuddin",slug:"muhammad-mohiuddin",fullName:"Muhammad Mohiuddin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10979",title:"Parenting",subtitle:"Challenges of Child Rearing in a Changing Society",isOpenForSubmission:!1,hash:"6f345ebcf4fd61e73643c69063a12c7b",slug:"parenting-challenges-of-child-rearing-in-a-changing-society",bookSignature:"Sayyed Ali Samadi",coverURL:"https://cdn.intechopen.com/books/images_new/10979.jpg",publishedDate:"May 4th 2022",numberOfDownloads:1107,editors:[{id:"52145",title:"Dr.",name:"Sayyed Ali",middleName:null,surname:"Samadi",slug:"sayyed-ali-samadi",fullName:"Sayyed Ali Samadi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9808",title:"Contemporary Topics in Patient Safety",subtitle:"Volume 1",isOpenForSubmission:!1,hash:"fb6371607c2c6c02c6a2af8892765aba",slug:"contemporary-topics-in-patient-safety-volume-1",bookSignature:"Stanislaw P. Stawicki and Michael S. Firstenberg",coverURL:"https://cdn.intechopen.com/books/images_new/9808.jpg",publishedDate:"April 20th 2022",numberOfDownloads:3307,editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10681",title:"Biodegradation Technology of Organic and Inorganic Pollutants",subtitle:null,isOpenForSubmission:!1,hash:"9a6e10e02788092872fd249436898e97",slug:"biodegradation-technology-of-organic-and-inorganic-pollutants",bookSignature:"Kassio Ferreira Mendes, Rodrigo Nogueira de Sousa and Kamila Cabral Mielke",coverURL:"https://cdn.intechopen.com/books/images_new/10681.jpg",publishedDate:"April 20th 2022",numberOfDownloads:3266,editors:[{id:"197720",title:"Ph.D.",name:"Kassio",middleName:null,surname:"Ferreira Mendes",slug:"kassio-ferreira-mendes",fullName:"Kassio Ferreira Mendes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10764",title:"Antenna Systems",subtitle:null,isOpenForSubmission:!1,hash:"2fbf1c7a5d92723f08198fc9b526a8ad",slug:"antenna-systems",bookSignature:"Hussain Al-Rizzo and Said Abushamleh",coverURL:"https://cdn.intechopen.com/books/images_new/10764.jpg",publishedDate:"April 28th 2022",numberOfDownloads:1868,editors:[{id:"153384",title:"Prof.",name:"Hussain",middleName:null,surname:"Al-Rizzo",slug:"hussain-al-rizzo",fullName:"Hussain Al-Rizzo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10668",title:"Sustainability of Concrete With Synthetic and Recycled Aggregates",subtitle:null,isOpenForSubmission:!1,hash:"55856c6a8bc3a5b21dae5a1af09a56b6",slug:"sustainability-of-concrete-with-synthetic-and-recycled-aggregates",bookSignature:"Hosam M. Saleh",coverURL:"https://cdn.intechopen.com/books/images_new/10668.jpg",publishedDate:"May 4th 2022",numberOfDownloads:856,editors:[{id:"144691",title:"Prof.",name:"Hosam",middleName:null,surname:"Saleh",slug:"hosam-saleh",fullName:"Hosam Saleh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10803",title:"Reactive Oxygen Species",subtitle:null,isOpenForSubmission:!1,hash:"176adcf090fdd1f93cb8ce3146e79ca1",slug:"reactive-oxygen-species",bookSignature:"Rizwan Ahmad",coverURL:"https://cdn.intechopen.com/books/images_new/10803.jpg",publishedDate:"April 28th 2022",numberOfDownloads:1704,editors:[{id:"40482",title:null,name:"Rizwan",middleName:null,surname:"Ahmad",slug:"rizwan-ahmad",fullName:"Rizwan Ahmad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9032",title:"Corporate Social Responsibility",subtitle:null,isOpenForSubmission:!1,hash:"f609bf3251d7cc7bae0099a4374adfc3",slug:"corporate-social-responsibility",bookSignature:"Beatrice Orlando",coverURL:"https://cdn.intechopen.com/books/images_new/9032.jpg",publishedDate:"March 16th 2022",numberOfDownloads:7489,editors:[{id:"232969",title:"Prof.",name:"Beatrice",middleName:null,surname:"Orlando",slug:"beatrice-orlando",fullName:"Beatrice Orlando"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"8737",title:"Rabies Virus at the Beginning of 21st Century",subtitle:null,isOpenForSubmission:!1,hash:"49cce3f548da548c718c865feb343509",slug:"rabies-virus-at-the-beginning-of-21st-century",bookSignature:"Sergey Tkachev",coverURL:"https://cdn.intechopen.com/books/images_new/8737.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"61139",title:"Dr.",name:"Sergey",middleName:null,surname:"Tkachev",slug:"sergey-tkachev",fullName:"Sergey Tkachev"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10861",title:"Furan Derivatives",subtitle:"Recent Advances and Applications",isOpenForSubmission:!1,hash:"fdfc39cecd82f91b0effac994f75c877",slug:"furan-derivatives-recent-advances-and-applications",bookSignature:"Anish Khan, Mohammed Muzibur Rahman, M. Ramesh, Salman Ahmad Khan and Abdullah Mohammed Ahmed Asiri",coverURL:"https://cdn.intechopen.com/books/images_new/10861.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"293058",title:"Dr.",name:"Anish",middleName:null,surname:"Khan",slug:"anish-khan",fullName:"Anish Khan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10356",title:"Natural Medicinal Plants",subtitle:null,isOpenForSubmission:!1,hash:"943e56ccaaf19ff696d25aa638ae37d6",slug:"natural-medicinal-plants",bookSignature:"Hany A. El-Shemy",coverURL:"https://cdn.intechopen.com/books/images_new/10356.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"54719",title:"Prof.",name:"Hany",middleName:null,surname:"El-Shemy",slug:"hany-el-shemy",fullName:"Hany El-Shemy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10870",title:"Ultrasound Imaging",subtitle:"Current Topics",isOpenForSubmission:!1,hash:"2f0bc3733ab226d67fa73759ef0e12ad",slug:"ultrasound-imaging-current-topics",bookSignature:"Felix Okechukwu Erondu",coverURL:"https://cdn.intechopen.com/books/images_new/10870.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"68312",title:"Prof.",name:"Felix",middleName:null,surname:"Okechukwu Erondu",slug:"felix-okechukwu-erondu",fullName:"Felix Okechukwu Erondu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11392",title:"Leadership in a Changing World",subtitle:"A Multidimensional Perspective",isOpenForSubmission:!1,hash:"86a6d33cf601587e591064ce92effc02",slug:"leadership-in-a-changing-world-a-multidimensional-perspective",bookSignature:"Muhammad Mohiuddin, Bilal Khalid, Md. Samim Al Azad and Slimane Ed-dafali",coverURL:"https://cdn.intechopen.com/books/images_new/11392.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"418514",title:"Dr.",name:"Muhammad",middleName:null,surname:"Mohiuddin",slug:"muhammad-mohiuddin",fullName:"Muhammad Mohiuddin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10400",title:"The Application of Ant Colony Optimization",subtitle:null,isOpenForSubmission:!1,hash:"f4fdfd07ee1ab99fb7c740d6d0c144c6",slug:"the-application-of-ant-colony-optimization",bookSignature:"Ali Soofastaei",coverURL:"https://cdn.intechopen.com/books/images_new/10400.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"257455",title:"Dr.",name:"Ali",middleName:null,surname:"Soofastaei",slug:"ali-soofastaei",fullName:"Ali Soofastaei"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10915",title:"Leadership",subtitle:"New Insights",isOpenForSubmission:!1,hash:"0d72e79892f2a020cee66a52d09de5a4",slug:"leadership-new-insights",bookSignature:"Mário Franco",coverURL:"https://cdn.intechopen.com/books/images_new/10915.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"105529",title:"Dr.",name:"Mário",middleName:null,surname:"Franco",slug:"mario-franco",fullName:"Mário Franco"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10683",title:"Technological Innovations and Advances in Hydropower Engineering",subtitle:null,isOpenForSubmission:!1,hash:"7ce7ad8768bd2cad155470fe1fd883f4",slug:"technological-innovations-and-advances-in-hydropower-engineering",bookSignature:"Yizi Shang, Ling Shang and Xiaofei Li",coverURL:"https://cdn.intechopen.com/books/images_new/10683.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"349630",title:"Dr.",name:"Yizi",middleName:null,surname:"Shang",slug:"yizi-shang",fullName:"Yizi Shang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7102",title:"Pneumonia",subtitle:null,isOpenForSubmission:!1,hash:"9fd70142814192dcec58a176749f1b60",slug:"pneumonia",bookSignature:"Nima Rezaei",coverURL:"https://cdn.intechopen.com/books/images_new/7102.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"116250",title:"Dr.",name:"Nima",middleName:null,surname:"Rezaei",slug:"nima-rezaei",fullName:"Nima Rezaei"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9670",title:"Current Trends in Wheat Research",subtitle:null,isOpenForSubmission:!1,hash:"89d795987f1747a76eee532700d2093d",slug:"current-trends-in-wheat-research",bookSignature:"Mahmood-ur-Rahman Ansari",coverURL:"https://cdn.intechopen.com/books/images_new/9670.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"185476",title:"Dr.",name:"Mahmood-ur-Rahman",middleName:null,surname:"Ansari",slug:"mahmood-ur-rahman-ansari",fullName:"Mahmood-ur-Rahman Ansari"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"1162",title:"Endourology",slug:"endourology",parent:{id:"204",title:"Urology",slug:"urology"},numberOfBooks:9,numberOfSeries:0,numberOfAuthorsAndEditors:228,numberOfWosCitations:86,numberOfCrossrefCitations:52,numberOfDimensionsCitations:138,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicId:"1162",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"7957",title:"Lower Urinary Tract Dysfunction",subtitle:"From Evidence to Clinical Practice",isOpenForSubmission:!1,hash:"e29f9949691e86e226d6c7f7aa81134c",slug:"lower-urinary-tract-dysfunction-from-evidence-to-clinical-practice",bookSignature:"Ran Pang",coverURL:"https://cdn.intechopen.com/books/images_new/7957.jpg",editedByType:"Edited by",editors:[{id:"186524",title:"Prof.",name:"Ran",middleName:null,surname:"Pang",slug:"ran-pang",fullName:"Ran Pang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6147",title:"Urinary Tract Infection",subtitle:"The Result of the Strength of the Pathogen, or the Weakness of the Host",isOpenForSubmission:!1,hash:"16821e1bfd105986c31e991510e94e70",slug:"urinary-tract-infection-the-result-of-the-strength-of-the-pathogen-or-the-weakness-of-the-host",bookSignature:"Tomas Jarzembowski, Agnieszka Daca and Maria Alicja Dębska-Ślizień",coverURL:"https://cdn.intechopen.com/books/images_new/6147.jpg",editedByType:"Edited by",editors:[{id:"205604",title:"Dr.",name:"Tomas",middleName:null,surname:"Jarzembowski",slug:"tomas-jarzembowski",fullName:"Tomas Jarzembowski"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5352",title:"Synopsis in the Management of Urinary Incontinence",subtitle:null,isOpenForSubmission:!1,hash:"7793498d8fd7ab427e9449e34faf438c",slug:"synopsis-in-the-management-of-urinary-incontinence",bookSignature:"Ammar Alhasso and Holly Bekarma",coverURL:"https://cdn.intechopen.com/books/images_new/5352.jpg",editedByType:"Edited by",editors:[{id:"124685",title:"Mr.",name:"Ammar",middleName:null,surname:"Alhasso",slug:"ammar-alhasso",fullName:"Ammar Alhasso"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3313",title:"Recent Advances in the Field of Urinary Tract Infections",subtitle:null,isOpenForSubmission:!1,hash:"02d234a9ee56794bfa06cce7bb94fdf1",slug:"recent-advances-in-the-field-of-urinary-tract-infections",bookSignature:"Thomas Nelius",coverURL:"https://cdn.intechopen.com/books/images_new/3313.jpg",editedByType:"Edited by",editors:[{id:"53464",title:"Prof.",name:"Thomas",middleName:null,surname:"Nelius",slug:"thomas-nelius",fullName:"Thomas Nelius"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2676",title:"Current Concepts in Kidney Transplantation",subtitle:null,isOpenForSubmission:!1,hash:"9513ddae671c1c1d920820209c22ca4c",slug:"current-concepts-in-kidney-transplantation",bookSignature:"Sandip Kapur, Cheguevara Afaneh and Meredith J. Aull",coverURL:"https://cdn.intechopen.com/books/images_new/2676.jpg",editedByType:"Edited by",editors:[{id:"78020",title:"Dr.",name:"Sandip",middleName:null,surname:"Kapur",slug:"sandip-kapur",fullName:"Sandip Kapur"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1762",title:"Evolving Trends in Urology",subtitle:null,isOpenForSubmission:!1,hash:"4b9965c1c8ed456914c0a375d06d1df8",slug:"evolving-trends-in-urology",bookSignature:"Sashi S. Kommu",coverURL:"https://cdn.intechopen.com/books/images_new/1762.jpg",editedByType:"Edited by",editors:[{id:"9902",title:"Dr.",name:"Sashi S.",middleName:"S",surname:"Kommu",slug:"sashi-s.-kommu",fullName:"Sashi S. Kommu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1448",title:"Urinary Incontinence",subtitle:null,isOpenForSubmission:!1,hash:"0c33f52801c170a775dceb2163295aa3",slug:"urinary-incontinence",bookSignature:"Ammar Alhasso",coverURL:"https://cdn.intechopen.com/books/images_new/1448.jpg",editedByType:"Edited by",editors:[{id:"124685",title:"Mr.",name:"Ammar",middleName:null,surname:"Alhasso",slug:"ammar-alhasso",fullName:"Ammar Alhasso"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"369",title:"Current Concepts of Urethroplasty",subtitle:null,isOpenForSubmission:!1,hash:"b4cf5fd57e6ce8906f3770e50c4ac21d",slug:"current-concepts-of-urethroplasty",bookSignature:"Ivo Donkov",coverURL:"https://cdn.intechopen.com/books/images_new/369.jpg",editedByType:"Edited by",editors:[{id:"61180",title:"Dr.",name:"Ivo",middleName:null,surname:"Donkov",slug:"ivo-donkov",fullName:"Ivo Donkov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1318",title:"Urinary Tract Infections",subtitle:null,isOpenForSubmission:!1,hash:"018471a7330e239e2bfbd8b11b1111ca",slug:"urinary-tract-infections",bookSignature:"Peter Tenke",coverURL:"https://cdn.intechopen.com/books/images_new/1318.jpg",editedByType:"Edited by",editors:[{id:"62770",title:"Dr.",name:"Peter",middleName:null,surname:"Tenke",slug:"peter-tenke",fullName:"Peter Tenke"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:9,seriesByTopicCollection:[],seriesByTopicTotal:0,mostCitedChapters:[{id:"45345",doi:"10.5772/55200",title:"Role of Bacterial Biofilms in Catheter-Associated Urinary Tract Infections (CAUTI) and Strategies for Their Control",slug:"role-of-bacterial-biofilms-in-catheter-associated-urinary-tract-infections-cauti-and-strategies-for-",totalDownloads:3219,totalCrossrefCites:4,totalDimensionsCites:15,abstract:null,book:{id:"3313",slug:"recent-advances-in-the-field-of-urinary-tract-infections",title:"Recent Advances in the Field of Urinary Tract Infections",fullTitle:"Recent Advances in the Field of Urinary Tract Infections"},signatures:"Mary Anne Roshni Amalaradjou and Kumar Venkitanarayanan",authors:[{id:"61657",title:"Prof.",name:"Kumar",middleName:null,surname:"Venkitanarayanan",slug:"kumar-venkitanarayanan",fullName:"Kumar Venkitanarayanan"},{id:"158931",title:"Dr.",name:"Mary Anne Roshni",middleName:null,surname:"Amalaradjou",slug:"mary-anne-roshni-amalaradjou",fullName:"Mary Anne Roshni Amalaradjou"}]},{id:"57656",doi:"10.5772/intechopen.71374",title:"Uropathogenic Escherichia coli and Fimbrial Adhesins Virulome",slug:"uropathogenic-escherichia-coli-and-fimbrial-adhesins-virulome",totalDownloads:1338,totalCrossrefCites:4,totalDimensionsCites:13,abstract:"Urinary tract infections (UTIs) rank second among infectious diseases around the world, and this makes them significant. There are many microbial agents which may cause UTIs. Enterobacteriaceae family members are recognized as important UTI bacterial causative agents. Among them, uropathogenic Escherichia coli (UPEC) pathotypes are considered as the most important bacterial agents of UTIs. Today, genomics and bioinformatics explain us why UPEC strains are so considerable pathogens regarding UTIs. There is a diversity of E. coli strains involving commensal and pathogenic strains. Genomics shows that commensal strains of E. coli encompass the minimal amount of genome and genetic elements among E. coli populations, whereas the pathotypes of E. coli possess the maximal or a big portion of genomic elements. Previous studies confirm the presence of a vast range of virulence genes within the pool of E. coli pathotypes like UPEC. So, the pool of virulence genes (virulome) belonging to UPEC enables UPEC pathotypes to have huge genomes with the ability of different levels of pathogenesis. The more virulence factors, the more pathogenicity. Due to the presence of a mass of virulence factors within UPEC cellular structures, well-known fimbrial adhesins in UPEC pathotypes are discussed in this chapter.",book:{id:"6147",slug:"urinary-tract-infection-the-result-of-the-strength-of-the-pathogen-or-the-weakness-of-the-host",title:"Urinary Tract Infection",fullTitle:"Urinary Tract Infection - The Result of the Strength of the Pathogen, or the Weakness of the Host"},signatures:"Payam Behzadi",authors:[{id:"45803",title:"Ph.D.",name:"Payam",middleName:null,surname:"Behzadi",slug:"payam-behzadi",fullName:"Payam Behzadi"}]},{id:"34718",doi:"10.5772/33742",title:"Epidemiology of Urinary Incontinence in Pregnancy and Postpartum",slug:"epidemiology-of-urinary-incontinence-during-pregnancy-and-postpartum",totalDownloads:3702,totalCrossrefCites:1,totalDimensionsCites:10,abstract:null,book:{id:"1448",slug:"urinary-incontinence",title:"Urinary Incontinence",fullTitle:"Urinary Incontinence"},signatures:"Stian Langeland Wesnes, Steinar Hunskaar and Guri Rortveit",authors:[{id:"96897",title:"Dr.",name:"Stian Langeland",middleName:null,surname:"Wesnes",slug:"stian-langeland-wesnes",fullName:"Stian Langeland Wesnes"},{id:"97544",title:"Prof.",name:"Steinar",middleName:null,surname:"Hunskaar",slug:"steinar-hunskaar",fullName:"Steinar Hunskaar"},{id:"97545",title:"Prof.",name:"Guri",middleName:null,surname:"Rortveit",slug:"guri-rortveit",fullName:"Guri Rortveit"}]},{id:"45363",doi:"10.5772/55371",title:"Problem of Catheter Associated Urinary Tract Infections in Sub–Saharan Africa",slug:"problem-of-catheter-associated-urinary-tract-infections-in-sub-saharan-africa",totalDownloads:2561,totalCrossrefCites:4,totalDimensionsCites:7,abstract:null,book:{id:"3313",slug:"recent-advances-in-the-field-of-urinary-tract-infections",title:"Recent Advances in the Field of Urinary Tract Infections",fullTitle:"Recent Advances in the Field of Urinary Tract Infections"},signatures:"Mohamed Labib and Nenad Spasojevic",authors:[{id:"155793",title:"Prof.",name:"Mohamed",middleName:null,surname:"Labib",slug:"mohamed-labib",fullName:"Mohamed Labib"},{id:"158764",title:"Dr.",name:"Nenad",middleName:null,surname:"Spasojevic",slug:"nenad-spasojevic",fullName:"Nenad Spasojevic"}]},{id:"23987",doi:"10.5772/22951",title:"Tunica Albuginea Urethroplasty",slug:"tunica-albuginea-urethroplasty",totalDownloads:2421,totalCrossrefCites:0,totalDimensionsCites:6,abstract:null,book:{id:"369",slug:"current-concepts-of-urethroplasty",title:"Current Concepts of Urethroplasty",fullTitle:"Current Concepts of Urethroplasty"},signatures:"RK Mathur",authors:[{id:"49936",title:"Dr.",name:"Rajkumar",middleName:null,surname:"Mathur",slug:"rajkumar-mathur",fullName:"Rajkumar Mathur"}]}],mostDownloadedChaptersLast30Days:[{id:"71493",title:"Pelvic Organ Prolapse: Examination and Assessment",slug:"pelvic-organ-prolapse-examination-and-assessment",totalDownloads:1073,totalCrossrefCites:0,totalDimensionsCites:0,abstract:"Pelvic organ prolapse (POP) is a common, benign condition in women, and patient can present with complaints of vaginal bulge and pressure, voiding and defecatory, and sexual dysfunction, which may adversely affect quality of life. Although POP can occur in younger women, it is commonly seen in aging population with a prevalence of 45–50%. Older terms describing pelvic organ prolapse (e.g., cystocele, urethrocele, rectocele) have been replaced because they do not provide complete information regarding the structures on the other side of the vaginal bulge, especially in women who have had previous pelvic organ prolapse surgery. Therefore, a thorough history and performing a careful physical examination with dignity and care, using some basic tools that aid in the accurate evaluation of anatomical and functional defects, should be conducted. A standardized assessment system has been used to document findings which should explain everything in understandable terms.",book:{id:"7957",slug:"lower-urinary-tract-dysfunction-from-evidence-to-clinical-practice",title:"Lower Urinary Tract Dysfunction",fullTitle:"Lower Urinary Tract Dysfunction - From Evidence to Clinical Practice"},signatures:"Priyanka Bhadana",authors:[{id:"287080",title:"Associate Prof.",name:"Priyanka",middleName:null,surname:"Bhadana",slug:"priyanka-bhadana",fullName:"Priyanka Bhadana"}]},{id:"53697",title:"Physiotherapy in Women with Urinary Incontinence",slug:"physiotherapy-in-women-with-urinary-incontinence",totalDownloads:2331,totalCrossrefCites:2,totalDimensionsCites:2,abstract:"Urinary incontinence is a complex and serious condition that can affect all age groups around the world. It is not only a serious medical condition but also an undeniable psychosocial problem creating embarrassment and negative self‐perception, and it has a severe impact on a patient's quality of life. Today, there are wide different treatment options in urinary incontinence from surgery to conservative modalities. Among these, conservative management approaches are recommended as the first‐line treatment to manage with urinary incontinence. The choice of the most suitable option to treat for urinary incontinence differs according to the underlying pathophysiological mechanism defining subtypes of urinary incontinence and severity of symptoms. In this chapter, we addressed the different components of physiotherapy management of urinary incontinence, including pelvic floor muscle training, electrical stimulation, biofeedback, vaginal cones, mechanical devices and magnetic stimulation. We concluded that the optimal physiotherapy care should be individualised to ensure applicability the clinic setting for each patient.",book:{id:"5352",slug:"synopsis-in-the-management-of-urinary-incontinence",title:"Synopsis in the Management of Urinary Incontinence",fullTitle:"Synopsis in the Management of Urinary Incontinence"},signatures:"Özlem Çinar Özdemir and Mahmut Surmeli",authors:[{id:"185712",title:"Ph.D.",name:"Özlem",middleName:null,surname:"Çinar Özdemir",slug:"ozlem-cinar-ozdemir",fullName:"Özlem Çinar Özdemir"},{id:"193852",title:"Mr.",name:"Mahmut",middleName:null,surname:"Surmeli",slug:"mahmut-surmeli",fullName:"Mahmut Surmeli"}]},{id:"43981",title:"Functional Anatomy of the Vesicoureteric Junction: Implication on the Management of VUR/ UTI",slug:"functional-anatomy-of-the-vesicoureteric-junction-implication-on-the-management-of-vur-uti",totalDownloads:3611,totalCrossrefCites:0,totalDimensionsCites:2,abstract:null,book:{id:"3313",slug:"recent-advances-in-the-field-of-urinary-tract-infections",title:"Recent Advances in the Field of Urinary Tract Infections",fullTitle:"Recent Advances in the Field of Urinary Tract Infections"},signatures:"Vivian Yee-Fong Leung and Winnie Chiu-Wing Chu",authors:[{id:"53633",title:"Prof.",name:"Winnie Chiu Wing",middleName:null,surname:"Chu",slug:"winnie-chiu-wing-chu",fullName:"Winnie Chiu Wing Chu"},{id:"55589",title:"Dr.",name:"Vivian Yee-fong",middleName:null,surname:"Leung",slug:"vivian-yee-fong-leung",fullName:"Vivian Yee-fong Leung"}]},{id:"53692",title:"Assessment of Urinary Incontinence (UI) in Adult Patients",slug:"assessment-of-urinary-incontinence-ui-in-adult-patients",totalDownloads:2004,totalCrossrefCites:3,totalDimensionsCites:4,abstract:"The diagnosis and assessment of urinary incontinence (UI) are variable. In general, diagnosis is made in primary care using clinical evaluation (a good history and physical examination), bladder diary and validated symptom scales. Condition-specific diagnosis is made in secondary care, and it often involves interventional tools such as urodynamic studies. The evidence available on the accuracy and acceptability of the assessment of UI is inconsistent and variable. A structured data collection tool was used for initial assessment of UI. Some key questions are required for initial assessment of UI in order to diagnose the type of UI. This chapter includes a gender-specific evaluation based on history and clinical examination. Pelvic organ prolapse (POP) in female patients is associated with UI and POP diagnosis, and staging is made by clinical examination only, while male patients are examined for prostate obstructive urinary symptoms. Basic evaluation includes bladder diary in cases of overactive bladder and stress test, for stress urinary incontinence. Other diagnostic tests include urine analysis, uroflowmetry and measurement of post-void residual volume in cases of neurogenic bladder and benign prostate hypertrophy. Patients referred to specialist require further assessment of UI using urodynamic testing, electrophysiological test and imaging.",book:{id:"5352",slug:"synopsis-in-the-management-of-urinary-incontinence",title:"Synopsis in the Management of Urinary Incontinence",fullTitle:"Synopsis in the Management of Urinary Incontinence"},signatures:"Raheela M. Rizvi and Mohammad Hammad Ather",authors:[{id:"88868",title:"Prof.",name:"M Hammad",middleName:null,surname:"Ather",slug:"m-hammad-ather",fullName:"M Hammad Ather"},{id:"185970",title:"Dr.",name:"Raheela",middleName:"Mohsin",surname:"Rizvi",slug:"raheela-rizvi",fullName:"Raheela Rizvi"}]},{id:"45043",title:"Developments Regarding Dysfunctional Voiding and Urinary Tract Infections in Children",slug:"developments-regarding-dysfunctional-voiding-and-urinary-tract-infections-in-children",totalDownloads:2272,totalCrossrefCites:0,totalDimensionsCites:0,abstract:null,book:{id:"3313",slug:"recent-advances-in-the-field-of-urinary-tract-infections",title:"Recent Advances in the Field of Urinary Tract Infections",fullTitle:"Recent Advances in the Field of Urinary Tract Infections"},signatures:"Yusuf Kibar and Faysal Gok",authors:[{id:"51399",title:"Dr.",name:"Yusuf",middleName:null,surname:"Kibar",slug:"yusuf-kibar",fullName:"Yusuf Kibar"}]}],onlineFirstChaptersFilter:{topicId:"1162",limit:6,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},subscriptionForm:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[],offset:8,limit:8,total:0},allSeries:{pteSeriesList:[{id:"14",title:"Artificial Intelligence",numberOfPublishedBooks:8,numberOfPublishedChapters:87,numberOfOpenTopics:6,numberOfUpcomingTopics:0,issn:"2633-1403",doi:"10.5772/intechopen.79920",isOpenForSubmission:!0},{id:"7",title:"Biomedical Engineering",numberOfPublishedBooks:12,numberOfPublishedChapters:98,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2631-5343",doi:"10.5772/intechopen.71985",isOpenForSubmission:!0}],lsSeriesList:[{id:"11",title:"Biochemistry",numberOfPublishedBooks:27,numberOfPublishedChapters:286,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2632-0983",doi:"10.5772/intechopen.72877",isOpenForSubmission:!0},{id:"25",title:"Environmental Sciences",numberOfPublishedBooks:1,numberOfPublishedChapters:9,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2754-6713",doi:"10.5772/intechopen.100362",isOpenForSubmission:!0},{id:"10",title:"Physiology",numberOfPublishedBooks:11,numberOfPublishedChapters:139,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-8261",doi:"10.5772/intechopen.72796",isOpenForSubmission:!0}],hsSeriesList:[{id:"3",title:"Dentistry",numberOfPublishedBooks:8,numberOfPublishedChapters:129,numberOfOpenTopics:0,numberOfUpcomingTopics:2,issn:"2631-6218",doi:"10.5772/intechopen.71199",isOpenForSubmission:!1},{id:"6",title:"Infectious Diseases",numberOfPublishedBooks:13,numberOfPublishedChapters:105,numberOfOpenTopics:3,numberOfUpcomingTopics:1,issn:"2631-6188",doi:"10.5772/intechopen.71852",isOpenForSubmission:!0},{id:"13",title:"Veterinary Medicine and Science",numberOfPublishedBooks:9,numberOfPublishedChapters:101,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2632-0517",doi:"10.5772/intechopen.73681",isOpenForSubmission:!0}],sshSeriesList:[{id:"22",title:"Business, Management and Economics",numberOfPublishedBooks:1,numberOfPublishedChapters:11,numberOfOpenTopics:2,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100359",isOpenForSubmission:!0},{id:"23",title:"Education and Human Development",numberOfPublishedBooks:0,numberOfPublishedChapters:0,numberOfOpenTopics:2,numberOfUpcomingTopics:0,issn:null,doi:"10.5772/intechopen.100360",isOpenForSubmission:!1},{id:"24",title:"Sustainable Development",numberOfPublishedBooks:0,numberOfPublishedChapters:9,numberOfOpenTopics:4,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100361",isOpenForSubmission:!0}],testimonialsList:[{id:"13",text:"The collaboration with and support of the technical staff of IntechOpen is fantastic. The whole process of submitting an article and editing of the submitted article goes extremely smooth and fast, the number of reads and downloads of chapters is high, and the contributions are also frequently cited.",author:{id:"55578",name:"Antonio",surname:"Jurado-Navas",institutionString:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRisIQAS/Profile_Picture_1626166543950",slug:"antonio-jurado-navas",institution:{id:"720",name:"University of Malaga",country:{id:null,name:"Spain"}}}},{id:"6",text:"It is great to work with the IntechOpen to produce a worthwhile collection of research that also becomes a great educational resource and guide for future research endeavors.",author:{id:"259298",name:"Edward",surname:"Narayan",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/259298/images/system/259298.jpeg",slug:"edward-narayan",institution:{id:"3",name:"University of Queensland",country:{id:null,name:"Australia"}}}}]},series:{item:{id:"24",title:"Sustainable Development",doi:"10.5772/intechopen.100361",issn:null,scope:"
\r\n\tTransforming our World: the 2030 Agenda for Sustainable Development endorsed by United Nations and 193 Member States, came into effect on Jan 1, 2016, to guide decision making and actions to the year 2030 and beyond. Central to this Agenda are 17 Goals, 169 associated targets and over 230 indicators that are reviewed annually. The vision envisaged in the implementation of the SDGs is centered on the five Ps: People, Planet, Prosperity, Peace and Partnership. This call for renewed focused efforts ensure we have a safe and healthy planet for current and future generations.
\r\n
\r\n\t
\r\n
\r\n\tThis Series focuses on covering research and applied research involving the five Ps through the following topics:
\r\n
\r\n\t
\r\n
\r\n\t1. Sustainable Economy and Fair Society that relates to SDG 1 on No Poverty, SDG 2 on Zero Hunger, SDG 8 on Decent Work and Economic Growth, SDG 10 on Reduced Inequalities, SDG 12 on Responsible Consumption and Production, and SDG 17 Partnership for the Goals
\r\n
\r\n\t
\r\n
\r\n\t2. Health and Wellbeing focusing on SDG 3 on Good Health and Wellbeing and SDG 6 on Clean Water and Sanitation
\r\n
\r\n\t
\r\n
\r\n\t3. Inclusivity and Social Equality involving SDG 4 on Quality Education, SDG 5 on Gender Equality, and SDG 16 on Peace, Justice and Strong Institutions
\r\n
\r\n\t
\r\n
\r\n\t4. Climate Change and Environmental Sustainability comprising SDG 13 on Climate Action, SDG 14 on Life Below Water, and SDG 15 on Life on Land
\r\n
\r\n\t
\r\n
\r\n\t5. Urban Planning and Environmental Management embracing SDG 7 on Affordable Clean Energy, SDG 9 on Industry, Innovation and Infrastructure, and SDG 11 on Sustainable Cities and Communities.
\r\n
\r\n\t
\r\n
\r\n\tThe series also seeks to support the use of cross cutting SDGs, as many of the goals listed above, targets and indicators are all interconnected to impact our lives and the decisions we make on a daily basis, making them impossible to tie to a single topic.
",coverUrl:"https://cdn.intechopen.com/series/covers/24.jpg",latestPublicationDate:"April 24th, 2022",hasOnlineFirst:!0,numberOfPublishedBooks:0,editor:{id:"262440",title:"Prof.",name:"Usha",middleName:null,surname:"Iyer-Raniga",slug:"usha-iyer-raniga",fullName:"Usha Iyer-Raniga",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRYSXQA4/Profile_Picture_2022-02-28T13:55:36.jpeg",biography:"Usha Iyer-Raniga is a professor in the School of Property and Construction Management at RMIT University. Usha co-leads the One Planet Network’s Sustainable Buildings and Construction Programme (SBC), a United Nations 10 Year Framework of Programmes on Sustainable Consumption and Production (UN 10FYP SCP) aligned with Sustainable Development Goal 12. The work also directly impacts SDG 11 on Sustainable Cities and Communities. She completed her undergraduate degree as an architect before obtaining her Masters degree from Canada and her Doctorate in Australia. Usha has been a keynote speaker as well as an invited speaker at national and international conferences, seminars and workshops. Her teaching experience includes teaching in Asian countries. She has advised Austrade, APEC, national, state and local governments. She serves as a reviewer and a member of the scientific committee for national and international refereed journals and refereed conferences. She is on the editorial board for refereed journals and has worked on Special Issues. Usha has served and continues to serve on the Boards of several not-for-profit organisations and she has also served as panel judge for a number of awards including the Premiers Sustainability Award in Victoria and the International Green Gown Awards. Usha has published over 100 publications, including research and consulting reports. Her publications cover a wide range of scientific and technical research publications that include edited books, book chapters, refereed journals, refereed conference papers and reports for local, state and federal government clients. She has also produced podcasts for various organisations and participated in media interviews. She has received state, national and international funding worth over USD $25 million. Usha has been awarded the Quarterly Franklin Membership by London Journals Press (UK). Her biography has been included in the Marquis Who's Who in the World® 2018, 2016 (33rd Edition), along with approximately 55,000 of the most accomplished men and women from around the world, including luminaries as U.N. Secretary-General Ban Ki-moon. In 2017, Usha was awarded the Marquis Who’s Who Lifetime Achiever Award.",institutionString:null,institution:{name:"RMIT University",institutionURL:null,country:{name:"Australia"}}},editorTwo:null,editorThree:null},subseries:{paginationCount:4,paginationItems:[{id:"14",title:"Cell and Molecular Biology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/14.jpg",isOpenForSubmission:!0,editor:{id:"165627",title:"Dr.",name:"Rosa María",middleName:null,surname:"Martínez-Espinosa",slug:"rosa-maria-martinez-espinosa",fullName:"Rosa María Martínez-Espinosa",profilePictureURL:"https://mts.intechopen.com/storage/users/165627/images/system/165627.jpeg",biography:"Dr. Rosa María Martínez-Espinosa has been a Spanish Full Professor since 2020 (Biochemistry and Molecular Biology) and is currently Vice-President of International Relations and Cooperation development and leader of the research group 'Applied Biochemistry” (University of Alicante, Spain). Other positions she has held at the university include Vice-Dean of Master Programs, Vice-Dean of the Degree in Biology and Vice-Dean for Mobility and Enterprise and Engagement at the Faculty of Science (University of Alicante). She received her Bachelor in Biology in 1998 (University of Alicante) and her PhD in 2003 (Biochemistry, University of Alicante). She undertook post-doctoral research at the University of East Anglia (Norwich, U.K. 2004-2005; 2007-2008).\nHer multidisciplinary research focuses on investigating archaea and their potential applications in biotechnology. She has an H-index of 21. She has authored one patent and has published more than 70 indexed papers and around 60 book chapters.\nShe has contributed to more than 150 national and international meetings during the last 15 years. Her research interests include archaea metabolism, enzymes purification and characterization, gene regulation, carotenoids and bioplastics production, antioxidant\ncompounds, waste water treatments, and brines bioremediation.\nRosa María’s other roles include editorial board member for several journals related\nto biochemistry, reviewer for more than 60 journals (biochemistry, molecular biology, biotechnology, chemistry and microbiology) and president of several organizing committees in international meetings related to the N-cycle or respiratory processes.",institutionString:null,institution:{name:"University of Alicante",institutionURL:null,country:{name:"Spain"}}},editorTwo:null,editorThree:null},{id:"15",title:"Chemical Biology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/15.jpg",isOpenForSubmission:!0,editor:{id:"441442",title:"Dr.",name:"Şükrü",middleName:null,surname:"Beydemir",slug:"sukru-beydemir",fullName:"Şükrü Beydemir",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y00003GsUoIQAV/Profile_Picture_1634557147521",biography:"Dr. Şükrü Beydemir obtained a BSc in Chemistry in 1995 from Yüzüncü Yıl University, MSc in Biochemistry in 1998, and PhD in Biochemistry in 2002 from Atatürk University, Turkey. He performed post-doctoral studies at Max-Planck Institute, Germany, and University of Florence, Italy in addition to making several scientific visits abroad. He currently works as a Full Professor of Biochemistry in the Faculty of Pharmacy, Anadolu University, Turkey. Dr. Beydemir has published over a hundred scientific papers spanning protein biochemistry, enzymology and medicinal chemistry, reviews, book chapters and presented several conferences to scientists worldwide. He has received numerous publication awards from various international scientific councils. He serves in the Editorial Board of several international journals. Dr. Beydemir is also Rector of Bilecik Şeyh Edebali University, Turkey.",institutionString:null,institution:{name:"Anadolu University",institutionURL:null,country:{name:"Turkey"}}},editorTwo:{id:"13652",title:"Prof.",name:"Deniz",middleName:null,surname:"Ekinci",slug:"deniz-ekinci",fullName:"Deniz Ekinci",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYLT1QAO/Profile_Picture_1634557223079",biography:"Dr. Deniz Ekinci obtained a BSc in Chemistry in 2004, MSc in Biochemistry in 2006, and PhD in Biochemistry in 2009 from Atatürk University, Turkey. He studied at Stetson University, USA, in 2007-2008 and at the Max Planck Institute of Molecular Cell Biology and Genetics, Germany, in 2009-2010. Dr. Ekinci currently works as a Full Professor of Biochemistry in the Faculty of Agriculture and is the Head of the Enzyme and Microbial Biotechnology Division, Ondokuz Mayıs University, Turkey. He is a member of the Turkish Biochemical Society, American Chemical Society, and German Genetics society. Dr. Ekinci published around ninety scientific papers, reviews and book chapters, and presented several conferences to scientists. He has received numerous publication awards from several scientific councils. Dr. Ekinci serves as the Editor in Chief of four international books and is involved in the Editorial Board of several international journals.",institutionString:null,institution:{name:"Ondokuz Mayıs University",institutionURL:null,country:{name:"Turkey"}}},editorThree:null},{id:"17",title:"Metabolism",coverUrl:"https://cdn.intechopen.com/series_topics/covers/17.jpg",isOpenForSubmission:!0,editor:{id:"138626",title:"Dr.",name:"Yannis",middleName:null,surname:"Karamanos",slug:"yannis-karamanos",fullName:"Yannis Karamanos",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002g6Jv2QAE/Profile_Picture_1629356660984",biography:"Yannis Karamanos, born in Greece in 1953, completed his pre-graduate studies at the Université Pierre et Marie Curie, Paris, then his Masters and Doctoral degree at the Université de Lille (1983). He was associate professor at the University of Limoges (1987) before becoming full professor of biochemistry at the Université d’Artois (1996). He worked on the structure-function relationships of glycoconjugates and his main project was the investigations on the biological roles of the de-N-glycosylation enzymes (Endo-N-acetyl-β-D-glucosaminidase and peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidase). From 2002 he contributes to the understanding of the Blood-brain barrier functioning using proteomics approaches. He has published more than 70 papers. His teaching areas are energy metabolism and regulation, integration and organ specialization and metabolic adaptation.",institutionString:null,institution:{name:"Artois University",institutionURL:null,country:{name:"France"}}},editorTwo:null,editorThree:null},{id:"18",title:"Proteomics",coverUrl:"https://cdn.intechopen.com/series_topics/covers/18.jpg",isOpenForSubmission:!0,editor:{id:"200689",title:"Prof.",name:"Paolo",middleName:null,surname:"Iadarola",slug:"paolo-iadarola",fullName:"Paolo Iadarola",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bSCl8QAG/Profile_Picture_1623568118342",biography:"Paolo Iadarola graduated with a degree in Chemistry from the University of Pavia (Italy) in July 1972. He then worked as an Assistant Professor at the Faculty of Science of the same University until 1984. In 1985, Prof. Iadarola became Associate Professor at the Department of Biology and Biotechnologies of the University of Pavia and retired in October 2017. Since then, he has been working as an Adjunct Professor in the same Department at the University of Pavia. His research activity during the first years was primarily focused on the purification and structural characterization of enzymes from animal and plant sources. During this period, Prof. Iadarola familiarized himself with the conventional techniques used in column chromatography, spectrophotometry, manual Edman degradation, and electrophoresis). Since 1995, he has been working on: i) the determination in biological fluids (serum, urine, bronchoalveolar lavage, sputum) of proteolytic activities involved in the degradation processes of connective tissue matrix, and ii) on the identification of biological markers of lung diseases. In this context, he has developed and validated new methodologies (e.g., Capillary Electrophoresis coupled to Laser-Induced Fluorescence, CE-LIF) whose application enabled him to determine both the amounts of biochemical markers (Desmosines) in urine/serum of patients affected by Chronic Obstructive Pulmonary Disease (COPD) and the activity of proteolytic enzymes (Human Neutrophil Elastase, Cathepsin G, Pseudomonas aeruginosa elastase) in sputa of these patients. More recently, Prof. Iadarola was involved in developing techniques such as two-dimensional electrophoresis coupled to liquid chromatography/mass spectrometry (2DE-LC/MS) for the proteomic analysis of biological fluids aimed at the identification of potential biomarkers of different lung diseases. He is the author of about 150 publications (According to Scopus: H-Index: 23; Total citations: 1568- According to WOS: H-Index: 20; Total Citations: 1296) of peer-reviewed international journals. He is a Consultant Reviewer for several journals, including the Journal of Chromatography A, Journal of Chromatography B, Plos ONE, Proteomes, International Journal of Molecular Science, Biotech, Electrophoresis, and others. He is also Associate Editor of Biotech.",institutionString:null,institution:{name:"University of Pavia",institutionURL:null,country:{name:"Italy"}}},editorTwo:{id:"201414",title:"Dr.",name:"Simona",middleName:null,surname:"Viglio",slug:"simona-viglio",fullName:"Simona Viglio",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRKDHQA4/Profile_Picture_1630402531487",biography:"Simona Viglio is an Associate Professor of Biochemistry at the Department of Molecular Medicine at the University of Pavia. She has been working since 1995 on the determination of proteolytic enzymes involved in the degradation process of connective tissue matrix and on the identification of biological markers of lung diseases. She gained considerable experience in developing and validating new methodologies whose applications allowed her to determine both the amount of biomarkers (Desmosine and Isodesmosine) in the urine of patients affected by COPD, and the activity of proteolytic enzymes (HNE, Cathepsin G, Pseudomonas aeruginosa elastase) in the sputa of these patients. Simona Viglio was also involved in research dealing with the supplementation of amino acids in patients with brain injury and chronic heart failure. She is presently engaged in the development of 2-DE and LC-MS techniques for the study of proteomics in biological fluids. The aim of this research is the identification of potential biomarkers of lung diseases. She is an author of about 90 publications (According to Scopus: H-Index: 23; According to WOS: H-Index: 20) on peer-reviewed journals, a member of the “Società Italiana di Biochimica e Biologia Molecolare,“ and a Consultant Reviewer for International Journal of Molecular Science, Journal of Chromatography A, COPD, Plos ONE and Nutritional Neuroscience.",institutionString:null,institution:{name:"University of Pavia",institutionURL:null,country:{name:"Italy"}}},editorThree:null}]},overviewPageOFChapters:{paginationCount:48,paginationItems:[{id:"81799",title:"Cross Talk of Purinergic and Immune Signaling: Implication in Inflammatory and Pathogenic Diseases",doi:"10.5772/intechopen.104978",signatures:"Richa Rai",slug:"cross-talk-of-purinergic-and-immune-signaling-implication-in-inflammatory-and-pathogenic-diseases",totalDownloads:3,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81764",title:"Involvement of the Purinergic System in Cell Death in Models of Retinopathies",doi:"10.5772/intechopen.103935",signatures:"Douglas Penaforte Cruz, Marinna Garcia Repossi and Lucianne Fragel Madeira",slug:"involvement-of-the-purinergic-system-in-cell-death-in-models-of-retinopathies",totalDownloads:3,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81756",title:"Alteration of Cytokines Level and Oxidative Stress Parameters in COVID-19",doi:"10.5772/intechopen.104950",signatures:"Marija Petrusevska, Emilija Atanasovska, Dragica Zendelovska, Aleksandar Eftimov and Katerina Spasovska",slug:"alteration-of-cytokines-level-and-oxidative-stress-parameters-in-covid-19",totalDownloads:5,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Chemokines Updates",coverURL:"https://cdn.intechopen.com/books/images_new/11672.jpg",subseries:{id:"18",title:"Proteomics"}}},{id:"81681",title:"Immunomodulatory Effects of a M2-Conditioned Medium (PRS® CK STORM): Theory on the Possible Complex Mechanism of Action through Anti-Inflammatory Modulation of the TLR System and the Purinergic System",doi:"10.5772/intechopen.104486",signatures:"Juan Pedro Lapuente",slug:"immunomodulatory-effects-of-a-m2-conditioned-medium-prs-ck-storm-theory-on-the-possible-complex-mech",totalDownloads:5,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}}]},overviewPagePublishedBooks:{paginationCount:27,paginationItems:[{type:"book",id:"7006",title:"Biochemistry and Health Benefits of Fatty Acids",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7006.jpg",slug:"biochemistry-and-health-benefits-of-fatty-acids",publishedDate:"December 19th 2018",editedByType:"Edited by",bookSignature:"Viduranga Waisundara",hash:"c93a00abd68b5eba67e5e719f67fd20b",volumeInSeries:1,fullTitle:"Biochemistry and Health Benefits of Fatty Acids",editors:[{id:"194281",title:"Dr.",name:"Viduranga Y.",middleName:null,surname:"Waisundara",slug:"viduranga-y.-waisundara",fullName:"Viduranga Y. Waisundara",profilePictureURL:"https://mts.intechopen.com/storage/users/194281/images/system/194281.jpg",biography:"Dr. Viduranga Waisundara obtained her Ph.D. in Food Science and Technology from the Department of Chemistry, National University of Singapore, in 2010. She was a lecturer at Temasek Polytechnic, Singapore from July 2009 to March 2013. She relocated to her motherland of Sri Lanka and spearheaded the Functional Food Product Development Project at the National Institute of Fundamental Studies from April 2013 to October 2016. She was a senior lecturer on a temporary basis at the Department of Food Technology, Faculty of Technology, Rajarata University of Sri Lanka. She is currently Deputy Principal of the Australian College of Business and Technology – Kandy Campus, Sri Lanka. She is also the Global Harmonization Initiative (GHI) Ambassador to Sri Lanka.",institutionString:"Australian College of Business & Technology",institution:null}]},{type:"book",id:"6820",title:"Keratin",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/6820.jpg",slug:"keratin",publishedDate:"December 19th 2018",editedByType:"Edited by",bookSignature:"Miroslav Blumenberg",hash:"6def75cd4b6b5324a02b6dc0359896d0",volumeInSeries:2,fullTitle:"Keratin",editors:[{id:"31610",title:"Dr.",name:"Miroslav",middleName:null,surname:"Blumenberg",slug:"miroslav-blumenberg",fullName:"Miroslav Blumenberg",profilePictureURL:"https://mts.intechopen.com/storage/users/31610/images/system/31610.jpg",biography:"Miroslav Blumenberg, Ph.D., was born in Subotica and received his BSc in Belgrade, Yugoslavia. He completed his Ph.D. at MIT in Organic Chemistry; he followed up his Ph.D. with two postdoctoral study periods at Stanford University. Since 1983, he has been a faculty member of the RO Perelman Department of Dermatology, NYU School of Medicine, where he is codirector of a training grant in cutaneous biology. Dr. Blumenberg’s research is focused on the epidermis, expression of keratin genes, transcription profiling, keratinocyte differentiation, inflammatory diseases and cancers, and most recently the effects of the microbiome on the skin. He has published more than 100 peer-reviewed research articles and graduated numerous Ph.D. and postdoctoral students.",institutionString:null,institution:{name:"New York University Langone Medical Center",institutionURL:null,country:{name:"United States of America"}}}]},{type:"book",id:"7978",title:"Vitamin A",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7978.jpg",slug:"vitamin-a",publishedDate:"May 15th 2019",editedByType:"Edited by",bookSignature:"Leila Queiroz Zepka, Veridiana Vera de Rosso and Eduardo Jacob-Lopes",hash:"dad04a658ab9e3d851d23705980a688b",volumeInSeries:3,fullTitle:"Vitamin A",editors:[{id:"261969",title:"Dr.",name:"Leila",middleName:null,surname:"Queiroz Zepka",slug:"leila-queiroz-zepka",fullName:"Leila Queiroz Zepka",profilePictureURL:"https://mts.intechopen.com/storage/users/261969/images/system/261969.png",biography:"Prof. Dr. Leila Queiroz Zepka is currently an associate professor in the Department of Food Technology and Science, Federal University of Santa Maria, Brazil. She has more than fifteen years of teaching and research experience. She has published more than 550 scientific publications/communications, including 15 books, 50 book chapters, 100 original research papers, 380 research communications in national and international conferences, and 12 patents. She is a member of the editorial board of five journals and acts as a reviewer for several national and international journals. Her research interests include microalgal biotechnology with an emphasis on microalgae-based products.",institutionString:"Universidade Federal de Santa Maria",institution:{name:"Universidade Federal de Santa Maria",institutionURL:null,country:{name:"Brazil"}}}]},{type:"book",id:"7953",title:"Bioluminescence",subtitle:"Analytical Applications and Basic Biology",coverURL:"https://cdn.intechopen.com/books/images_new/7953.jpg",slug:"bioluminescence-analytical-applications-and-basic-biology",publishedDate:"September 25th 2019",editedByType:"Edited by",bookSignature:"Hirobumi Suzuki",hash:"3a8efa00b71abea11bf01973dc589979",volumeInSeries:4,fullTitle:"Bioluminescence - Analytical Applications and Basic Biology",editors:[{id:"185746",title:"Dr.",name:"Hirobumi",middleName:null,surname:"Suzuki",slug:"hirobumi-suzuki",fullName:"Hirobumi Suzuki",profilePictureURL:"https://mts.intechopen.com/storage/users/185746/images/system/185746.png",biography:"Dr. Hirobumi Suzuki received his Ph.D. in 1997 from Tokyo Metropolitan University, Japan, where he studied firefly phylogeny and the evolution of mating systems. He is especially interested in the genetic differentiation pattern and speciation process that correlate to the flashing pattern and mating behavior of some fireflies in Japan. He then worked for Olympus Corporation, a Japanese manufacturer of optics and imaging products, where he was involved in the development of luminescence technology and produced a bioluminescence microscope that is currently being used for gene expression analysis in chronobiology, neurobiology, and developmental biology. Dr. Suzuki currently serves as a visiting researcher at Kogakuin University, Japan, and also a vice president of the Japan Firefly Society.",institutionString:"Kogakuin University",institution:null}]}]},openForSubmissionBooks:{paginationCount:5,paginationItems:[{id:"11576",title:"Malaria - Recent Advances, and New Perspectives",coverURL:"https://cdn.intechopen.com/books/images_new/11576.jpg",hash:"5a01644fb0b4ce24c2f947913d154abe",secondStepPassed:!0,currentStepOfPublishingProcess:3,submissionDeadline:"April 26th 2022",isOpenForSubmission:!0,editors:[{id:"76041",title:"Prof.",name:"Pier Paolo",surname:"Piccaluga",slug:"pier-paolo-piccaluga",fullName:"Pier Paolo Piccaluga"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{id:"11577",title:"Tick-Borne Diseases - A Review and an Update of Knowledge on Infections in Human and Animal Population",coverURL:"https://cdn.intechopen.com/books/images_new/11577.jpg",hash:"3d72ae651ee2a04b2368bf798a3183ca",secondStepPassed:!0,currentStepOfPublishingProcess:3,submissionDeadline:"April 29th 2022",isOpenForSubmission:!0,editors:[{id:"51521",title:"Prof.",name:"Elisa",surname:"Pieragostini",slug:"elisa-pieragostini",fullName:"Elisa Pieragostini"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{id:"11570",title:"Influenza - New Approaches",coverURL:"https://cdn.intechopen.com/books/images_new/11570.jpg",hash:"157b379b9d7a4bf5e2cc7a742f155a44",secondStepPassed:!0,currentStepOfPublishingProcess:3,submissionDeadline:"May 10th 2022",isOpenForSubmission:!0,editors:[{id:"139889",title:"Dr.",name:"Seyyed Shamsadin",surname:"Athari",slug:"seyyed-shamsadin-athari",fullName:"Seyyed Shamsadin Athari"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{id:"11569",title:"Bacterial Sexually Transmitted Infections - New Findings, Diagnosis, Treatment, and Prevention",coverURL:"https://cdn.intechopen.com/books/images_new/11569.jpg",hash:"069d6142ecb0d46d14920102d48c0e9d",secondStepPassed:!1,currentStepOfPublishingProcess:2,submissionDeadline:"May 31st 2022",isOpenForSubmission:!0,editors:[{id:"189561",title:"Dr.",name:"Mihaela Laura",surname:"Vica",slug:"mihaela-laura-vica",fullName:"Mihaela Laura Vica"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{id:"11568",title:"Staphylococcal Infections - Recent Advances and Perspectives",coverURL:"https://cdn.intechopen.com/books/images_new/11568.jpg",hash:"92c881664d1921c7f2d0fee34b78cd08",secondStepPassed:!1,currentStepOfPublishingProcess:2,submissionDeadline:"June 1st 2022",isOpenForSubmission:!0,editors:[{id:"59719",title:"Dr.",name:"Jaime",surname:"Bustos-Martínez",slug:"jaime-bustos-martinez",fullName:"Jaime Bustos-Martínez"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},onlineFirstChapters:{paginationCount:26,paginationItems:[{id:"81791",title:"Self-Supervised Contrastive Representation Learning in Computer Vision",doi:"10.5772/intechopen.104785",signatures:"Yalin Bastanlar and Semih Orhan",slug:"self-supervised-contrastive-representation-learning-in-computer-vision",totalDownloads:1,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Pattern Recognition - New Insights",coverURL:"https://cdn.intechopen.com/books/images_new/11442.jpg",subseries:{id:"26",title:"Machine Learning and Data Mining"}}},{id:"79345",title:"Application of Jump Diffusion Models in Insurance Claim Estimation",doi:"10.5772/intechopen.99853",signatures:"Leonard Mushunje, Chiedza Elvina Mashiri, Edina Chandiwana and Maxwell Mashasha",slug:"application-of-jump-diffusion-models-in-insurance-claim-estimation-1",totalDownloads:2,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Data Clustering",coverURL:"https://cdn.intechopen.com/books/images_new/10820.jpg",subseries:{id:"26",title:"Machine Learning and Data Mining"}}},{id:"81557",title:"Object Tracking Using Adapted Optical Flow",doi:"10.5772/intechopen.102863",signatures:"Ronaldo Ferreira, Joaquim José de Castro Ferreira and António José Ribeiro Neves",slug:"object-tracking-using-adapted-optical-flow",totalDownloads:10,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Information Extraction and Object Tracking in Digital Video",coverURL:"https://cdn.intechopen.com/books/images_new/10652.jpg",subseries:{id:"24",title:"Computer Vision"}}},{id:"81558",title:"Thresholding Image Techniques for Plant Segmentation",doi:"10.5772/intechopen.104587",signatures:"Miguel Ángel Castillo-Martínez, Francisco Javier Gallegos-Funes, Blanca E. Carvajal-Gámez, Guillermo Urriolagoitia-Sosa and Alberto J. Rosales-Silva",slug:"thresholding-image-techniques-for-plant-segmentation",totalDownloads:13,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Information Extraction and Object Tracking in Digital Video",coverURL:"https://cdn.intechopen.com/books/images_new/10652.jpg",subseries:{id:"24",title:"Computer Vision"}}},{id:"81471",title:"Semantic Map: Bringing Together Groups and Discourses",doi:"10.5772/intechopen.103818",signatures:"Theodore Chadjipadelis and Georgia Panagiotidou",slug:"semantic-map-bringing-together-groups-and-discourses",totalDownloads:11,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Data Clustering",coverURL:"https://cdn.intechopen.com/books/images_new/10820.jpg",subseries:{id:"26",title:"Machine Learning and Data Mining"}}},{id:"79491",title:"Fuzzy Perceptron Learning for Non-Linearly Separable Patterns",doi:"10.5772/intechopen.101312",signatures:"Raja Kishor Duggirala",slug:"fuzzy-perceptron-learning-for-non-linearly-separable-patterns",totalDownloads:13,totalCrossrefCites:0,totalDimensionsCites:0,authors:[{name:"Raja Kishor",surname:"Duggirala"}],book:{title:"Data Clustering",coverURL:"https://cdn.intechopen.com/books/images_new/10820.jpg",subseries:{id:"26",title:"Machine Learning and Data Mining"}}},{id:"81234",title:"Cognitive Visual Tracking of Hand Gestures in Real-Time RGB Videos",doi:"10.5772/intechopen.103170",signatures:"Richa Golash and Yogendra Kumar Jain",slug:"cognitive-visual-tracking-of-hand-gestures-in-real-time-rgb-videos",totalDownloads:11,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Information Extraction and Object Tracking in Digital Video",coverURL:"https://cdn.intechopen.com/books/images_new/10652.jpg",subseries:{id:"24",title:"Computer Vision"}}},{id:"81331",title:"Machine Learning Algorithm-Based Contraceptive Practice among Ever-Married Women in Bangladesh: A Hierarchical Machine Learning Classification Approach",doi:"10.5772/intechopen.103187",signatures:"Iqramul Haq, Md. Ismail Hossain, Md. Moshiur Rahman, Md. Injamul Haq Methun, Ashis Talukder, Md. Jakaria Habib and Md. Sanwar Hossain",slug:"machine-learning-algorithm-based-contraceptive-practice-among-ever-married-women-in-bangladesh-a-hie",totalDownloads:18,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Machine Learning and Data Mining - Annual Volume 2022",coverURL:"https://cdn.intechopen.com/books/images_new/11422.jpg",subseries:{id:"26",title:"Machine Learning and Data Mining"}}},{id:"81321",title:"Velocity Planning via Model-Based Reinforcement Learning: Demonstrating Results on PILCO for One-Dimensional Linear Motion with Bounded Acceleration",doi:"10.5772/intechopen.103690",signatures:"Hsuan-Cheng Liao, Han-Jung Chou and Jing-Sin Liu",slug:"velocity-planning-via-model-based-reinforcement-learning-demonstrating-results-on-pilco-for-one-dime",totalDownloads:2,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Applied Intelligence - Annual Volume 2022",coverURL:"https://cdn.intechopen.com/books/images_new/11418.jpg",subseries:{id:"22",title:"Applied Intelligence"}}},{id:"81272",title:"Pain Identification in Electroencephalography Signal Using Fuzzy Inference System",doi:"10.5772/intechopen.103753",signatures:"Vahid Asadpour, Reza Fazel-Rezai, Maryam Vatankhah and Mohammad-Reza Akbarzadeh-Totonchi",slug:"pain-identification-in-electroencephalography-signal-using-fuzzy-inference-system",totalDownloads:11,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Brain-Computer Interface",coverURL:"https://cdn.intechopen.com/books/images_new/10654.jpg",subseries:{id:"23",title:"Computational Neuroscience"}}}]},subseriesFiltersForOFChapters:[{caption:"Applied Intelligence",value:22,count:1,group:"subseries"},{caption:"Computer Vision",value:24,count:8,group:"subseries"},{caption:"Machine Learning and Data Mining",value:26,count:8,group:"subseries"},{caption:"Computational Neuroscience",value:23,count:9,group:"subseries"}],publishedBooks:{paginationCount:1,paginationItems:[{type:"book",id:"11392",title:"Leadership in a Changing World",subtitle:"A Multidimensional Perspective",coverURL:"https://cdn.intechopen.com/books/images_new/11392.jpg",slug:"leadership-in-a-changing-world-a-multidimensional-perspective",publishedDate:"May 11th 2022",editedByType:"Edited by",bookSignature:"Muhammad Mohiuddin, Bilal Khalid, Md. Samim Al Azad and Slimane Ed-dafali",hash:"86a6d33cf601587e591064ce92effc02",volumeInSeries:1,fullTitle:"Leadership in a Changing World - A Multidimensional Perspective",editors:[{id:"418514",title:"Dr.",name:"Muhammad",middleName:null,surname:"Mohiuddin",slug:"muhammad-mohiuddin",fullName:"Muhammad Mohiuddin",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y000038UqSfQAK/Profile_Picture_2022-05-13T10:39:03.jpg",institutionString:null,institution:{name:"Université Laval",institutionURL:null,country:{name:"Canada"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},subseriesFiltersForPublishedBooks:[{group:"subseries",caption:"Business and Management",value:86,count:1}],publicationYearFilters:[{group:"publicationYear",caption:"2022",value:2022,count:1}],authors:{paginationCount:0,paginationItems:[]}},subseries:{item:{id:"26",type:"subseries",title:"Machine Learning and Data Mining",keywords:"Intelligent Systems, Machine Learning, Data Science, Data Mining, Artificial Intelligence",scope:"The scope of machine learning and data mining is immense and is growing every day. It has become a massive part of our daily lives, making predictions based on experience, making this a fascinating area that solves problems that otherwise would not be possible or easy to solve. This topic aims to encompass algorithms that learn from experience (supervised and unsupervised), improve their performance over time and enable machines to make data-driven decisions. It is not limited to any particular applications, but contributions are encouraged from all disciplines.",coverUrl:"https://cdn.intechopen.com/series_topics/covers/26.jpg",hasOnlineFirst:!0,hasPublishedBooks:!0,annualVolume:11422,editor:{id:"24555",title:"Dr.",name:"Marco Antonio",middleName:null,surname:"Aceves Fernandez",slug:"marco-antonio-aceves-fernandez",fullName:"Marco Antonio Aceves Fernandez",profilePictureURL:"https://mts.intechopen.com/storage/users/24555/images/system/24555.jpg",biography:"Dr. Marco Antonio Aceves Fernandez obtained his B.Sc. (Eng.) in Telematics from the Universidad de Colima, Mexico. He obtained both his M.Sc. and Ph.D. from the University of Liverpool, England, in the field of Intelligent Systems. He is a full professor at the Universidad Autonoma de Queretaro, Mexico, and a member of the National System of Researchers (SNI) since 2009. Dr. Aceves Fernandez has published more than 80 research papers as well as a number of book chapters and congress papers. He has contributed in more than 20 funded research projects, both academic and industrial, in the area of artificial intelligence, ranging from environmental, biomedical, automotive, aviation, consumer, and robotics to other applications. He is also a honorary president at the National Association of Embedded Systems (AMESE), a senior member of the IEEE, and a board member of many institutions. His research interests include intelligent and embedded systems.",institutionString:"Universidad Autonoma de Queretaro",institution:{name:"Autonomous University of Queretaro",institutionURL:null,country:{name:"Mexico"}}},editorTwo:null,editorThree:null,series:{id:"14",title:"Artificial Intelligence",doi:"10.5772/intechopen.79920",issn:"2633-1403"},editorialBoard:[{id:"43680",title:"Prof.",name:"Ciza",middleName:null,surname:"Thomas",slug:"ciza-thomas",fullName:"Ciza Thomas",profilePictureURL:"https://mts.intechopen.com/storage/users/43680/images/system/43680.jpeg",institutionString:null,institution:{name:"Government of Kerala",institutionURL:null,country:{name:"India"}}},{id:"16614",title:"Prof.",name:"Juan Ignacio",middleName:null,surname:"Guerrero Alonso",slug:"juan-ignacio-guerrero-alonso",fullName:"Juan Ignacio Guerrero Alonso",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002g6HB8QAM/Profile_Picture_1627901127555",institutionString:null,institution:{name:"University of Seville",institutionURL:null,country:{name:"Spain"}}},{id:"3095",title:"Prof.",name:"Kenji",middleName:null,surname:"Suzuki",slug:"kenji-suzuki",fullName:"Kenji Suzuki",profilePictureURL:"https://mts.intechopen.com/storage/users/3095/images/1592_n.jpg",institutionString:null,institution:{name:"University of Chicago",institutionURL:null,country:{name:"United States of America"}}},{id:"214067",title:"Dr.",name:"W. David",middleName:null,surname:"Pan",slug:"w.-david-pan",fullName:"W. David Pan",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bSEI9QAO/Profile_Picture_1623656213532",institutionString:null,institution:{name:"University of Alabama in Huntsville",institutionURL:null,country:{name:"United States of America"}}},{id:"72920",title:"Prof.",name:"Yves",middleName:"Philippe",surname:"Rybarczyk",slug:"yves-rybarczyk",fullName:"Yves Rybarczyk",profilePictureURL:"https://mts.intechopen.com/storage/users/72920/images/system/72920.jpeg",institutionString:"Dalarna University, Faculty of Data and Information Sciences",institution:{name:"Dalarna University",institutionURL:null,country:{name:"Sweden"}}}]},onlineFirstChapters:{paginationCount:0,paginationItems:[]},publishedBooks:{paginationCount:3,paginationItems:[{type:"book",id:"10859",title:"Data Mining",subtitle:"Concepts and Applications",coverURL:"https://cdn.intechopen.com/books/images_new/10859.jpg",slug:"data-mining-concepts-and-applications",publishedDate:"March 30th 2022",editedByType:"Edited by",bookSignature:"Ciza Thomas",hash:"63a4e514e537d3962cf53ef1c6b9d5eb",volumeInSeries:8,fullTitle:"Data Mining - Concepts and Applications",editors:[{id:"43680",title:"Prof.",name:"Ciza",middleName:null,surname:"Thomas",slug:"ciza-thomas",fullName:"Ciza Thomas",profilePictureURL:"https://mts.intechopen.com/storage/users/43680/images/system/43680.jpeg",institutionString:null,institution:{name:"Government of Kerala",institutionURL:null,country:{name:"India"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"10651",title:"Machine Learning",subtitle:"Algorithms, Models and Applications",coverURL:"https://cdn.intechopen.com/books/images_new/10651.jpg",slug:"machine-learning-algorithms-models-and-applications",publishedDate:"December 22nd 2021",editedByType:"Edited by",bookSignature:"Jaydip Sen",hash:"6208156401c496e0a4ca5ff4265324cc",volumeInSeries:7,fullTitle:"Machine Learning - Algorithms, Models and Applications",editors:[{id:"4519",title:"Prof.",name:"Jaydip",middleName:null,surname:"Sen",slug:"jaydip-sen",fullName:"Jaydip Sen",profilePictureURL:"https://mts.intechopen.com/storage/users/4519/images/system/4519.jpeg",institutionString:"Praxis Business School",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9963",title:"Advances and Applications in Deep Learning",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/9963.jpg",slug:"advances-and-applications-in-deep-learning",publishedDate:"December 9th 2020",editedByType:"Edited by",bookSignature:"Marco Antonio Aceves-Fernandez",hash:"0d51ba46f22e55cb89140f60d86a071e",volumeInSeries:4,fullTitle:"Advances and Applications in Deep Learning",editors:[{id:"24555",title:"Dr.",name:"Marco Antonio",middleName:null,surname:"Aceves Fernandez",slug:"marco-antonio-aceves-fernandez",fullName:"Marco Antonio Aceves Fernandez",profilePictureURL:"https://mts.intechopen.com/storage/users/24555/images/system/24555.jpg",institutionString:"Universidad Autonoma de Queretaro",institution:{name:"Autonomous University of Queretaro",institutionURL:null,country:{name:"Mexico"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},testimonialsList:[{id:"8",text:"I work with IntechOpen for a number of reasons: their professionalism, their mission in support of Open Access publishing, and the quality of their peer-reviewed publications, but also because they believe in equality.",author:{id:"202192",name:"Catrin",surname:"Rutland",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/202192/images/system/202192.png",slug:"catrin-rutland",institution:{id:"134",name:"University of Nottingham",country:{id:null,name:"United Kingdom"}}}},{id:"18",text:"It was great publishing with IntechOpen, the process was straightforward and I had support all along.",author:{id:"71579",name:"Berend",surname:"Olivier",institutionString:"Utrecht University",profilePictureURL:"https://mts.intechopen.com/storage/users/71579/images/system/71579.jpg",slug:"berend-olivier",institution:{id:"253",name:"Utrecht University",country:{id:null,name:"Netherlands"}}}},{id:"27",text:"The opportunity to work with a prestigious publisher allows for the possibility to collaborate with more research groups interested in animal nutrition, leading to the development of new feeding strategies and food valuation while being more sustainable with the environment, allowing more readers to learn about the subject.",author:{id:"175967",name:"Manuel",surname:"Gonzalez Ronquillo",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/175967/images/system/175967.png",slug:"manuel-gonzalez-ronquillo",institution:{id:"6221",name:"Universidad Autónoma del Estado de México",country:{id:null,name:"Mexico"}}}}]},submityourwork:{pteSeriesList:[{id:"14",title:"Artificial Intelligence",numberOfPublishedBooks:8,numberOfPublishedChapters:86,numberOfOpenTopics:6,numberOfUpcomingTopics:0,issn:"2633-1403",doi:"10.5772/intechopen.79920",isOpenForSubmission:!0},{id:"7",title:"Biomedical Engineering",numberOfPublishedBooks:12,numberOfPublishedChapters:96,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2631-5343",doi:"10.5772/intechopen.71985",isOpenForSubmission:!0}],lsSeriesList:[{id:"11",title:"Biochemistry",numberOfPublishedBooks:27,numberOfPublishedChapters:283,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2632-0983",doi:"10.5772/intechopen.72877",isOpenForSubmission:!0},{id:"25",title:"Environmental Sciences",numberOfPublishedBooks:1,numberOfPublishedChapters:9,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2754-6713",doi:"10.5772/intechopen.100362",isOpenForSubmission:!0},{id:"10",title:"Physiology",numberOfPublishedBooks:11,numberOfPublishedChapters:138,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-8261",doi:"10.5772/intechopen.72796",isOpenForSubmission:!0}],hsSeriesList:[{id:"3",title:"Dentistry",numberOfPublishedBooks:8,numberOfPublishedChapters:128,numberOfOpenTopics:0,numberOfUpcomingTopics:2,issn:"2631-6218",doi:"10.5772/intechopen.71199",isOpenForSubmission:!1},{id:"6",title:"Infectious Diseases",numberOfPublishedBooks:13,numberOfPublishedChapters:105,numberOfOpenTopics:3,numberOfUpcomingTopics:1,issn:"2631-6188",doi:"10.5772/intechopen.71852",isOpenForSubmission:!0},{id:"13",title:"Veterinary Medicine and Science",numberOfPublishedBooks:9,numberOfPublishedChapters:100,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2632-0517",doi:"10.5772/intechopen.73681",isOpenForSubmission:!0}],sshSeriesList:[{id:"22",title:"Business, Management and Economics",numberOfPublishedBooks:1,numberOfPublishedChapters:11,numberOfOpenTopics:2,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100359",isOpenForSubmission:!0},{id:"23",title:"Education and Human Development",numberOfPublishedBooks:0,numberOfPublishedChapters:0,numberOfOpenTopics:2,numberOfUpcomingTopics:0,issn:null,doi:"10.5772/intechopen.100360",isOpenForSubmission:!1},{id:"24",title:"Sustainable Development",numberOfPublishedBooks:0,numberOfPublishedChapters:9,numberOfOpenTopics:4,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100361",isOpenForSubmission:!0}],subseriesList:[{id:"22",title:"Applied Intelligence",scope:"This field is the key in the current industrial revolution (Industry 4.0), where the new models and developments are based on the knowledge generation on applied intelligence. The motor of the society is the industry and the research of this topic has to be empowered in order to increase and improve the quality of our lives.",coverUrl:"https://cdn.intechopen.com/series_topics/covers/22.jpg",keywords:"Machine Learning, Intelligence Algorithms, Data Science, Artificial Intelligence, Applications on Applied Intelligence"},{id:"23",title:"Computational Neuroscience",scope:"Computational neuroscience focuses on biologically realistic abstractions and models validated and solved through computational simulations to understand principles for the development, structure, physiology, and ability of the nervous system. This topic is dedicated to biologically plausible descriptions and computational models - at various abstraction levels - of neurons and neural systems. This includes, but is not limited to: single-neuron modeling, sensory processing, motor control, memory, and synaptic plasticity, attention, identification, categorization, discrimination, learning, development, axonal patterning, guidance, neural architecture, behaviors, and dynamics of networks, cognition and the neuroscientific basis of consciousness. Particularly interesting are models of various types of more compound functions and abilities, various and more general fundamental principles (e.g., regarding architecture, organization, learning, development, etc.) found at various spatial and temporal levels.",coverUrl:"https://cdn.intechopen.com/series_topics/covers/23.jpg",keywords:"Single-Neuron Modeling, Sensory Processing, Motor Control, Memory and Synaptic Pasticity, Attention, Identification, Categorization, Discrimination, Learning, Development, Axonal Patterning and Guidance, Neural Architecture, Behaviours and Dynamics of Networks, Cognition and the Neuroscientific Basis of Consciousness"},{id:"24",title:"Computer Vision",scope:"The scope of this topic is to disseminate the recent advances in the rapidly growing field of computer vision from both the theoretical and practical points of view. Novel computational algorithms for image analysis, scene understanding, biometrics, deep learning and their software or hardware implementations for natural and medical images, robotics, VR/AR, applications are some research directions relevant to this topic.",coverUrl:"https://cdn.intechopen.com/series_topics/covers/24.jpg",keywords:"Image Analysis, Scene Understanding, Biometrics, Deep Learning, Software Implementation, Hardware Implementation, Natural Images, Medical Images, Robotics, VR/AR"},{id:"25",title:"Evolutionary Computation",scope:"Evolutionary computing is a paradigm that has grown dramatically in recent years. This group of bio-inspired metaheuristics solves multiple optimization problems by applying the metaphor of natural selection. It so far has solved problems such as resource allocation, routing, schedule planning, and engineering design. Moreover, in the field of machine learning, evolutionary computation has carved out a significant niche both in the generation of learning models and in the automatic design and optimization of hyperparameters in deep learning models. This collection aims to include quality volumes on various topics related to evolutionary algorithms and, alternatively, other metaheuristics of interest inspired by nature. For example, some of the issues of interest could be the following: Advances in evolutionary computation (Genetic algorithms, Genetic programming, Bio-inspired metaheuristics, Hybrid metaheuristics, Parallel ECs); Applications of evolutionary algorithms (Machine learning and Data Mining with EAs, Search-Based Software Engineering, Scheduling, and Planning Applications, Smart Transport Applications, Applications to Games, Image Analysis, Signal Processing and Pattern Recognition, Applications to Sustainability).",coverUrl:"https://cdn.intechopen.com/series_topics/covers/25.jpg",keywords:"Genetic Algorithms, Genetic Programming, Evolutionary Programming, Evolution Strategies, Hybrid Algorithms, Bioinspired Metaheuristics, Ant Colony Optimization, Evolutionary Learning, Hyperparameter Optimization"},{id:"26",title:"Machine Learning and Data Mining",scope:"The scope of machine learning and data mining is immense and is growing every day. It has become a massive part of our daily lives, making predictions based on experience, making this a fascinating area that solves problems that otherwise would not be possible or easy to solve. This topic aims to encompass algorithms that learn from experience (supervised and unsupervised), improve their performance over time and enable machines to make data-driven decisions. It is not limited to any particular applications, but contributions are encouraged from all disciplines.",coverUrl:"https://cdn.intechopen.com/series_topics/covers/26.jpg",keywords:"Intelligent Systems, Machine Learning, Data Science, Data Mining, Artificial Intelligence"},{id:"27",title:"Multi-Agent Systems",scope:"Multi-agent systems are recognised as a state of the art field in Artificial Intelligence studies, which is popular due to the usefulness in facilitation capabilities to handle real-world problem-solving in a distributed fashion. The area covers many techniques that offer solutions to emerging problems in robotics and enterprise-level software systems. Collaborative intelligence is highly and effectively achieved with multi-agent systems. Areas of application include swarms of robots, flocks of UAVs, collaborative software management. Given the level of technological enhancements, the popularity of machine learning in use has opened a new chapter in multi-agent studies alongside the practical challenges and long-lasting collaboration issues in the field. It has increased the urgency and the need for further studies in this field. We welcome chapters presenting research on the many applications of multi-agent studies including, but not limited to, the following key areas: machine learning for multi-agent systems; modeling swarms robots and flocks of UAVs with multi-agent systems; decision science and multi-agent systems; software engineering for and with multi-agent systems; tools and technologies of multi-agent systems.",coverUrl:"https://cdn.intechopen.com/series_topics/covers/27.jpg",keywords:"Collaborative Intelligence, Learning, Distributed Control System, Swarm Robotics, Decision Science, Software Engineering"}],annualVolumeBook:{},thematicCollection:[],selectedSeries:{title:"Artificial Intelligence",id:"14"},selectedSubseries:null},seriesLanding:{item:{id:"7",title:"Biomedical Engineering",doi:"10.5772/intechopen.71985",issn:"2631-5343",scope:"Biomedical Engineering is one of the fastest-growing interdisciplinary branches of science and industry. The combination of electronics and computer science with biology and medicine has improved patient diagnosis, reduced rehabilitation time, and helped to facilitate a better quality of life. Nowadays, all medical imaging devices, medical instruments, or new laboratory techniques result from the cooperation of specialists in various fields. The series of Biomedical Engineering books covers such areas of knowledge as chemistry, physics, electronics, medicine, and biology. This series is intended for doctors, engineers, and scientists involved in biomedical engineering or those wanting to start working in this field.",coverUrl:"https://cdn.intechopen.com/series/covers/7.jpg",latestPublicationDate:"May 7th, 2022",hasOnlineFirst:!0,numberOfOpenTopics:3,numberOfPublishedChapters:96,numberOfPublishedBooks:12,editor:{id:"50150",title:"Prof.",name:"Robert",middleName:null,surname:"Koprowski",fullName:"Robert Koprowski",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYTYNQA4/Profile_Picture_1630478535317",biography:"Robert Koprowski, MD (1997), PhD (2003), Habilitation (2015), is an employee of the University of Silesia, Poland, Institute of Computer Science, Department of Biomedical Computer Systems. For 20 years, he has studied the analysis and processing of biomedical images, emphasizing the full automation of measurement for a large inter-individual variability of patients. Dr. Koprowski has authored more than a hundred research papers with dozens in impact factor (IF) journals and has authored or co-authored six books. Additionally, he is the author of several national and international patents in the field of biomedical devices and imaging. Since 2011, he has been a reviewer of grants and projects (including EU projects) in biomedical engineering.",institutionString:null,institution:{name:"University of Silesia",institutionURL:null,country:{name:"Poland"}}},subseries:[{id:"7",title:"Bioinformatics and Medical Informatics",keywords:"Biomedical Data, Drug Discovery, Clinical Diagnostics, Decoding Human Genome, AI in Personalized Medicine, Disease-prevention Strategies, Big Data Analysis in Medicine",scope:"Bioinformatics aims to help understand the functioning of the mechanisms of living organisms through the construction and use of quantitative tools. The applications of this research cover many related fields, such as biotechnology and medicine, where, for example, Bioinformatics contributes to faster drug design, DNA analysis in forensics, and DNA sequence analysis in the field of personalized medicine. Personalized medicine is a type of medical care in which treatment is customized individually for each patient. Personalized medicine enables more effective therapy, reduces the costs of therapy and clinical trials, and also minimizes the risk of side effects. Nevertheless, advances in personalized medicine would not have been possible without bioinformatics, which can analyze the human genome and other vast amounts of biomedical data, especially in genetics. The rapid growth of information technology enabled the development of new tools to decode human genomes, large-scale studies of genetic variations and medical informatics. The considerable development of technology, including the computing power of computers, is also conducive to the development of bioinformatics, including personalized medicine. In an era of rapidly growing data volumes and ever lower costs of generating, storing and computing data, personalized medicine holds great promises. Modern computational methods used as bioinformatics tools can integrate multi-scale, multi-modal and longitudinal patient data to create even more effective and safer therapy and disease prevention methods. Main aspects of the topic are: Applying bioinformatics in drug discovery and development; Bioinformatics in clinical diagnostics (genetic variants that act as markers for a condition or a disease); Blockchain and Artificial Intelligence/Machine Learning in personalized medicine; Customize disease-prevention strategies in personalized medicine; Big data analysis in personalized medicine; Translating stratification algorithms into clinical practice of personalized medicine.",annualVolume:11403,isOpenForSubmission:!0,coverUrl:"https://cdn.intechopen.com/series_topics/covers/7.jpg",editor:{id:"351533",title:"Dr.",name:"Slawomir",middleName:null,surname:"Wilczynski",fullName:"Slawomir Wilczynski",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y000035U1loQAC/Profile_Picture_1630074514792",institutionString:null,institution:{name:"Medical University of Silesia",institutionURL:null,country:{name:"Poland"}}},editorTwo:null,editorThree:null,editorialBoard:[{id:"5886",title:"Dr.",name:"Alexandros",middleName:"T.",surname:"Tzallas",fullName:"Alexandros Tzallas",profilePictureURL:"https://mts.intechopen.com/storage/users/5886/images/system/5886.png",institutionString:"University of Ioannina, Greece & Imperial College London",institution:{name:"University of Ioannina",institutionURL:null,country:{name:"Greece"}}},{id:"257388",title:"Distinguished Prof.",name:"Lulu",middleName:null,surname:"Wang",fullName:"Lulu Wang",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRX6kQAG/Profile_Picture_1630329584194",institutionString:null,institution:{name:"Shenzhen Technology University",institutionURL:null,country:{name:"China"}}},{id:"225387",title:"Prof.",name:"Reda",middleName:"R.",surname:"Gharieb",fullName:"Reda Gharieb",profilePictureURL:"https://mts.intechopen.com/storage/users/225387/images/system/225387.jpg",institutionString:"Assiut University",institution:{name:"Assiut University",institutionURL:null,country:{name:"Egypt"}}}]},{id:"8",title:"Bioinspired Technology and Biomechanics",keywords:"Bioinspired Systems, Biomechanics, Assistive Technology, Rehabilitation",scope:'Bioinspired technologies take advantage of understanding the actual biological system to provide solutions to problems in several areas. Recently, bioinspired systems have been successfully employing biomechanics to develop and improve assistive technology and rehabilitation devices. The research topic "Bioinspired Technology and Biomechanics" welcomes studies reporting recent advances in bioinspired technologies that contribute to individuals\' health, inclusion, and rehabilitation. Possible contributions can address (but are not limited to) the following research topics: Bioinspired design and control of exoskeletons, orthoses, and prostheses; Experimental evaluation of the effect of assistive devices (e.g., influence on gait, balance, and neuromuscular system); Bioinspired technologies for rehabilitation, including clinical studies reporting evaluations; Application of neuromuscular and biomechanical models to the development of bioinspired technology.',annualVolume:11404,isOpenForSubmission:!0,coverUrl:"https://cdn.intechopen.com/series_topics/covers/8.jpg",editor:{id:"144937",title:"Prof.",name:"Adriano",middleName:"De Oliveira",surname:"Andrade",fullName:"Adriano Andrade",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRC8QQAW/Profile_Picture_1625219101815",institutionString:null,institution:{name:"Federal University of Uberlândia",institutionURL:null,country:{name:"Brazil"}}},editorTwo:null,editorThree:null,editorialBoard:[{id:"49517",title:"Prof.",name:"Hitoshi",middleName:null,surname:"Tsunashima",fullName:"Hitoshi Tsunashima",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYTP4QAO/Profile_Picture_1625819726528",institutionString:null,institution:{name:"Nihon University",institutionURL:null,country:{name:"Japan"}}},{id:"425354",title:"Dr.",name:"Marcus",middleName:"Fraga",surname:"Vieira",fullName:"Marcus Vieira",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y00003BJSgIQAX/Profile_Picture_1627904687309",institutionString:null,institution:{name:"Universidade Federal de Goiás",institutionURL:null,country:{name:"Brazil"}}},{id:"196746",title:"Dr.",name:"Ramana",middleName:null,surname:"Vinjamuri",fullName:"Ramana Vinjamuri",profilePictureURL:"https://mts.intechopen.com/storage/users/196746/images/system/196746.jpeg",institutionString:"University of Maryland, Baltimore County",institution:{name:"University of Maryland, Baltimore County",institutionURL:null,country:{name:"United States of America"}}}]},{id:"9",title:"Biotechnology - Biosensors, Biomaterials and Tissue Engineering",keywords:"Biotechnology, Biosensors, Biomaterials, Tissue Engineering",scope:"The Biotechnology - Biosensors, Biomaterials and Tissue Engineering topic within the Biomedical Engineering Series aims to rapidly publish contributions on all aspects of biotechnology, biosensors, biomaterial and tissue engineering. We encourage the submission of manuscripts that provide novel and mechanistic insights that report significant advances in the fields. Topics can include but are not limited to: Biotechnology such as biotechnological products and process engineering; Biotechnologically relevant enzymes and proteins; Bioenergy and biofuels; Applied genetics and molecular biotechnology; Genomics, transcriptomics, proteomics; Applied microbial and cell physiology; Environmental biotechnology; Methods and protocols. Moreover, topics in biosensor technology, like sensors that incorporate enzymes, antibodies, nucleic acids, whole cells, tissues and organelles, and other biological or biologically inspired components will be considered, and topics exploring transducers, including those based on electrochemical and optical piezoelectric, thermal, magnetic, and micromechanical elements. Chapters exploring biomaterial approaches such as polymer synthesis and characterization, drug and gene vector design, biocompatibility, immunology and toxicology, and self-assembly at the nanoscale, are welcome. Finally, the tissue engineering subcategory will support topics such as the fundamentals of stem cells and progenitor cells and their proliferation, differentiation, bioreactors for three-dimensional culture and studies of phenotypic changes, stem and progenitor cells, both short and long term, ex vivo and in vivo implantation both in preclinical models and also in clinical trials.",annualVolume:11405,isOpenForSubmission:!0,coverUrl:"https://cdn.intechopen.com/series_topics/covers/9.jpg",editor:{id:"126286",title:"Dr.",name:"Luis",middleName:"Jesús",surname:"Villarreal-Gómez",fullName:"Luis Villarreal-Gómez",profilePictureURL:"https://mts.intechopen.com/storage/users/126286/images/system/126286.jpg",institutionString:null,institution:{name:"Autonomous University of Baja California",institutionURL:null,country:{name:"Mexico"}}},editorTwo:null,editorThree:null,editorialBoard:[{id:"35539",title:"Dr.",name:"Cecilia",middleName:null,surname:"Cristea",fullName:"Cecilia Cristea",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYQ65QAG/Profile_Picture_1621007741527",institutionString:null,institution:{name:"Iuliu Hațieganu University of Medicine and Pharmacy",institutionURL:null,country:{name:"Romania"}}},{id:"40735",title:"Dr.",name:"Gil",middleName:"Alberto Batista",surname:"Gonçalves",fullName:"Gil Gonçalves",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYRLGQA4/Profile_Picture_1628492612759",institutionString:null,institution:{name:"University of Aveiro",institutionURL:null,country:{name:"Portugal"}}},{id:"211725",title:"Associate Prof.",name:"Johann F.",middleName:null,surname:"Osma",fullName:"Johann F. Osma",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bSDv7QAG/Profile_Picture_1626602531691",institutionString:null,institution:{name:"Universidad de Los Andes",institutionURL:null,country:{name:"Colombia"}}},{id:"69697",title:"Dr.",name:"Mani T.",middleName:null,surname:"Valarmathi",fullName:"Mani T. Valarmathi",profilePictureURL:"https://mts.intechopen.com/storage/users/69697/images/system/69697.jpg",institutionString:"Religen Inc. | A Life Science Company, United States of America",institution:null},{id:"205081",title:"Dr.",name:"Marco",middleName:"Vinícius",surname:"Chaud",fullName:"Marco Chaud",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bSDGeQAO/Profile_Picture_1622624307737",institutionString:null,institution:{name:"Universidade de Sorocaba",institutionURL:null,country:{name:"Brazil"}}}]}]}},libraryRecommendation:{success:null,errors:{},institutions:[]},route:{name:"profile.detail",path:"/profiles/353922",hash:"",query:{},params:{id:"353922"},fullPath:"/profiles/353922",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()